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Abstract 
 
Nail fungal infections frequently addressed as onychomycosis present a considerable 
prevalence on the global population. 
 
Despite not being a life-threatening disease, this infection causes several social problems to 
the infected patients. Unfortunately, the topical therapy available, does not include one of the 
most effectively drugs and oral therapy comprises several problems. 
 
Nail lacquers are solutions of film forming polymers, which leave a film on the nail plate after 
solvent evaporation. This polymer film can be water resistant or water soluble and can act as a 
drug reservoir, allowing a drug to permeate through the nail plate. The nail lacquers water 
resistant are occlusive and adhesive to the nail. They present advantages regarding nail 
hydration, permanence on the nail plate and patient compliance, when compared to creams, 
gels and solutions. 
 
The development of polyurethane based nail lacquers for the delivery drugs to treat 
onychomycosis is still a challenge. Nowadays there are drugs with pharmacological activity 
(antifungal) for treatment of onychomycosis (i.e. terbinafine hydrochloride), but there is no 
nail lacquer formulation in the market capable of delivering them into the nail with success. 
 
Polyurethanes are being used for sustained and controlled delivery of various drugs. The 
development of a new polyurethane based on carbohydrates for the delivery of antifungal 
(terbinafine hydrochloride and ciclopirox olamine) to treat onychomycosis, is the main aim of 
this thesis. 
The thesis is divided in two main topics:  
The first part presents the synthesis of polyurethanes from carbohydrates and derivatives. The 
biocompatible polyurethanes were successfully synthesized employing carbohydrates and 
aliphatic isocyanates. The polyurethanes were synthesized by pre-polymerization method. 
This process allows maintain better control the structure and properties of the final polymer, 
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through a simple change of chain extender. It was possible to obtain polyurethanes with 
different properties from the same pre-polymer, that are typically liquids, which facilitates 
handling on an industrial scale, when compared with monomeric isocyanate systems. The 
polyurethanes were characterized by FTIR, NMR, GPC and MALDI-TOF. The 
biocompatibility of these materials was also assessed using keratinocytes cell. 
In the second part of our work, four polymers were used to prepare nail lacquers containing 
terbinafine hydrochloride as a model drug. The results obtained from the 
structural/characterization analysis of these PU based nail lacquers, comprising all the data 
and information that allowed the selection of the best of them to optimize the final 
formulations.  
At this stage, only one of the tested PU was selected to the complete physical, chemical and 
microbiological studies with two drug models: terbinafine hydrochloride and ciclopirox 
olamine. PU based nail lacquers with different amounts of the polyurethane selected previous 
were prepared. Cytotoxicity, wettability, SEM, adhesion test, viscosity, in vitro release and 
permeation studies as well as the antifungal activity were performed. 
 
Keywords: Onychomycosis, nail lacquer; polyurethanes; adhesion to keratin, transungual 
drug delivery. 
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 Resumo 
As três últimas décadas foram marcadas por significativas alterações nos padrões das 
infecções fúngicas. Este fato, aliado ao aumento da população de risco, como doentes com 
Síndrome de Imunodeficiência Adquirida (SIDA), transplantados, com patologias 
hematológicas ou com outros comprometimentos imunitários, como terapêuticas 
imunossupressoras, fez com que estas infecções assumissem uma maior importância no 
contexto de saúde pública.  
A onicomicose é uma infecção fúngica da lâmina ungueal (unha) que representa entre 15 a 
40% de todas as onicopatias.  Pode ser provocada por dermatófitos, fungos filamentosos, não 
dermatófitos ou leveduras, principalmente as do género Candida. Apesar de estar associada a 
diferentes agentes etiológicos, em 90% dos casos os responsáveis são dermatófitos, 
principalmente Trichophyton rubrum. 
 
A prevalência das onicomicoses na população em geral tem sido estimada entre 14% e 23%, 
sendo que estes números têm aumentado consideravelmente nas últimas décadas e estão 
relacionados com a diabetes, doença arterial periférica, psoríase, imunodepressão e 
envelhecimento. Em estados avançados, esta patologia pode causar dor, desconforto, 
limitações físicas e ocupacionais, condições estas que interferem com a qualidade de vida do 
doente. 
 
Os antifúngicos são largamente prescritos na prática clínica para o tratamento de infeções 
fúngicas na unha. Os antifúngicos podem ser administrados por via sistémica ou tópica. A 
escolha da terapêutica é feita tendo em conta factores como o grau de infeção da unha e 
potenciais interações e contraindicações. No entanto, a administração tópica apresenta maior 
conforto para o doente. 
 
 Para tratamento das onicomicoses (tratamento de iniciais e bem delimitadas),  têm sido 
usados com muita aceitação desde 1990, sistemas de libertação  transungueal baseados em 
vernizes medicamentosos. Os vernizes medicamentosos são soluções ungueais, onde se 
incluem polímeros, solventes voláteis, promotores da permeação e fármacos. Depois de 
aplicado na unha, os solventes voláteis evaporam e os polímeros deixam um sistema matricial 
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(filme) onde o fármaco pode estar incluído. Este sistema é formado por cadeias de uma ou de 
várias substâncias químicas polimerizadas, que funcionam como agentes moduladores da 
permeação. A partir desta matriz o fármaco difunde-se até à estrutura da unha e exerce ação 
fungicida. A penetração e o transporte de um fármaco na unha é um requisito para que o 
mesmo desempenhe a sua atividade terapêutica. A maioria dos fármacos não consegue 
permear a unha, pelo que é necessário um veículo para promover a sua libertação no local de 
ação.   
 
Os vernizes medicamentosos preparados a partir de polímeros hidrófobos posuem vantagens 
sobre outras formulações. Estes sistemas não são soluvéls em água deixando uma camada de 
polímero com maior durabilidade na unha, o que permite manter a sua ação por um maior 
período de tempo. O tratamento é simples e indolor, o progresso é visível e permite a remoção 
da zona infectada da unha. 
 
Os antifúngicos selecionados nesta tese, como moléculas modelos, foram o cloridrato de 
terbinafina (TH) e o ciclopirox olamina (CPX). 
 
O cloridrato de terbinafina, composto sintético derivado da alilamina (C3H5NH2), tem como 
mecanismo de ação a inibição da esqualeno epoxidase, uma enzima crucial no processo de 
síntese do ergosterol, o que origina a acumulação de esqualeno, levando à disrupção da 
membrana com consequente morte da célula fúngica. O cloridrato de terbinafina apresenta 
concentrações mínimas inibitórias para o T. rubrum de 0.004–0.06 μg/mL, C. Albicans  0.06-
16 μg/mL e A. fumigatus 1.4 μg/mL. O seu peso molecular é 291.43 g/mol. Trata-se de uma 
molécula lipofílica, que possui elevada eficácia no tratamento das onicomicoses por se 
difundir muito bem no leito ungueal. Esta molécula ainda não se encontra no mercado em 
vernizes medicamentosos. 
 
O ciclopirox olamina é um agente antimicótico sintético da família das piridonas. Possui 
amplo espetro com atividade inibitória contra dermatófitos, C.Candida, M. furfur, entre outros 
fungos. O mecanismo de ação estudado para a Candida albicans indica que este inibe a 
captação de precursores da síntese macromolecular que ocorre em duas etapas: i) inibindo a 
entrada de iões metálicos, dos iões fosfatos e do potássio; ii) atuando sobre a cadeia 
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respiratória da célula fúngica devido às propriedades quelantes. O ciclopirox olamina 
apresenta uma concentração mínima inibitoria para o T. rubrum de 0.031–0.5 μg/mL, C. 
Albicans  0.06-0.5 μg/mL e para o A. fumigatus 0.42 μg/mL e um peso molecular 207.03 
g/mol. A sua eficácia está relacionada com o fato desta molécula se difundir na epiderme e 
nos folículos pilossebáceos, com destaque para a impregnação das camadas superficiais do 
estrato córneo. Possui a capacidade de penetrar e atravessar a queratina das unhas. Encontra-
se disponível em verniz medicamentoso e foi utilizado nesta tese como fármaco modelo e 
para avaliar a capacidade da utilização de poliuretanos como polímeros de vernizes 
medicamentosos.  
 
As formulaçoes de vernizes medicamentosos desenvolvidas nesta fase incluríam solventes 
voláteis: etanol, acetato de etilo e butilo. Esta seleção foi realizada de acordo com a pesquisa 
efectuada essencialmente em patentes.  
 
Os poliuretanos (PU) são polímeros de grande aplicação industrial, pois apresentam 
propriedades físicas e químicas diferentes de acordo com a estrutura dos monómeros que dá 
origem ao polímero final.  Otto Bayer e colaboradores pela Ferbenindustri na Alemanha, em 
1937 foram os primeiros a sintetiza-los.  É um material notável por sua alta performance 
devido à excelente resistência química, a solventes, à abrasão e à hidrólise, além de possuir 
resistência antifungica, e por apresentar dureza e tenacidade combinada com flexibilidade à 
baixa temperatura. A ligação uretana (–NH–COO–) é um resultado da reação entre um grupo 
isocianato (–NCO) do diisocianato e um grupo hidroxilo (–OH) do poliol. 
 
Os poliuretanos têm sidos aplicados nas indústrias médica e farmacêutica desde 1970 em 
próteses e microesferas para regeneração óssea. No entanto, o uso de PU como um excipiente 
para a veiculação de farmacos na unha ainda não foi objeto de estudo. 
 
A presente tese está dividida em dois grandes tópicos: 
 
1 – Síntese e caracterização de poliuretanos a partir de carbohidratos.   
Esta síntese tem como objetivo a obtenção de polímeros biocompatíveis. Deste modo, os 
polímeros foram sintetizados a partir de polipropileno glicol, polietileno glicol, metil difenil 
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diisocianato polimérico, diisocianato de isoforona e de uma fonte renovável, representada 
pelos carbohidratos e seus derivados (sacarose e D-isossorbida). Os poliuretanos sintetizados 
a partir de sacarose, polietileno glicol e metil difenil diisocianto polimérico deram origem a 
polímeros insolúveis em solventes polares, com uma estrutura extremadamente entrecruzada e 
não apresentarom biocompatibilidade. A dissolução do polietileno glicol com 
dimetilsulfoxido a baixa temperatura de reação contribuí para elevados tempos de síntese e 
com a presença do solvente no processo de produção. A proposta para eliminar estes 
problemas consistiu em substituir o diisocianto aromático por diisocianatos alifáticos, em 
substituir os poliglicolos (sacarose) con glicolos de 2 OH (D-isossorbida) e em substituir o 
polietileno glicol por polipropileno glicol. 
 
A síntese de poliuretano a partir de moléculas hidrofílicas com dos hidroxilos livres, permitiu 
obter poliuretanos lineares e com solubilidade em solventes polares. A solubilização do 
polímero é muito importante porque deste modo é garantido a solubilidade do fármaco na 
matriz polimérica. Por outro lado, a síntese de polímeros pouco reticulados permitire obter 
uma matriz com um volume livre que permitirá depois a libertação do fármaco.  Foram 
efetuadas sínteses de poliuretanos a partir de dois isocianatos alifáticos o diisocianato de 
isoforona (IPDI) e 4,4' -diciclo-hexil-metileno (HMDI). O resultado destas sínteses, 
permitiram obter os poliuretanos obtidos a partir de IPDI mais biocompatíveis quando 
comparados com os poliuretanos obtidos a partir de HMDI. Todos os poliuretanos foram 
caraterizados por FTIR e RMN para confirmar a sua estrutura. Foram ainda efetuados estudos 
dos coeficientes de difusão e volume hidrodinámico, confirmando-se que à medida que 
aumenta o peso molecular e a viscosidade, diminui o raio hidrodinámico e o polímero difunde 
menos no solvente onde foi solubilizado previamente. Foram determinados os pesos 
moleculares por duas técnicas diferentes, Cromatografia de Permeação em Gel e Ionização 
por Dessorção a Laser Assistida por Matriz Tempo de Vôo. Ambas técnicas permitiram 
concluir que existe uma relação entre peso molecular e relação estequiométrica entre 
monómeros que formam parte da estrutura do polímero. 
Uma vez sintetizados os poliuretanos com as características ideais, estes foram selecionados 
como excipientes de vernizes medicamentosos. 
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2- Preparação de vernizes medicamentosos  
O desafio desta fase do trabalho consistiu em obter formulações de vernizes medicamentosos 
empregando quatro poliuretanos como excipientes biocompatíveis, seguros, eficazes e com 
adesividade a unha como forma farmacêutica com actividade antifúngica. 
 
Para avaliar o melhor polímero, foram preparadas e avaliadas várias formulações de vernizes 
medicamentosos contendo cloridrato de terbinafina. Estudos de biocompatibilidade celular 
(queratinócitos), determinação do ângulo de contacto entre a unha e os vernizes, o volume 
livre das formulações, a morfologia dos filmes bem como a adesão dos vernizes à queratina e 
sua  viscosidade foram efectuados. Para além destes, foram realizados estudos in vitro de 
libertação e de eficácia antifúngica. A selecção do poliuretano foi realizada com base nestes 
estudos.  
Numa ultima fase, e com o objetivo de optimizar a formulação do verniz medicamentoso, foi 
estudado  a influência da concentração polímero nos vernizes e a inclusão de ciclopirox 
olamina como segundo fármaco modelo. 
As formulações desenvolvidas foram caracterizadas avaliadas através de estudos de 
biocompatibilidade, de molhabilidade, de microscopia, de adesividade, de viscosidade e de 
ensaios in vitro de libertação e de permeação das substâncias ativas bem como de avaliação da 
eficácia antifúngica.  
 
Palavras-chave: Onicomicoses, verniz medicamentoso; poliuretanos; adesão à queratina, 
sistemas para libertação transungual, ação antifúngica. 
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Andreia Ascenso, Helena Ribeiro, Sandra Simões (eds). Carrier-Mediated Dermal Delivery: 
Applications. in: the Prevention and Treatment of Skin Disorders. Pan Stanford Publishing. 
2016. 503-553. 
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1.Onychomycosis 
Onychomycosis is a fungal infection of the nail that causes a great concern because of the 
disfiguring appearance of the nails (1). The nail problem is caused by different types of fungi 
that can easily attack the nails due to their keratinolytic enzyme (2). In the Figure 1.1 is 
showed the aspect of the microorganism and the debased structure of keratin of the nail. 
 
Figure 1. 1. Scanning electron micrograph of nail plate a) no affecting by fungal infection and 
b) nail affected by a fungal infection. 
1.1 Epidemiology   
Onychomycosis prevalence has been reported to occur from 3 to 26% in the general 
population (1,3–6). 
Onychomycosis cases have been increasing in the past decades, from a prevalence of 1-2% to 
14-15% in a 20 year time window (4). According to several large studies, it is expected that 
onychomycosis prevalence will increase to 20% or more in the next decade (4).  
Onychomycosis is a serious public health problem leading to detrimental physical and 
psychological effects. There are specific population groups affected by this disease.  About 
50% of all psoriasis patients (1-8% of general population) report nail psoriasis and 40 to 60% 
are affected by onychomycosis (5,7,8). Onychomycosis also affects about 1/3 of diabetes 
patients since they are more prone to suffer foot complications that can lead to dermatophyte 
infections, ulceration, osteomyelitis, cellulitis and tissue necrosis that may result at worst in 
amputation (9). 
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Onychomycosis greatly affects the patients´ quality of life even not being a life threatening 
condition. Approximately half of the patients with onychomycosis report some discomfort 
due to this condition: pain, difficulty on wearing footwear and walking, emotional 
embarrassment and work related difficulties.  
 
1.2 Risk factors 
Onychomycosis is an ailment that has several different risk factors.  With regard to age, it is 
reported that onychomycosis is more prevalent at an older age, being the elderly the most 
affected population with an age/infection correlation of 20% and up to 50% of subjects over 
60 and 70 years old, respectively (1,10,11). This correlation is often attributed to poor 
peripheral circulation, sedentary lifestyle, weaker immune system, diabetes, nail trauma, 
difficulty in performing foot hygiene and slower growing nails (2,10,12,13). Children are 
rarely affected by onychomycosis, with an incidence of just about 0.4%, since this group has 
smaller nail surface, faster nail growth, fewer nail injuries and lower tinea pedis incidence rate 
besides less contact with infected surfaces (5,14–16). 
Gender is also considered a risk factor being males more often affected by this type of nail 
infection (2,11,17). Several authors postulated that this may be due to hormone differences 
between sexes, leading to a difference in the capacity to inhibit the growth of dermatophytes 
(18). It is also considered that the use of occlusive footwear and nail injuries may contribute 
to a higher incidence in males (2). 
Recent studies had stated that onychomycosis may have a genetic basis, with an autosomal 
dominant pattern of inheritance related to T. rubrum infection, and increased susceptibility 
when at least one parent had onychomycosis (5,8,17,19–22). 
The environment plays a major role in contracting a fungal infection. The societal factor 
cannot be disregarded.  Those who regularly does not wear shoes  tend to show a lower 
infection rate (2,15). On the contrary, athletes display an increased infection rate due to 
occlusive footwear which allows a dark and moist environment for onychomycosis to 
develop. Also, athletes contact more with moist infected surfaces, like swimming pools, 
communal shower rooms and public toilets (23). Nail trauma, synthetic clothing (which 
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retains sweat) and tinea pedis are also associated with sports and the incidence of this disease 
(2,5,13,21,23–26). 
Immunodeficiency in HIV-infected individuals and transplant recipients also consists a risk 
factor for onychomycosis. Such persons whose T-lymphocyte count is as low as 400/mm3 
tend to have a more widespread infection affecting both toe and fingernails (1,5,11,23,25–29). 
Diabetic individuals are three times more likely to have onychomycosis than the general 
population, being 34% with onychomycosis. Diabetic people have decreased peripheral 
circulation, neuropathy, impaired wound healing and increased difficulty on foot checkups 
due to obesity, retinopathy or cataracts. Therefore, injuries in toenails may be unnoticed due 
to neuropathy and act as entryways for bacteria, fungi, and other pathogens, leading to serious 
complications (4,5,11,21,24,30). 
 
1.3 Clinical classification  
There are five types of onychomycosis established according to the mode and site of invasion 
by the pathogen: distal and lateral subungual onychomycosis, white superficial 
onychomycosis, proximal subungual onychomycosis, total dystrophic onychomycosis (Figure 
1.2) and endonyx onychomycosis (1,2,5,29,31–33).  
 
 
Figure 1. 2. Types of onychomycosis according to the mode and site of invasion of the 
pathogen. 
 
Distal and lateral subungual onychomycosis (DLSO) 
DLSO is the most common type of onychomycosis (1,2). The fungal infection progresses in 
the nail from the distal to the proximal edge, via the distal-lateral margins or through the 
lateral nail plate groove, originating from the hyponychium. This type of infection is mainly 
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caused by Trichophyton spp. and sometimes by Scytalidium spp. and Candida spp (5). It is 
frequent to find paronychia in these individuals, leading to subungual hyperkeratosis, nail 
thickening and onycholysis (nail detachment from the nail bed). The subungual space can be 
colonized by infectious bacteria and fungi, causing discoloration of the nail plate (1,2,5). 
Proximal subungual onychomycosis (PSO) 
In this type of onychomycosis, fungi invade the area under the nail cuticle and induce the 
infection of the proximal nail plate. Then, it progresses distally along the nail plate. This 
clinical manifestation of onychomycosis is mainly prevalent in immunocompromised 
individuals, being especially common in AIDS patients where it is considered an early HIV 
infection clinical marker. The fungi responsible for PSO are T. rubrum, C. albicans, Fusarium 
spp., Aspergillus spp. and Scopulariopsis brevicaulis (5, 25). 
Superficial white onychomycosis (SWO) 
SWO presents itself as opaque white patches on the dorsal surface of the nail plate. The upper 
layers of nail keratin are infected mainly by Trichophyton mentagrophytes and T. rubrum. 
Other pathogens responsible for this infection are non-dermatophyte molds such as Fusarium 
spp., Acremonium spp. and Aspergillus spp (28).  
Endonyx onychomycosis (EM) 
EM is the most recently described form of onychomycosis, being reported as an infection of 
both superficial and deeper layers of the nail plate. EM does not usually cause nail thickening, 
detachment, and inflammatory processes, but it leads to lamellar splitting, coarse pitting and 
milky white patches within affected nail plates (4). Usual pathogens are T. soudanense and T. 
violaceum (29, 30).  
Total dystrophic onychomycosis (TDO) 
TDO is usually considered the end stage of any other type of onychomycosis. It can also exist 
on its own - primary total dystrophic onychomycosis - occurring mostly in patients with 
chronic mucocutaneous candidiasis. It is described as the nearly complete destruction of the 
nail plate. 
Diagnosing onychomycosis is important in order to guarantee the best possible treatment and 
with less side effects. Nowadays, the diagnosis is based on a clinical evaluation in which nail 
samples are collected and analyzed by microscopy and fungal culture (1,15,23,25). 
Onychomycosis should be differentiated from other similar conditions, such as psoriasis of 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 1 
 
 
9 
 
the nail, eczema, bacterial infections, contact dermatitis, traumatic onycho-dystrophies, 
chronic onycholysis, lichen planus, chronic paronychia, hemorrhage or trauma, 
onychogryphosis, median canalicular dystrophy, pincer nail, yellow nail syndrome, subungual 
malignant melanoma and subungual squamous cell carcinoma (4,15). Among these disorders, 
it is especially difficult to differentiate onychomycosis from nail psoriasis, since they tend to 
share similar nail morphological changes (34). 
 
2.Transungual delivery 
All drugs must reach their target location to be more effective. Particularly, the nail unit has 
different characteristics from the rest of body surface, and consequently, topical formulations 
may not deliver enough drug amounts to the nail bed. Therefore, it is quite important to 
clearly understand the nail biology for the development of a more active topical formulations.  
 
2.1 Nail structure and transungual permeation 
The nail plate is the main obstacle in the nail unit for drug permeation. It is hard, thin (0.25-1 
mm), slightly elastic, translucent, convex shaped, and consists of 80-90 layers of dead, 
keratinized, flattened cells tightly bound to each other via intercellular links (35,36). The nail 
is constituted by nail plate, lateral fold, proximal fold, matrix, nail bed and distal groove as 
showed in Figure 1.3 (37). The nail plate can be divided into three macroscopic layers - 
dorsal, intermediate and ventral layers - being the dorsal layer the hardest one (37). Regarding 
its chemical composition, the nail is composed of fibrous proteins, keratins (80% “hard” 
keratin, remaining “soft” keratin), water and a low amount of lipids (0.1-1%) in contrast to the 
stratum corneum (~10%). Under normal conditions, the nail plate can contain 7-12% of water, 
but this content can rise to 35% (35–37). 
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Figure 1. 3. Representation of nail structure. 
Transungual permeation is dependent on drug properties (molecular weight, log P, charge, 
pKa, etc.), formulation characteristics (pH, water content, etc.), nail plate properties (diseased 
state, hydration, thickness and keratin content) and drug-keratin interactions. 
Accordingly, the most significant properties of the permeant drug are: 
Molecular weight – it shows an inverse relationship with the drug permeation into the nail 
plate. Heavier molecules have a higher time permeation through the keratin network on the 
nail plate (35). Drugs below 300 gmol-1 Mw have enhanced transungual permeation rate (37). 
Indeed, the molecular weight is considered to be the most significant property affecting the 
nail permeation. 
Log P – permeation rate was found to decrease with an increase in carbon chain length or 
lipophilicity attributed to the hydrophilic nature of the nail plate (37-40). 
Charge – non-ionic drugs were found to have about 10-fold greater permeability as compared 
to their ionic counterparts (38). However, Elsayed et al. (37) stated that these results did not 
take into account the molecular weight of the permeant drug, and regarding other studies, 
drug ionization can have a permeation enhancement effect due to an increase of aqueous 
solubility maximizing the transungual flux.  
pKa and other physicochemical properties – in general, soluble molecules have good 
permeation across the nail plate. Weak acidic drugs are well permeated at higher pH, while 
weak basic drugs exhibit better permeation at lower pH values. Ionization can also contribute 
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to increasing drug solubility. Conversely, if the molecule is sublimable at body temperature, it 
will be advantageous for permeating through the diseased nail plate, since it can overcome air 
cavities by being sublimed and reach the other side of the cavity (36). 
On the other hand, the formulation composition also plays an important role on drug 
transungual permeation, as follows: 
pH – nail keratin has an isoelectric point of 5.0, turning to a net negative charge at pH 7.4 and 
net positive charge at pH 2.0. Therefore, some molecules might be repelled due to charging 
depending on pH. Some studies have stated that antifungal drugs have lower activity in acidic 
environments (39).  
Water content – water enhances the diffusion through the nail plate. As water hydrates the 
nail plate, its volume increases, and this swelling causes larger pores, facilitating the 
permeation of bigger molecules. (35)  
Finally, the nail plate properties influence the drug transungual permeation as well (35,40): 
Diseased nail plate – this state has an enormous influence in permeation as diseased nail 
plates have uneven thickness, fungi concentration, and onycholysis, which can lead to a 
detached nail surrounded by non-detached areas. In some cases, this can be beneficial since 
some formulations can be applied to the detached space (41). 
Hydration – it increases the ungual permeability of polar compounds, as discussed before. 
Drug binding to keratin – it can lead to disappointing results since it reduces the availability 
of the permeant drug and weakens its concentration gradient. Although this interaction highly 
influences antifungal activity, it is not frequently considered in many studies (42). 
In summary, all factors that affect the drug transungual permeation are outlined in Figure 1.4. 
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Figure 1. 4. Factors that affect nail permeation of topically applied formulations. Adapted 
from (35). 
2.2 Mathematical description of nail permeability 
Fick’s adapted laws of permeability can be used for studying permeation through the nail 
plate.  
Flux (J) occurs when an amount of permeant (Q in mol or g) moves across a membrane with a 
certain area (A in m2) during time (t in s) (equation A). Fick’s first law describes the flux 
where D is the permeant diffusion coefficient (m2s-1) and  is the permeant 
concentration gradient. The negative sign indicates that the flux is in direction of decreasing 
concentration (equation B). 
(A)     (B)   
The permeability coefficient (P) is given by equation C:  
(C)    
In which K is the distribution equilibrium (distribution constant), and h is the membrane 
thickness (in m) (37,43). 
According to Kobayashi et al. (44), the functional dependence of D on Mw of the molecule 
can be described by equation D: 
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(D)     
Here D0 represents the diffusivity of a hypothetical molecule having zero molecular weight 
and β is a constant. 
Nail permeability was found to be independent of the drug lipophilicity according to equation 
E (44):  
(E)          , where β’ = β/2.303 
As human nails are not always available for studies, it is important to establish a viable in 
vitro model. Animal hooves have been used as a human nail model in the last decades. There 
are reports of bovine, porcine and equine hoof use (35). Saner et al. (35) described, the 
relationship between permeability coefficients through human nail plates and hoof 
membranes can be portrayed by the equation F: 
(F)   
In which PN is the human nail plate permeability coefficient and PH is the permeability 
coefficient through bovine hoof membrane obtained experimentally. Recently researchers 
have used keratin films made from human hair as a model for human nails (36,45,46). Other 
models used to study nail permeability included wax blocks, nail clippings, cadaver nail 
plates and excised cadaver toes (37). 
 
3.Onychomycosis topical therapy 
There are several therapeutic options to treat this fungal nail infection: oral, topical and 
combined therapy (5,10,15,27,29,47–51). Adhesive patches have also been studied but 
displayed very low drug permeation. Thus, these pharmaceutical forms have a low 
representatively in the market (52). 
Despite being more effective, oral therapy presents several risks for patients, including 
adverse reactions and possible drug interactions (10,53–57). This is especially relevant in the 
elderly (the most affected age group) who are polymedicated, and therefore, more susceptible 
to these reactions (10,12). Thus, it would be expected a higher investment on topical therapy. 
Currently, most common topical formulations present a low drug delivery to the infection site 
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mainly due to the nail plate characteristics, and the cure rate is lower than oral and combined 
therapy. Topical formulations are also bothersome to apply if there are several affected nails, 
reducing patient compliance (58,59). Nonetheless, there are several topical formulations 
available on the market used in mono or combined therapy. Firstly, it will be reviewed 
different drug delivery enhancers, antifungal drugs, and finally, several pharmaceutical forms 
employed in the topical treatment of onychomycosis. 
 
3.1 Drug delivery enhancers 
The nail plate is a great barrier to drug permeation, as stated before. Thus, it is important to 
enhance the permeation to guarantee effective drug delivery.  
There are several physical enhancement methods such as nail plate abrasion, etching of the 
nail surface with acid, ablation of the nail with pulsed lasers, microporation of the nail plate, 
application of low frequency ultrasound and electric current through the nail (38). Although 
these methods are effective, reduce patient compliance and need the presence of a specialized 
technician to perform them.  
Chemical enhancement of ungual drug delivery can also be useful. This type of 
enhancement is cheaper, easier to apply, and can be conducted  by the patient before or 
concomitantly with drug application. It focuses on breaking chemical and physical bonds that 
maintain the integrity of the nail plate keratin. Targets for ungual chemical penetration 
enhancers are disulfide, peptide, hydrogen and polar bonds. Chemical enhancers are classified 
according to the targeted bond and respective mechanism (40).  
The nail plate is cohesive due to S-S bonds, and these are great targets for enhancers. 
Enhancers targeting this bond will reduce the disulfide linkage, engaging in nucleophilic 
attacks as follows: 
Nail-S-S-Nail + 2 R-SH  2Nail-SH + R-S-S-R 
In this way, enhancers with thiol or ammonia groups with lone pairs of electrons will offer an 
advantage in breaking keratin bonding (43). 
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Disulfide bond cleaving by reducing agents  
Thiols 
Thiols are compounds containing sulfhydryl groups (–SH groups) that reduce the disulfide 
linkage in the keratin matrix of the nail (60). Examples of thiols used as permeation enhancers 
include N-acetylcysteine, mercaptoethanol, N-(2-mercaptopropionyl) glycine, pyrithione and 
thioglycolic acid. Once disulfide bonds are cleaved, they are unlikely to be reformed. Thus 
these alterations is permanent.  
Sulfites 
Sodium sulfite is known to cleave disulfide bonds when incubated with proteins and peptides, 
producing thiols and thiosulfates. It was then found to enhance transungual permeation both 
on pretreatment and co-application (61). 
Disulfide bond cleaving by oxidizing agents 
In this category of enhancers, hydrogen peroxide has been used alone or in combination. 
Pretreatment of nails with hydrogen peroxide has shown to increase mannitol permeation 3-
fold (62). MedNail® technology consists of the pretreating nail with reducing agent TGA, 
followed by this oxidizing agent UHP. Treatment with this technology increased terbinafine 
drug flux 18-fold (63). 
 
Enhancement by solvents  
 
Water 
The effect of water is recognized in the literature as a key enhancer. As nail hydration 
increases permeability by a mechanism that is thought to be related to swelling and formation 
of larger pores through the keratin matrix, the water content in formulations becomes 
necessary to guarantee maximum drug ungual flux. Gunt et al. (64) reported a several fold 
increase related to nail hydration. Kobayashi et al.(44) also reported the enhancement of nail 
permeation by nail hydration. Notwithstanding, in some cases, nail hydration caused by 
formulation does not seem to improve ungual permeation (38). 
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DMSO 
DMSO is a transdermal enhancer that interacts with the lipid domains of the stratum corneum, 
increasing fluidity and promoting partitioning of drugs into the skin. Stüttgen and Bauer (65) 
reported that DMSO had enhanced the delivery of econazole.  However, DMSO has irritating 
properties at high concentrations.  
 
Keratolytic agents 
Keratolytic agents disrupt the tertiary structure and hydrogen bonds present in the keratin 
matrix, ‘unfolding’ keratin and allowing larger molecules to pass through the nail pores (63). 
Urea and salicylic acid soften and hydrate the nail plate, enhancing drug permeation. This 
type of agents weakens and damages the nail plate (38). Nevertheless, urea cannot induce 
enhanced flux on its own, but it rather acts by synergizing with other enhancers to increase 
permeability. For example, urea combined with N-acetylcysteine increased the ungual 
concentration of itraconazole by 94-, 20- and 49-fold compared with control (no enhancer), 
only urea and only N-acetylcysteine, respectively (38). It was also reported an increase in 
permeation for the concomitant use of urea and MPG. This synergy may be explained by 
easier access of other permeation enhancers during the keratin unfolding by urea. 
Urea has also been used to chemically avulse infected nail at higher concentrations around 
40% (66,67). It has also been included in nail lacquers (68). 
 
Enzymes 
Keratinolytic enzymes hydrolyze the keratin matrix of the nail plate, altering its barrier 
properties and facilitating permeation. Studies have shown that keratinase enzyme markedly 
enhances nail permeation (61). This enzyme affects the surface of the human nail, causing 
corneocytes to detach and lift off the plate corroding the surface. 
Papain is an endopeptidase containing a highly reactive sulfhydryl group and has shown 
promising results as a transungual enhancer (35). 
 
Other enhancers 
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SEPA®), a skin penetration enhancer, has been reported by Hui et al.(69) to increase the 
ungual permeation of econazole. These findings suggest that adding SEPA® to an econazole 
lacquer can increase drug permeation up to 6 times, exceeding the MIC necessary to inhibit 
fungal growth. 
Some formulations contain etching agents which are surface modifiers used to disrupt the 
dorsal surface of the nail to enhance permeation and promote adhesion of films. Phosphoric 
acid and tartaric acid are two etching agents commonly used as enhancers of transungual 
permeation (63). Polyethylene glycols and hydrophobins are other two types of permeation 
enhancers (70,71). Curiously, methanol has also shown some advantages in drug permeation 
(63). 
All the enhancer are summarized in Table 1.1. 
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Enhancer Structure Increase in ungual permeation Experiment setup; permeant (Ref) 
Thiols/Mercaptans 
N-acetylcysteine (5%) 
 
 
49 x increase in nail drug content Nails immersed in drug solution; Itraconazole 
N-acetylcysteine (15%) 
2x increase in mean drug uptake, but not statistically significant. 
Mean residence time in nail plate increased from 4.2 weeks to 5.5 weeks 
Drug was applied twice daily on nail plates of humans 
for 6 weeks; Oxiconazole 
N-acetylcysteine (3%) 
13 x increase in flux from an aqueous formulation; 7x increase from lipidic 
formulation 
Diffusion cells; 5-fluoruracilo 
N-acetylcysteine (3%) Drug measurable in presence but not in the absence of enhancer Diffusion cells; tolnaftate 
Mercaptoethanol 
 
16 x increase in flux from an aqueous formulation; 8 x increase in flux from lipidic 
formulation 
Diffusion cells; 5- fluoruracilo 
Drug measurable in presence but not in the absence of enhancer Diffusion cells; tolnaftate 
Thioglycolic acid  
 
3.8x increase in flux Diffusion cells; caffeine 
Thioglycolic acid  2 x increase in mannitol concentration in receptor medium Diffusion cells; mannitol 
Cysteine 
 
1.7 x increase in mannitol concentration in receptor medium Diffusion cells; mannitol 
N-(2-mercaptopropionyl) glycine 
 
2.5 x increase in flux Diffusion cells; water 
Table 1. 1. Overview of the most referenced transungual permeation enhancers. 
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Enhancer Structure Increase in ungual permeation Experiment setup; permeant (Ref) 
Keratolytic agents 
Hydrogen peroxide  3.2 x increase in mannitol concentration in receptor medium Diffusion cells; mannitol 
Urea hydrogen peroxide 
 
18 x increase in flux Diffusion cells; terbinafine 
Urea 
 
- Human nail; Fluconazole (68) 
Salicylic acid 
 
- (72) 
Sulfites 
Sodium sulfite 
 
2 x increase in permeation through nail clipping Diffusion cells; 5.6-carboxyfluorescein 
Enzymes/Proteins 
Keratinase  2.3 x increase in flux Diffusion cells; Metformin (61) 
Hydrophobins  Up to 3.5x enhancement Diffusion cells; terbinafine (70) 
Etching agents 
Phosphoric acid 
 
Increase in nail roughness score Human nail (73) 
Tartaric acid 
 
Increase in nail roughness score Human nail (73) 
Other 
Pyrithione 
 
Up to 2.5x increase in flux Diffusion cells; water (60) 
2-n-nonyl-1,3-dioxolane  (SEPA®) 
 
7x increase in concentration, 1.3x increase in deeper layer flux Diffusion cell; econazole (69) 
Table 1.1. Continued. 
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3.2 Examples of antifungal drugs  
Table 1.2 represents several antifungal drugs and their main physicochemical characteristics 
that affect the transungual permeation. It should be noted that permeation coefficient and flux 
values were not included as reported in the literature considering that there are different 
methods and protocols to determine them (37). Since these coefficients are dependent on 
many factors, it is more appropriate to understand their values in the literature context. 
The capability of inhibiting fungal proliferation is usually measured by assessing the MIC of 
the drug (74,75). MIC values for antifungal drugs are summarized in Table 1.3. Although 
these values do not take into account some characteristics (keratin binding, pH influence), 
they can serve as guidance (37). 
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Table 1. 2. Antifungal drug properties that influences permeation. Measurement conditions, e.g. base/salt used, medium/solvent composition, pH, ionic 
strength, and temperature are provided in parentheses when available. Adapted from (37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antifungal Drugs Chemical Structure 
Mw 
(g/mol) 
Aqueous solubility (mg/ml) Log P 
log n-octanol/aqueous medium 
distribution constant 
pKa Ref 
Amorolfine 
 
317.5 
9.320 (CS, W, T20) 
9.995 (CS, W, T32) 
8.8 × 10− 3 (CS, pH 7.4 PB, T32) 
5.7 0.33 (CS, W, T20) 6.6 (37,76) 
Bifonazole 
 
310.4 
0.13 × 10− 3 (BS, pH 7.4 PBS, T32) 
0.51 × 10− 3 (BS, pH 8–10 0.1 M NC, T25) 
0.345 (BS, I = 0.02 M pH 7.0 UB, T25) 
4.8 
4.77 
5.2 (BS, 10 mM pH 7.4 PB, RT) 
5.85 (I = 0.01 M UB, 
T25) 
5.72 (0.1 M NC, T25) 
(37,76) 
Ciclopirox 
 
207.3 
12.4 (OS, W, RT) 
8.590 (OS, W, T32) 
1.47 (OS, 5 mM pH 7.0 TB, RT) 
1.020 (OS, pH 7.4 PB, T32) 
0.22 (OS, 0.1 M HCl, RT) 
2 0.53 (OS, 5 mM pH 7.0 TB, RT) 
7.2 
8.07 ± 0.05 (42% v/v 
EW, T32) 
(37,76) 
Clotrimazole 
 
344.8 
2.7 × 10− 3 (BS, pH 7.4 PB, T32) 
0.39 × 10− 3 (BS, W, T25) 
5 4.9 (BS, 10 mM pH 7.4 PBS, RT) 
6.02 ± 0.05 (0.15 M 
KC, T25) 
4.74 ± 0.04 (42% v/v 
EW, T32) 
(37,76) 
Efinaconazole 
 
348.4 Predicted: 0.61 2 - Predicted:7.45-12.7 (37,76) 
Fluconazole 
 
306.3 
5 (BS, W, T23) 
14 (BS, 0.1 M HCl, T23) 
0.4 0.5 (BS, 100 mM pH 7.4 PBS) 
1.76 ± 0.10 (0.1 M NC, 
T24) 
(37,76) 
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Table 1.2.  (continued). 
Antifungal 
Drugs 
Chemical Structure 
Mw 
(g/mol) 
Aqueous solubility (mg/ml) Log P 
log n-octanol/aqueous medium 
distribution constant 
pKa Ref 
Itraconazole 
 
705.63 0.00964 5.7 - 3.70 (37,76) 
Luliconazole 
 
354.3 0.00062 (BS, W) 4 
4.34 (pH 7.16 UB, T20) 
3.78 (pH 4.00 UB, T20) 
4.65 (37,76) 
Tavaborole 
 
151.9 ~ 1.0 1.24 
- 
 
 
 
- (37,76–78) 
Terbinafine 
 
291.43 
2.92 (CS, pH 3 UB, T25) 
1.57 (CS, pH 3 W, T25) 
1.12 (CS, pH 5 W, T25) 
0.101 (CS, pH 5 UB, T25) 
0.02 (CS, pH 6.8 SIF/P, T37) 
1.5 × 10− 3 (CS, pH 9 UB, T25) 
5.6 
6.0 ± 0.1 (neutral form, 0.15 M KC, 
T37) [50]2.3 ± 0.1 (ionized form, 0.15 
M KC, T37) 
5.5 ± 0.1 (calculated for pH 6.8 from the 
two above-mentioned values, T37) 
7.05 (0.15 M KC, T37) (37,70,76) 
Tioconazole 
 
387.7 0.0165 5.3 4.4 6.77 (76) 
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Table 1. 3.  Minimum inhibitory concentration for antifungals used in onychomycosis. (Values displayed in μg/mL, *MIC range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MIC (μg/mL) Amorolfine Bifonazole Butenafine Ciclopirox Efinaconazole Itraconazole Ketoconazole Tavaborole Terbinafine 
D
er
m
a
to
p
h
y
te
s 
T. rubrum 0.004-0.015* ≤0.12-1* 0.015-0.12* 0.031-0.5* ≤0.001–0.015* ≤0.015-0.125* 0.06-0.5* 1-2 0.004-0.06* 
T. mentagrophytes 0.004-0.06* 0.5-4* 0.06-0.12* 0.031-0.5* ≤0.001–0.03* ≤0.015-0.5* 0.5-2* 2 0.004-0.5* 
T. tonsurans 0.25 0.5-2* 0.12 0.25 0.016 0.06-0.25* 0.5-2*  0.015-0.06* 
T. verrucosum 0.12 0.25 0.12 0.13 0.0039 0.12 0.12  0.015 
M. canis 0.06-0.25* 1-2* 0.12 0.25 0.13-0.25* ≤0.015-0.03* 0.25-0.5*  0.008-0.03* 
M. gypseum 0.063-0.25* ≤0.12-8* 0.06-0.12* 0.31 0.010 0.031-0.25* 0.5-4*  0.004-0.06* 
E. floccosum 0.13-0.25* 0.25-0.5* 0.06 0.31 0.005 0.03-0.5* 0.25-0.5* 1 0.015-0.06* 
T. interdigitale         0.017 
N
o
n
-d
er
m
a
to
p
h
y
te
s 
Geo. candidum 1-2* >64 >0.5   1 2-4*  0.12-0.25* 
Scopulariopsis brevicaulis 0.09 2-4 0.5 0.59 0.25 >4 2-4*  0.12 
Aspergillus fumigatus >4 2-4* >0.5 0.42 0.089 0.5-1* 8 0.25 1.4 
Fusarium oxysporum >4 >64 >0.5 1 1 >4 >8  >2.5 
Fusarium solani 4 >64 >0.5 >4 0.5 >4 >8 2 4 
 References (79,80) (79) (79) (80,81) (80) (79,80) (79) (77,78) (79,80,82) 
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Table 1.3. (Continued). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MIC (μg/mL) 
Amorolfine Bifonazole Butenafine Ciclopirox Efinaconazole Itraconazole Ketoconazole Tavaborole Terbinafine 
N
o
n
-d
er
m
a
to
p
h
y
te
s 
Fusarium 
verticillioides 
>64 >64 >0.5   2 2  >0.5 
Acremonium 
potronii 
0.26   0.25 0.31 2.5   0.25 
Acremonium 
sclerotigenum 
1   1.4 0.18 4   0.09 
Aspergillus 
flavus 
4   3.4 0.11 0.18   0.11 
Aspergillus niger 4   0.63 0.2 0.63   0.16 
Aspergillus 
sydowii 
4   0.59 0.037 0.3   0.076 
Aspergillus 
terreus 
4   0.5 0.09 0.21   0.13 
Aspergillus 
nidulans 
4   1 0.0078 0.089   0.063 
Y
ea
st
s 
C. albicans 0.03-0.5*   0.06-0.5* 0.0005-0.25* 0.004-2*  0.5 0.06-16* 
C. glabrata 4.9   0.13 0.026 0.74   8 
C. krusei 0.27   0.21 0.024 0.38   8 
C.parapsilosis 0.56   0.22 0.0046 0.13   0.28 
C. ropicalis 4   0.5 0.014 0.31   8 
C.guilliermondii 0.25   0.25 0.016 0.13   1 
C. kefyr 0.063   0.13 0.002 0.031   2 
C. lusitaniae 0.5   0.25 0.0039 0.13   4 
References (79,80) (79) (79) (80,81) (80) (79,80) (79) (77,78) (79,80,82) 
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3.3 Examples of Topical Pharmaceutical Forms 
Antifungal drugs are formulated in several topical pharmaceutical forms, such as creams, solutions, gels and lacquers (Table 1.4). 
 
Table 1. 4. Topical formulation of antifungal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antifungal Chemical 
Group 
Commercial 
name 
Approved in Fungals Formulation Posology Effectiveness Reference 
Amorolfine Morpholine Loceryl, 
Locetar, Sinibal, 
Unglyfol, 
Curanail 
UK (1991), Switzerland 
(1991), France (1992), 
and more than 50 other 
countries Not approved 
in USA and Canada 
Candida sp, 
Trichophyton sp, 
Microsporum sp, 
Epidermophyton 
5% lacquer 1-2 weekly, 6-
12 months after 
removal of 
affected area 
50% 
mycological 
cure in cases 
of distal 
fingernail and 
toenail 
onychomycos
is 
(37,83–91) 
Bifonazole 
(+40% urea) 
Imidazole Canespor, 
Canesten, 
Mycospor, 
Amypor 
(Onyster, 
Canespro) 
Australia, Portugal, other 
countries 
T. rubrum, T. 
mentagrophytes, 
T. tonsurans, T. 
verrucosum, M. 
canis, M. 
gypseum, E. 
floccosum , 
Scopulariopsis 
brevicaulis, 
Aspergillus 
fumigatus 
1% cream 
(40% urea) 
After ablation 
of the nail with 
40% urea 
cream, 
application 
once daily for 4 
weeks 
33.6% overall 
cure rates 
(37,66,67,77,8
8–90) 
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Table 1.4. (Continued) 
 
 
 
 
Antifungal Chemical 
Group 
Commercial 
name 
Approved in Fungals Formulation Posology Effectiveness Reference 
Ciclopirox Hydroxypyri
done 
derivative 
Mycoster, 
Niogermos, 
Batrafen, Kitonail, 
Ony-Tec, 
Stieprox, Loprox, 
Penlac, Ciclopoli, 
RejuveNail 
France (1991), Germany 
(1992/2008), Austria (1999), 
Canada 
Trichophyton sp, S. 
brevicalis, Candida 
sp, Malassezia 
furfur, Aspergillus 
sp, Fusarium solan 
8% lacquer Once daily, 48 
weeks 
34-46% 
mycological 
cure 
29-36% overall 
cure 
(37,77,83,88–90,92–
94) 
Efinaconazole Triazole Jublia Canada (2013), USA 
(2014) 
T. rubrum, T. 
mentagrophytes, 
Aspergillus sp, 
Candida albicans 
10% topical 
solution 
Once daily for 48 
weeks 
53-55% 
mycological 
cure rate, 15-
18% complete 
cure 
(37,87–90,95) 
Tavaborole Oxaborale 
antifungal 
Kerydin USA (2014) T. rubrum, T. 
mentagrophytes, 
Aspergillus sp, 
Fusarium sp, 
Candida albicans 
5% topical 
solution 
Once daily for 48 
weeks 
31-36% 
mycological 
cure, 6.5-9.5% 
complete cure 
(37,77,87–
90,96,97) 
Tioconazole Imidazole Trosyl, Trosyd Portugal, UK, France and 
30 more countries 
T. rubrum, T. 
mentagrophytes 
28% solution Daily, 3-12 
months 
22% of 
patients 
mycological 
cure 
(3,37,83,88–90,98) 
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Cream 
Creams are semi-solid topical preparations used for delivery of one or more active substances, 
or for their emollient or protective action. The base may consist of natural or synthetic 
substances, being a multiphase preparation with lipophilic and aqueous phases. Lipophilic 
creams have the lipophilic phase as the continuous one, containing water-in-oil emulsifying 
agents at a higher percentage. The opposite is observed in hydrophilic creams. Creams may 
also contain other suitable excipients, such as preservatives, antioxidants, stabilizers, 
emulsifiers, thickeners and penetration enhancers (99–101). 
As reported by Tietz et al. (67), a 1% bifonazole cream used after nail ablation by 40% urea 
paste (Canespor®, Canespro®) was effective in the treatment of onychomycosis. Bifonazole 
is an imidazole antifungal drug, acting by blocking the conversion of 24-
methylendihydrolanosterol to desmethylsterol in fungi as well as inhibiting HMG-CoA (3-
hydroxy-3-methylglutaryl-coenzyme A) and compromising the cell membrane. It is active 
against most dermatophytes, some non-dermatophytes, and molds. This bifonazole cream also 
contained benzylic alcohol, cetostearyl alcohol, cetyl palmitate, octyldodecanol, polysorbate 
60, sorbitan monostearate and purified water (102). The urea paste was applied daily with an 
impermeable bandage until the ablation of the nail was achieved, and then 1% bifonazole 
cream was applied once daily for 4 weeks. At the end, 33.6% of patients were cured 
(55,66,67,79,88–90). 
Lahfa et al. (66) studied the efficacy of using bifonazole and urea in the same formulation 
(Amycor Onychoset®). 
Other cream formulations in the European market include Selergo®, Loprox®, Ertaczo®, 
Avage®, Mycoster®, Locetar® and Fougera® (35,88,89). 
Solution 
Topical solutions are liquid preparations used for the delivery of one or more active 
substances that are solubilized in a suitable vehicle. These formulations are transparent and 
free of visible particles. They may also contain preservatives, antioxidants, stabilizers and 
buffers (99–101). 
Solutions have some advantages compared to other topical formulations (41,42,103). As a 
liquid solution, the formula can be applied to the stratum corneum and subungual space as 
well as on the nail plate surface, and it does not require the patient to posteriorly remove the 
film as necessary for a nail lacquer (103). 
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In the USA market (42,96,104–107), a 10% efinaconazole solution has been recently 
available. This formulation contains 100 mg of efinaconazole per gram and its inactive 
ingredients are alcohol, anhydrous citric acid, butylated hydroxytoluene, C12-15 alkyl lactate 
(co-solvent), cyclomethicone (wetting agent), diisopropyl adipate (co-solvent), disodium 
edetate and purified water. This formulation should be applied once daily for 48 weeks. 
Overall cure rates were reported in 15-18% of patients, being mycological cure rates between 
53-56% of patients studied. Efinaconazole acts by inhibiting the conversion of lanosterol to 
ergosterol in the ergosterol synthesis pathway. It possesses a broad spectrum of activity 
against dermatophytes, non-dermatophytes and yeasts (16,23,37,77,80,83,87,108,109). 
5% Tavaborole solution (Kerydin®) is also available in the United States of American 
market, and it contains ethanol USP, propylene glycol USP and edetate calcium disodium 
USP (41,77). This solution should be applied once daily for 48 weeks. In conducted clinical 
trials, 31-36% mycological cure and 6.5-9.5% complete cure was achieved in patients treated 
with this drug. It shows activity against yeasts, molds, dermatophytes and filamentous fungi. 
It was specially developed for onychomycosis treatment (96,97).  
There is a 28% tioconazole topical solution in the European market (Trosyd®, Trosyl®) 
formulated with undecylenic acid and ethyl acetate (110). It is applied daily for 3-12 months. 
The average overall cure rate is 22%. Nowadays, its use is in decline as other more effective 
antifungal drugs appear on the market (83). 
Naumann et al. (111) describe several formulations, including a topical solution for the use of 
EV-086K, a new antifungal with a high lipophilicity which is not beneficial to transungual 
delivery (111). This solution was formulated by dissolving 5.7% of EV-086K in 30% ethanol 
and 63.75% water, besides the presence of Transcutol®P as solubilizer, 0.05% each of citric 
acid and sodium phosphatemonobasic for pH adjustment and 0.1% of butylated 
hydroxytoluene and, EDTA for chemical stability. The study showed that this formulation 
provided high permeability at the beginning of the penetration process (test in equine hoof), 
but the maximum drug concentration stabilized at 35% in the acceptor phase after 24h. These 
results were not significant compared to other formulations. 
Other topical solutions available in the market are Canespor®, Mycoster®, and Lamisil® 
among others (88). 
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Gel 
Gels are formed by suitable gelling agents and can be classified as lipophilic gels or 
hydrophilic gels. Lipophilic gels (oleogels) usually consist of liquid paraffin with 
polyethylene or fatty oils gelled with colloidal silica, aluminum or zinc soaps. Hydrogels 
(hydrophilic gels) are prepared with water, glycerol or propylene glycol gelled with gelling 
agents such as starch, cellulose derivatives, carbomers and magnesium-aluminium silicates 
(100). 
Although there are some gel formulations in the market (e.g. Lamisil®, a terbinafine 
formulation), they are mostly used for skin fungal infections instead of onychomycosis.  
Along with the cream formulation previously referred, Naumann et al. (111) also studied a gel 
formulation for EV-086K delivery. Hydroxyethyl cellulose gel was formulated with the 
following excipients: 10% of EV-086K, 1.5% glycerol, 1% Tylose and 87.5% water. Among 
other tested formulations, the hydrogel had the less promising results in equine and bovine 
hoof penetration test (only 22% and 15% of applied dose was recovered, respectively), and 
thus it was not evaluated in the human nail. 
Kerai et al. (53) have recently investigated the use of UV-curable gels (currently used in 
cosmetics) for the treatment of onychomycosis. The formulated gels contained diurethane 
dimethacrylate, ethyl methacrylate, 2-hydroxy-2-methylpropiophenone, an antifungal drug 
(amorolfine HCl or terbinafine HCl) and an organic liquid (ethanol or 1-Methyl-2-
pyrrolidone) as drug solvent. Amorolfine was released to a greater extent than terbinafine, and 
even not reaching concentrations as high as the comparative nail lacquer, the concentrations 
were well above the MIC for T.rubrum, the main pathogen for onychomycosis. In addition, 
cured gel formulation could maintain the drug release for longer periods, being a promising 
candidate for future onychomycosis treatment. 
 
Advances in Nail Formulations 
 
Colloidal Carriers 
The literature reports the success of some colloidal carriers for onychomycosis treatment 
since the drug easily diffuses along the skin tissue to the nail bed. Therefore, application to 
the skin surrounding the nail could be an effective area to treat for onychomycosis (112–114). 
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Colloidal carriers or colloidal drug delivery systems are particulates or vesicular dosage 
forms, having a size range from 1 nm to 0.5 μm (Figure 1.5). They are essential for successful 
drug transport and delivery by protecting and maintaining the loaded drug until the site of 
action is reached.  
 
Figure 1. 5. Colloidal carriers for drug delivery. Adapted from (113). 
Along with gel and solution formulations, Naumann also studied a colloidal carrier 
formulation for the delivery of EV-086K, containing water, propylene glycol, emulsifiers 
(Tagat®O2V and Synperonic™PE/L 101) and an oil component (Pelemol® BIP). This 
colloidal carrier system contributed to recovering 7.25 ± 0.30% drug from the nail slices. 
These results were comparable to those obtained with a tested solution and nail lacquer (111). 
Nogueiras-Nieto et al. (115) developed in 2013 an aqueous formulation based on 
polypseudorotaxanes of Pluronic® F-127 and ciclopirox complexed with partially 
methylated β-cyclodextrin. The obtainment of in situ gelling thermosensitive hydrogels was 
due to the presence of the poloxamer Pluronic ®F127 (PF127), which facilitated drug 
solubilization via micelle creation forming a gel upon nail application. Partially mβ-CD was 
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also added to further improve drug solubilization. In addition, a penetration enhancer (N-
acetyl-l-cysteine) alone or in combination with urea was also added to the formulations. 
Ciclopirox was incorporated into three different vehicles–simple aqueous solutions, 
thermosensitive hydrogels, and polypseudorotaxanes thermosensitive hydrogels. The 
composition of these vehicles is presented in Table 1.5. 
 
Table 1. 5. Vehicles composition of CPX nail formulations. Adapted from (115). 
 
 
 
 
 
 
 
 
Recently Yang et al. (113) have developed a gel with transfersomes containing terbinafine 
prepared by ethanol injection method. The final formulation contained terbinafine, 
phospholipids, polysorbate 80, sodium cholesteryl sulfate, anhydrous ethanol, sodium 
benzoate, sodium pyrosulfate and phosphate buffer (pH 5.0). After 12h, it was obtained 88.52 
± 4.06 mg.cm-2 and 94.38 ± 5.26 mg.cm-2 of permeated and penetrated drug, respectively. 
Vaghasiya et al. (116) studied another formulation composed of solid lipid nanoparticles for 
sustained release and skin targeting of terbinafine for the treatment of onychomycosis. The 
terbinafine loaded solid lipid nanoparticles formulation consisted of Compritol® 888 ATO as 
lipid matrix, Pluronic® F-127 as a stabilizer and distilled water as a dispersion medium, and 
prepared by the solvent injection technique. It was observed 40.57 ± 1.76% of the applied 
drug retained in the skin after 8h (116). 
Terbinafine in transfersome 067 is a carrier -based liquid spray that has been developed for 
the delivery of terbinafine to the nail bed to treat onychomycosis. A 2011 study demonstrated 
that Terbinafine in transfersome 067 had greater antifungal activity against onychomycosis 
caused by dermatophytes compared to the free form vehiculated in an oral formulation (117). 
This formulation has also been tested in clinical trials (118).  
Name Solvent 
AC  
(%) 
PF127 
(%) 
Mβ-
CD 
(%) 
CPX–N-acetylcysteine solution (CPX–AC) Water 10 – – 
CPX–thermosensitive hydrogel (CPX–TH) Water 10 20 – 
CPX–polypseudorotaxanes thermosensitive 
hydrogel (CPO–PPR) 
Water 10 20 10 
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There is another study with terbinafine -loaded liposomes formulation composed of 
bioadhesive polymers, pullulan, and Eudragit®L100, and prepared by thin film hydration 
method. This formulation also showed interesting results (119). 
Barot et al. (120) studied a microemulsion-based gel containing terbinafine, oleic acid, 
Labrasol, Transcutol, water and Carbomer 934P. This formulation was developed to be 
applied between the nail bed and nail plate generated by onycholysis. It was obtained 49.3% ± 
4.12% drug retention in the skin, and the total amount of terbinafine permeated after 12h was 
244.65 ±18.43 μg.cm−2. In 2012, Barot also described a microemulsion based antifungal gel 
incorporating itraconazole (120). 
Barot et al. (121) developed a gel microemulsion containing itraconazole for the topical 
treatment of onychomycosis. The microemulsion contained benzyl alcohol, isopropyl 
myristate, Pluronic F68 (surfactant), ethanol, double distilled water and itraconazole. The 
microemulsion was incorporated into a gel by adding Carbomer 934P. Nail permeation 
enhancers like urea and salicylic acid were also used to increase drug penetration through the 
nail plate. The optimized formulation showed promising results: 92.75% drug entrapment 
efficacy and a complete drug release in 60 min with a highest nail uptake of 0.386%/mm2 (39 
mg drug) (72). 
Angamuthu (122) described the study of poly (lactide-co-glycolide)) microspheres for the 
controlled release of terbinafine administered by intralesion injection. These microspheres 
were developed using O/W emulsification and modified solvent extraction/evaporation 
technique with methylene chloride, and methanol. This formulation achieved controlled 
release through 30 days and proper deposition onto the nail bed and plate. 
Another microemulsion-based gel was studied by Kumar et al. (123). This gel contained 
fluconazole (against Aspergillus niger), oleic acid, polysorbate 80, propylene glycol and 
water. It exhibited an in vitro drug release of 72.23% in 7h. 
 
4. Nail Lacquer in onychomycosis therapy 
Nail lacquers have been used for a long time in cosmetics, with both protective and decorative 
purposes. In the 1990’s decade, nail lacquers started being used to administer drugs to the nail 
unit. Nail lacquers are solutions of film-forming polymers which leave a polymer film on 
the nail plate after solvent evaporation. This polymer film can be water resistant or water 
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soluble and acts as a drug reservoir, allowing it to permeate through the nail plate. Depending 
on the formulation and drug, the lacquer can be removed either mechanically or with organic 
solvents after a certain time, and it should be reapplied to reestablish the drug pool. Thus, the 
duration of the film residence in the nail constitutes an important property of a lacquer 
formulation (124). Although these formulations are commonly applied with a brush, there are 
also other types of applicators such as spatulas and sponge tips. 
Being occlusive and adhesive to the nail, nail lacquers’ films have advantages regarding nail 
hydration, permanence on the nail plate and patient compliance (when compared to creams, 
gels, and solutions).  
These preparations usually contain the intended drug, a polymer, a volatile solvent and 
suspension agents (56,91,125).  
The drug should present the following properties: a) low MIC for pathogens causing the 
disease (dermatophytes, yeasts, etc.), being effective at low concentrations; b) low molecular 
weight and volume to better permeate through the keratin matrix pores; c) water soluble, since 
water easily permeates through the matrix vehiculating the drug; and d) affordable and easily 
obtainable, so that the nail lacquer can be easily produced and obtained by patients (61). 
The polymer choice can also influence the nail lacquer quality. Hydrophilic polymers have 
advantages regarding permeation and adhesion to the nail plate, having a soft, flexible and 
matte finish, which can improve patient compliance. However, these polymers allow more 
drug loss and are less occlusive. Hydrophobic polymers have a more durable, harder and 
glossier finish. This contributes for a more occlusive lacquer which can compromise the 
cumulative amount of permeated drug. Employing both types of polymers seems to be a good 
approach since it will combine both excellent permeation characteristics and higher resistance 
to environmental drug loss (126). 
Effective formulations usually include permeation enhancers such as thiols/mercaptans, 
keratolytic agents, keratinases, etc. Other excipients can also be critical to allow better 
permeation conditions, including hydration, pH, and solubility. This can be achieved by using 
plasticizers, humectants, solvents, solubilizers, etc (127). 
Colorless and non-glossy medicated nail lacquers are more acceptable by male patients (39). 
Despite male patient compliance, it could be considered advantageous for female patients to 
formulate a colored medicated nail lacquer for the treatment of onychomycosis since this 
disease alters the normal appearance of the nail. 
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After screening for the most suitable formulation components, it is important to check their 
compatibility and progressively adjust the quantities through pre-formulation studies.  
There are several parameters to be evaluated in nail lacquer formulations to assess a higher 
quality, such as drug content, drug permeation studies (permeation coefficient, flow, the 
cumulative amount of permeated drug); gloss; flow; film adhesivity; viscosity; pH; drying 
time; non-volatile content, etc. According to this quality control, nail lacquers must present 
the final properties: a) be physically and chemically stable; b) release therapeutic levels of 
drug onto the nail; c) have a suitable viscosity to freely flow into all the edges and grooves of 
the nail for easy application; d) dry quickly (3-5 minutes) and form an even film once applied; 
e) adhere to the nail plate to not come off or flake during daily activities, but at the same time, 
be easily removed with an enamel remover and f) be cosmetically pleasant and well tolerated 
(38).  
Several examples of nail lacquer formulations for onychomycosis treatment are presented in 
Table 1.6. However, only nail lacquers containing amorolfine and ciclopirox are currently 
commercialized (39).  
Amorolfine is a morpholine antifungal agent approved for the treatment of onychomycosis in 
1981 (128). It is usually presented as a nail lacquer containing 5% amorolfine. This active 
substance inhibits delta14 reductase and delta7-delta8 isomerase, causing ergosterol depletion 
and ignosterol accumulation in the cytoplasmatic membrane of the fungus cell. Amorolfine is 
effective against dermatophytes (Trichophyton spp., Microsporum spp., Epidermophyton 
spp.), yeasts (Candida spp., Cryptococcus spp., Malassezia spp.) and some molds (Alternaria 
spp., Hendersonula spp., Scopulariopsis spp.). Amorolfine can be present in the nail up to 
27% from the nail lacquer formulation after 2 weeks treatment, being this concentration 
enough to inhibit most fungi. This formulation should be applied once or twice weekly for 6 
months. Studies report mycological cures in 52-60% of the patients, and complete cures (both 
clinical and mycological) up to 44% of patients (54,77). Even after apparent cure, some 
authors recommend the use of amorolfine as prophylaxis (129). Amorolfine is available in 
Europe (e.g. Loceryl®, Locetar®, Curanail®), but not in USA (77,89–91,130). 
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Table 1. 6. Nail lacquer formulations. 
 
 
Drug Commercial name Polymer Solvents & other excipients Ref. 
Econazole 
 Butyl methacrylate, 
dimethylaminoethyl 
methacrylate, methyl 
methacrylate polymer 
2-n-nonyl-1,3-dioxolane 
Ethanol 
(69) 
Ciclopirox 
 
 
Hydroxypropyl chitosan (HPCH) 
Cetostearyl alcohol 
Ethyl alcohol (95°) 
Ethyl acetate 
Purified water 
(131) 
Ciclopoli® 
Hydroxypropyl chitosan (HPCH) 
Ethyl acetate 
Ethanol 96% 
Cetostearyl alcohol 
Water 
(126) 
 
Pluronic F127 
Partially methylated β-cyclodextrin 
N-acetyl-l-cysteine 
(115) 
Mycoster® 
Methylvinyl ether 
Ethyl acetate 
Isopropanol 
Maleic acid monobutylester 
(128) 
Fluconazole 
 
Polyvinylpyrrolidone K25 
Glycerol triacetate 
Docusate sodium 
Urea 
Ethanol 
Demineralized water 
(68) 
Tavaborole 
 Poly (vinyl methyl ether alt maleic acid 
monobutylester) 
Ethanol 
(78) 
 Poly (2-hydroxyethyl methacrylate) Ethanol 
Dibutyl sebacate 
Water 
 
 Poly (vinylacetate) Ethanol 
Ethyl acetate 
Dibutyl sebacate 
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Table 1.6. (Continued) 
 
 
Drug Commercial name Polymer Solvents & other excipients Ref 
Terbinafine 
 
 HPMC E-15 
PEG 400 
Ethanol 
Purified water (132) 
 Poly (4-vinyl phenol) Ethyl acetate 
Dibutyl phthalate 
Triethyl citrate 
Hydroxypropyl-β-cyclodextrin 
Isopropyl alcohol 
Acetone 
 
Cellulose acetate 
Ethyl cellulose 
(57) 
Ketoconazole 
 
 
Propylene glycol 
PEG 400 
Glycerin 
Urea hydrogen peroxide 
Ethanol 
Thioglycolic acid 
 
(133) 
 
Polysilicone-8 
Acrylates copolymer 
Ethanol 
Panthenol 
Tocopheryl acetate 
Phytantriol 
Butylene glycol 
Benzophenone-3 
Calcium chloride 
Fragrance 
(134) 
Miconazole 
 Nitrocellulose 
Propylene glycol 
Urea hydrogen peroxide 
Salicylic acid 
Ethanol 
 
Transcutol® P 
Ethanol 
 
(135) 
EV-086K 
 
Eudragit® E100 (111) 
Amorolfine 
 
 
Loceryl® 
Metacrylic acid 
copolymer 
Glycerol triacetate 
Butyl acetate 
Ethyl acetate 
Ethanol 
(110) 
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Ciclopiroxolamine belongs to the group of hydroxyl-pyridone derivatives, and it has been 
used as a nail lacquer to treat onychomycosis since 1990. It exerts its antifungal activity by 
chelating trivalent cations, like Fe3+ and Al3+, compromising fungal metal-dependent enzymes 
and reducing the fungus nutrient intake. Ciclopirox is active against dermatophytes 
(Trichophyton spp., Microsporum spp., Epidermophyton floccosum), yeasts (Candida spp., 
Malassezia furfur, Cryptococcus neoformans, Sacchromyces cerevisiae), molds (Aspergillus 
spp., Scopulariopsis brevicaulis, Fusarium solani) and some bacteria, which is advantageous 
in cases of mixed infection. It is also reported to have some anti-inflammatory activity by 
inhibiting the local production of prostaglandins and leukotrienes. The nail lacquer available 
in the market has a concentration of 8% ciclopirox, which increases to 35% after application 
and evaporation of the volatile solvents. Studies show that it can exceed MIC for the three 
most important onychomycosis pathogens–T.rubrum, T. mentagrophytes, and Candida 
albicans. Common posology is once daily application for 6-12 months over the clean nail 
plate and slightly over the surrounding skin. However, there are trials stating that once the 
weekly application is effective. Clinical trials have reported complete cure in 29-36% of 
patients. Ciclopirox is available in both Europe and United Stated of American: Mycoster®, 
Niogermos®, Batrafen®, Kitonail®, Onytec®, Stieprox®, Loprox®, Penlac®, Ciclopoli® 
and RejuveNail® (77,83,88–94). 
Besides these main drugs, others have been recently studied as well as specific excipients as 
follows. 
Monti et al. (131) purposed to evaluate the water-soluble film forming agent hydroxypropyl 
chitosan included in an experimental nail lacquer (P-3051) containing ciclopirox. 
Hydroxypropyl chitosan is a water-soluble derivative of chitosan. Chitosans are 
polysaccharides derived from chitin and natural components of the exoskeleton of crustaceans 
being widely employed in medicine for their wound healing, bacteriostatic, skin moisturizing, 
and protecting properties. In particular, hydroxypropyl chitosan was chosen considering its 
favorable properties, such as high water solubility; high plasticity; affinity to keratin; wound-
healing activity; high compatibility with human tissues, etc. P-3051 was composed by 1% 
hydroxypropyl chitosan, 1% cetostearyl alcohol, 73% ethyl alcohol (95°), 4% ethyl acetate 
and 13% purified water. This formulation was compared with a commercial brand (Penlac™) 
constituted by 8% ciclopirox, ethyl acetate, isopropyl alcohol, butyl monoester of poly 
(methylvinyl ether/maleic acid) in isopropyl alcohol. Bovine hoof membranes were used as 
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the human nail plate model. Drug concentrations were determined by HPLC (high-
performance liquid chromatography). Regarding lag times, the respective values obtained 
were 3.36±0.46 h for P-3051 vs. 12.48±1.31 for Penlac™. The percent of permeated drug 
(Q%30h) was also significantly different for the two formulations: 2.58% for P-3051 vs. 
1.06% for Penlac™. In fact, a faster drug penetration time might allow the drug to permeate 
the nail before the hydro soluble film is degraded. Greater efficiency of P-3051 could be 
attributed to a affinity of hydroxypropyl chitosan to the nail matrix, resulting in an intimate 
contact and strong adhesion of the lacquer to keratin substrate (131).  
An in vitro study with the formulation previously developed by Monti et al (131) reported an 
achievement of 13% complete cure rate, which was quite low. It was concluded that 
ciclopirox formulated in the new hydrolacquer technology is more active and better tolerated 
than the reference ciclopirox nail lacquer for the long-term treatment of onychomycosis. In 
addition, it is much easier to apply without needing any bothersome removal procedures 
(136). 
In 2009, Monti et al. compared the transungual permeation of ciclopirox with amorolfine 
vehiculated in the same hydroxypropyl chitosan-based lacquer and a water insoluble 
reference (Loceryl® containing Eudragit® RL100, triacetine, butyl acetate, ethyl acetate, 
ethyl alcohol and drug). The study was performed on bovine hoof slices, and drug 
concentration was determined by HPLC. Amorolfine experimental lacquer showed higher 
permeation than the commercial water-insoluble option. Also, ciclopirox lacquers showed a 
better performance than amorolfine lacquers (114). 
Later in 2012, a clinical trial with these formulations was conducted (56). The results 
supported in vitro data except from day 15 to day 25 in which the nail concentration of these 
drugs decreased. The authors hypothesized that the steady state had not been reached yet. 
Moreover, in vitro studies do not take into account all the environmental interactions that 
occur under in vivo conditions where both fingers and toenails are constantly exposed to 
tissues, liquids, and blood circulation, resulting in some drug loss. This may be a disadvantage 
for water soluble formulations since the contact with water can lead to a loss of medication; 
however, it can be countered by a more frequent application (56).   
Chouhan et al. (57) studied the influence of a permeation enhancer hydroxypropyl-β-
cyclodextrin in a terbinafine nail lacquer formulation. This formulation was composed of 
cellulose acetate and ethyl cellulose as film forming polymers, triethyl citrate as a plasticizer, 
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and isopropyl alcohol and acetone as solvents. Formulations containing this enhancer 
demonstrated a higher flux than the control formulation in in vitro studies. The lacquer 
containing 10% (w/v) hydroxypropyl-β-cyclodextrin showed maximum flux of 4.586± 0.08 
µg/mL/cm2 as compared to the control flux of 0.868 ± 0.06 µg/mL/cm2, demonstrating its 
ability to enhance the transungual permeation of poorly soluble drugs (57). 
A ketoconazole nail lacquer for onychomycosis treatment was also described by Kiran et al. 
in 2010 (122). The studied formulations contained ketoconazole, propylene glycol, glycerin, 
ethanol, polyethylene glycol 400, thioglycolic acid and urea solution in H2O2. Several factors 
were evaluated including non-volatile content, drying time, smoothness of flow, gloss and 
permeation studies in human nail plates. Urea hydrogen peroxide enhanced hydration state 
and thioglycolic acid cleaved keratin bonds, allowing better penetration results which could 
be promising upon formulation optimization (133).  
In 2011, a novel lacquer formulation for the transungual delivery of ketoconazole was 
reported by Hafeez et al. The vehicle used had an anhydrous/alcohol composition with a dual 
acrylate-silicone hybrid copolymer system that offered film forming and occlusion properties 
due to synergistic plasticizing components (134). It contained ethanol, polysilicone-8, 
panthenol, acrylates copolymer, tocopheryl acetate, phytantriol, butylene glycol, 
benzophenone-3, calcium chloride and fragrance, as well as radiolabeled [1-14C]-
Ketoconazole. This test formulation was compared with a commercial ketoconazole cream. 
The study was conducted on human nails placed in a diffusion cell simulating physiological 
conditions. The formulations were then administered once daily for 7 days. Sampling was 
made by drilling and radioactivity was measured from the samples obtained. Following the 7-
day exposure, the ketoconazole content measured in the ventral/intermediate layers was 0.81 
± 0.39 µg/mg or 535 ± 260 µg/cm3 for the lacquer formulation and 0.09 ± 0.05 µg/mg or 53 ± 
29 µg/cm3 for the control formulation. The drug concentration attained in the nail was 
approximately 2,140 times higher than the MIC for common dermatophytes, exceeding the 
MIC for most common onychomycosis pathogens. According to these results, this lacquer 
formulation can be a potential effective topical treatment for onychomycosis (134). 
Hui et al. (69) assessed the enhancing properties of 2-n-nonyl-1,3-dioxolane in a lacquer 
formulation (EcoNail™) to increase the permeation of econazole. The test formulation 
contained 5% (w/w) econazole, Eudragit® RL/PO, ethanol and 18% (w/w) 2-n-nonyl-1,3-
dioxolane. The assay was performed on healthy human nail plates collected from cadavers 
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and using a diffusion cell. An aliquot of all tested formulations was applied on the nails twice 
daily for 14 days, washing the nail plates between applications. After incubation, nail samples 
were obtained with a drill and radioactivity of labeled compounds was measured. The 
concentration and flux of econazole into the deep layer of the human nail in the test group 
was about 6.3-fold and 7.5- fold higher than the control group, respectively. Econazole 
concentration was about 15,000 times the MIC for most dermatophytes species and 150 times 
that for most molds. On the contrary, dioxolane did not penetrate to deeper layers of the nail. 
These authors hypothesized that besides facilitating diffusion of the drug, dioxolane also 
functioned as an adhesion promoter and plasticizer for the film-forming polymer, softening 
the Eudragit film in the lacquer. These results suggest that 2-n-nonyl-1,3-dioxolane-enhanced 
econazole lacquer has the potential to be an effective topical treatment for onychomycosis 
(69). 
The same author performed another study (78) in which reported the nail penetration of 
tavaborole (AN2690) from different vehicles and compared with ciclopirox. Four 
formulations, all containing 10% (w/w) AN2690 were compared for their ability to deliver 
AN2690 to the deep layers of the nail plate and into the nail bed. The composition (w/w) of 
these different vehicles was: formulation A: 70% ethanol and 20% poly (vinyl methyl ether alt 
maleic acid monobutylester), a polymer that forms a water insoluble film, very durable and 
resistant to damage; formulation B: 56% ethanol, 14% water, 15% poly (2-hydroxyethyl 
methacrylate) and 5% dibutyl sebacate, forming a water soluble film; formulation C: 55% 
ethanol, 15% ethyl acetate, 15% poly (vinylacetate) and 5% dibutyl sebacate, forming a water 
insoluble film that can be removed by peeling or scratching the surface; formulation D: 20% 
propylene glycol and 70% ethanol (only solvents). Aliquots of those formulations were 
applied on human nail plates once daily for 14 days. The ventral/intermediate nail samples 
were collected at the end of the 14th day dose period, stored at 4°C and analyzed for drug by 
LC/MS/MS. Considering that any formulation showed a distinct advantage over the others, 
the simplest formulation (D) was chosen for further development (78). 
Baran et al. (68) evaluated the efficacy of a fluconazole-urea nail lacquer in onychomycosis 
treatment of 13 patients. The lacquer was composed of 1% fluconazole, 20% urea, 
polyvinylpyrrolidone k25, glycerol triacetate, docusate sodium, ethanol and demineralized 
water. After 12-18 months’ treatment, about 90% of patients had positive results regarding 
clinical and mycological cure (68).  
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A terbinafine bilayered nail lacquer for onychomycosis was developed by Shivakumar et 
al. in 2010. Since aqueous-based nail lacquers promote nail hydration and drug diffusion 
through the nail but lack durability, the authors studied an underlying drug-loaded hydrophilic 
lacquer with an overlying water resistant film. The hydrophilic nail lacquer was composed of 
5% (w/v) terbinafine, 6% (w/v) hydroxypropyl chitosan E-15 (water soluble polymer), 10% 
(v/v) PEG 400 (penetration enhancer, plasticizer and humectant), 60% (v/v) ethanol and 19% 
purified water. Formulation controls as a hydrophilic nail lacquer of E-15 containing 
terbinafine but devoid of PEG 400 and a placebo (formulation without the active drg) 
hydrophilic lacquer of hydroxypropyl chitosan E-15 containing PEG 400 were similarly 
prepared for comparison. Briefly, terbinafine was dissolved in a mixture of water and ethanol 
(pH 3.0) by a bath sonicator. Hydroxypropyl chitosan E-15 was soaked overnight in the 
hydroalcoholic mixture (pH 3.0) and sonicated to ensure complete polymer dissolution. The 
two hydroalcoholic solutions were mixed and stirred to obtain a clear homogeneous solution 
to which PEG 400 was added. The hydrophobic nail lacquer was prepared by dissolving poly 
(4-vinyl phenol) in ethyl acetate at 10% (w/v). Dibutyl phthalate was used as a plasticizer in 
the lacquer at 4% (v/v). The pH, viscosity and drying time of the hydrophilic nail lacquers 
were found to be around 4.0, 500 cps, and 300±75s, respectively. In vitro drug permeation 
studies were performed with cadaver nails. Although therapeutic concentration values were 
reached in in vitro studies, a clinical study on infected patients should be performed to 
ascertain clear results (132).  
Vipin et al. (135) presented in 2014 a miconazole nail lacquer. This formulation included a 
film former (nitrocellulose), permeation enhancers (urea in hydrogen peroxide and propylene 
glycol), a keratolytic agent (salicylic acid) and an antifungal agent (miconazole nitrate) in 
ethanol. Several formulations were tested regarding nonvolatile content, gloss, smoothness to 
flow, drug release (bovine hoof model), drug content (UV spectrophotometry) and antifungal 
activity. Among ten formulations, the nail lacquer prepared with 2% drug, 3% nitrocellulose, 
0.5% ethyl cellulose, 20% salicylic acid, 5% propylene glycol and 5% urea in H2O2 exhibited 
the best results, being a promising formulation for the treatment of Candida albicans (135). 
Naumann et al. (111) studied the controlled delivery of EV-086K nail lacquer through the 
nail plate. 5% Eudragit® E100, dimethylaminoethyl methacrylate, butyl methacrylate and 
methyl methacrylate were mixed with 85% ethanol and stirred until the polymer was 
completely dissolved. 5% EV-086K and 5% Transcutol® P were stirred in a separate amber 
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glass until a clear solution was obtained. Then, the polymer–ethanol mixture was added. 
Bovine hoof slices, equine hood slices, and human nails were employed for delivery studies. 
This nail lacquer penetrated into the nail at higher concentrations than other studied 
formulations. However, it did not reach the acceptor compartment (111).  
 
5. Polyurethane a potential excipient in therapeutic nail lacquer 
The polyurethanes (PU) are among one of the most important class of specialty polymers 
(137)). They are obtained by the reaction between isocyanate and hydroxyl compounds (138). 
The polyurethane production was developed by Otto Bayer and co-workers in 1937 (139) for 
the polyaddition reaction. Since then the polyurethanes have found many different 
applications and the polyurethanes market has been growing uninterruptedly (140). 
Polyurethanes are polymers containing urethane linkages (–NHCOO–) in the main polymer 
chain. They can be classified into the following major groups: flexible foams, rigid foams, 
elastomers, fibers, molding compositions, surface coatings and adhesives (137). 
 
5.1 Synthesis of polyurethane 
Polyurethanes are synthesized from three components, namely a polyol (polyglycol), a 
diisocyanate and a chain extender (diol) as shown in Figure 1.6. 
 
 
Figure 1. 6. Scheme of Synthesis of polyurethane adapted from (141). 
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They present a segmented architecture, where in the diisocyanate and the chain extender (diol 
of low molecular weight) form the hard segments of the polymer chain and the polyol  of high 
molecular weight (interception sections) form the soft segments as represent the Figure 1.7. 
 
 
Figure 1. 7. Architecture of the chain of polyurethane. Adapted from (142) 
 
 The hard and soft segments of the polyurethane are responsible for the wide range of 
elastomeric properties presented by this polymer. The soft segments, owing to their low glass 
transition temperatures are responsible for the elasticity of the polyurethane. However, the 
hard segments make the polymer stiffer due to the presence of inter-chain hydrogen bonds 
between the hard segment in the polymer. The hydrogen bonding causes the hard segments to 
pack themselves into crystalline domains which function as physical crosslinks between the 
polymer chains.  
For the producing a material with a broad range of mechanical properties which is both elastic 
and strong, the architecture of the polymer is modulated by variations such as:  
 
•  The ratio of the hard segment to the diol. 
•  The choice of the hard segment and soft segment components (139).  
 
5.2 Monomers for the synthesis of polyurethanes 
Polyglycols of high molecular weight 
 
Convenient long chain polyglycols such as polyethylene oxide diols, linear or ramified, and 
polyester diols are used as monomers for the synthesis of PU (137,138,139) (Table 1.7). 
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Table 1. 7. Polyglycols employing in synthesis of polyurethanes. 
Polyglycols Chemical structure 
Poly (tetramethylene oxide)  
Poly (propylene glycol)  
Poly (ethylene glycol) 
 
Poly (dimethyl siloxane) 
 
Poly ε-caprolactone 
 
 
Diisocyanates  
 
In order to obtain non-toxic polyurethanes, the diisocyanates (138,139), employing are 
representing in Table 1.8.  
 
Table 1. 8. Name, toxicity and chemical structure of diisocyanates. 
Diisocyanates LD50(mg/Kg) Chemical structure 
HMDI 9 900 
 
IPDI 1000 
 
LDI Value no relevant 
 
HDI Value no relevant 
 
MDI 2 200 
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Chain extenders 
  
Carbohydrates are frequently employed as chain extenders in the architecture of the polymer. 
Some examples of the synthesis of polyurethanes from a renewable source (143) are shown in 
Table 1.9. 
 
Table 1. 9. Carbohydrates employed as chain extender in the synthesis of polyurethanes. 
 
Chain extender Chemical structure 
Sucrose 
 
Fructose 
 
Glucose 
 
Galactose 
 
Lactose 
 
 
Maltose 
 
Sorbitol 
 
Isosorbide 
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Catalysts 
 
Currently, the flexible polyurethanes are made with the aid of at least one catalyst (139). They 
ensure the completion of the reaction in the polyurethane. Catalysts controlling the reaction 
time and for defining polymer architecture that influences the ultimate mechanical properties. 
Specifically, it is the catalyst’s activity and selectivity towards each of the many reactions 
occurring in the formation of polyurethanes that determine the structure of the resulting 
material. The amine and organometallic are among the most used catalysts employing in the 
synthesis of polyurethane, which  showed in Table 1.10.  
 
Table 1. 10. The most common catalyst in synthesis of polyurethane. 
 
Catalyst Structure       Class        
Dibutyltin dilaurate 
 
     Organometallic 
Tin(II) 2- ethylhexanoate Sn 
 
     Organometallic 
Bismuth 2- ethylhexanoate 
Bi 
 
     Organometallic 
DMDEE 
 
 amine     
DABCO 
 
Amine 
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5.3 Methods for synthesis of polyurethanes 
The polyurethanes are synthesized by three methods: 
• the one-shot method,  
• the prepolymer method,  
• the quasi-prepolymer method (144).  
 
The prepolymer method and the quasi-prepolymer method correspond to processes known as 
‘two-step methods’ or ‘two-step polymerization’. 
 The one-shot method is a process that takes place in one step. All the ingredients are mixed 
simultaneously, and the resulting mixture is allowed polymerize. 
In the prepolymer method, the macroglycol is pre-reacted with an excess of poly-isocyanate.  
This prepolymer is then mixed with the rest of the ingredients during processing. 
In the quasi-prepolymer method, a part of the diol is mixed with the isocyanate and the rest 
of the polymer and the other constituents are mixed as a second phase. 
In the pre-polymer process, the free content of isocyanate result of the reaction between the 
diisocyanate and polyol is about 1-12%. On the other hand the quasi-prepolymer present 
generally more that 25% of free isocyanate, in this process the NCO/OH ratio is 4:1, to yield a 
low viscosity system consisting of a pre-polymer dissolved in excess of isocyanate (137). 
 
 Advantages of quasi-prepolymer. 
- Allows maintain better control the structure and properties of the final polymer. Through a 
simple change of chain extender, it is possible to obtain polyurethanes with different 
properties from the same pre- polymer. 
 - The pre- polymers are typically liquids, which facilitates handling on an industrial scale. 
 - When compared with monomeric isocyanate systems, the prepolymers have a lower vapor 
pressure and consequently lower toxicity.  
- The viscosity of the prepolymers is higher than that of the monomeric isocyanates, which 
allows a better homogenization when mixed with the polyol and better control of the 
rheological properties when trying to lose fluidity. 
 - Allows better temperature control because the resulting heat bond formation is released in 
two stages (145). 
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5.4 Synthesis of polyurethanes from carbohydrates 
Kennedy et al, 1986 describe preparing polyurethanes from carbohydrates such as pectin and 
sucrose, one amine was employing as a catalyst. The syntheses were developed from 
polyisocyanates at temperatures above 60 °C, yielding highly crystalline polymers (146). 
Polyurethanes from prepolymers were obtained using different amounts of milliequivalents 
sucrose, glucose, and fructose which reacted with MDI and PEG. In the polyurethanes 
obtained was observed that the increasing of the content of saccharides influence in values of 
glass transition temperature (Tg), Young's modulus and tension stress. The synthesis of the 
prepolymer and polyurethane were developed at 25 ° C without solvent (147). 
They have been reported polyurethanes employing glycosylamines and glucosamines 
modifications. Only modified near the anomeric hydroxyl group, being the most reactive. 
Hexamethylene diisocyanate (HDI) and 2,5 dianhydro -2,5 -dideoxy - L- iditol - diisocyanate 
is used. The polymers were soluble in dimethylformamide, and their molecular weights were 
between 53 655-75 300, (148). 
In 2001, were proposed two polyurethanes obtained from partially protected carbohydrates. 
They developed reactions of HDI with methyl 2,6-di- O- pyranosyl - α - D - glucopyranose 
and methyl 4,6-O- benzylene - α -D - glucopyranose, in the ratio 1: 1, using 1,4- diazabicyclo 
catalyst (2,2,2) octane. Tetrahydrofuran was used as a solvent in the reaction, obtaining 
polyurethanes with values of Tg between 147-150ºC (149). 
According to polyaddition catalytic process, polyurethanes using monomers D- Sorbitol, L - 
iditol and D - mannitol were synthesized. The method was developed at 80 oC, with a stream 
of nitrogen (143). 
In 2005 was synthesized a polyurethane from sucrose and PEG 600 and 1000. The polymer 
was not toxic (151). According to acute oral toxicity test, the administration of the 
polyurethane did not  present  any clinical signs in any of the animals treated or damages in 
the organs analyzed, which suggest that the polyurethane was a safe product (150). 
In 2013 Aurelie Boyer and collaborates, synthesise a linear polyurethane from 
transesterification of sucrose and α-d glucopyranoside. In the research was employing dibutyl 
tin dilaurate as catalyst (151). 
The synthesis of the linear polymer has many applications in research of Vicent Besse et al, 
the aim of the work was obtaining a polyurethane with higher chemical and hydrolysis 
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resistance. The polyhydroxyurethane was obtained by reaction of isosorbide, hydroxylated 
polybutadiene and methylene diphenyl-4,4 diisocyanate (152).  
Another example of the synthesis of polyurethanes from carbohydrate was the polyurethane 
synthesized from the reaction of hexamethylene diisocyanate and various ratios of isosorbide 
to poly(tetra methylene glycol) by one-shot bulk polymerization without a catalyst. The rigid 
diols impart biocompatible and bioactive properties to thermoplastic polyurethane elastomers. 
The degradation test showed loss of mass in the polyurethane from 4–9% after 8 weeks. In the 
case of polymers with lowest isosorbide content, the weight loss was in a short time compared 
with polyurethane that present highest isosorbide content (153).  
The L-lactide is another carbohydrate to permit synthesized biodegradable crosslinked 
polyurethane using polyethylene glycol and hexamethylene diisocyanate (HDI). In the 
reaction, the iron acetylacetonate was using as catalyst (154).  
 
5.5 Application of polyurethane in biomedical industry 
The polyurethanes are copolymers which have been used for biomedical applications for over 
three decades.  
These desirable properties attract the attention of developers of biomedical devices. In 1958, 
polyurethane materials were first introduced in biomedical applications; Pangman described a 
composite breast prosthesis covered with a polyester-urethane foam (155). In the same year, 
Mandrino and Salvatore also used a rigid polyester-urethane foam called OstamerTM for in 
situ bone fixation (156).  
Three years later, the application of polyester-urethane Polyurethane Estane® VC was 
proposed by Dreyer et al to be used as components for heart valves and chambers, and aortic 
grafts (157). In the mid-1960s, Cordis Corp. started to commercialize polyester-urethane 
diagnostic catheters (137). 
 In 1954, textile chemistry at DuPont developed Lycra® spandex as a high-performance 
alternative to natural rubber in elastic thread. It was first introduced as a biomaterial in 1967 
by Boretos and Pierce who obtained the polymer in solution directly from the DuPont 
spinning line that produced Lycra spandex yarn. This material was first used as the 
elastomeric components of a cardiac assist pump and its arterial cannula (156). 
The years 1970-1972, were a time of designed of polyurethane specifically commercialized 
for medical use; Avcothane®-51TM, a polyurethane/silicone hybrid, Biomer®TM, a version 
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of Lycra® T-126. Avcothane® and Biomer® were regarded as the first ‘real’ biomedical 
polyurethanes, where some of them (156). Avcothane® was used clinically in the first intra-
aortic balloon pump (IAB), starting in about 1971, and is still in clinical use today in 
IABs(90). Biomer®TM components were used in the ‘Jarvik Heart’ in 1982, the first artificial 
heart used for implantation (137). 
In the Figure 1.8 showed the application of polyurethanes in biomedical. These polymers 
have been applied in some biomedical tissue engineering areas such as pacemaker lead 
insulators, heart valves, vascular prostheses, breast implants, gastric bubbles, drug release 
carriers, etc. 
 
 
Figure 1. 8. Biomedical application of polyurethanes. 
 
5.6 Application of polyurethane in drug delivery system. 
The polyurethane system is being used for sustained and controlled delivery of various dosage 
forms. These systems are based on a physical combination of the drug with polymers and 
kinetics of drug release is generally controlled by the diffusion phenomena through the 
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polymer (159). Some examples of polyurethane with application for controlled release, are 
described below:  
Controlled delivery System employing polyurethane and nystatin was development in 2001 
by Michaela Mandru, et al (160). Sustained release of nystatin from polyurethane membrane 
for biomedical application. The system was prepared by a mixture of a different amount of 
polyurethane and nystatin. The final system consists of a membrane of polymers with nystatin 
obtained by phase inversion methods. The mechanism for release of nystatin was according to 
fickian diffusion. 
Lijuan Zhou et, al in 2011, synthesized a pH-sensitive polyurethanes. For the synthesis of 
polymers was used LDI, PCL-Hyd-PEG- Hyd-PCL, and tripeptide chain extender. The 
reaction took place in two step.  The pH-sensitive polymers were employing for anticancer 
drug delivery. The polyurethane was degrading at pH 5-6, and release the antitumoral drug in 
tumor site (161). 
In other hand systems consisting of albumin nanoparticles were dispersed into a carboxylated 
polyurethane.  The release of drug was by diffusion phenomen, which observed in Figure 1.9, 
(162). 
 
 
Figure 1. 9. Release of nanoparticles from polyurethane matrix. Adapted from (162) 
 In 2006 the polyurethane was evaluated as theophylline delivery matrices. The polymers 
were synthesized from aliphatic diisocyanate (Lysine methyl ester diisocyanate), poly ε 
(caprolactone) and 1,4 butanediamine. The release of drug from the polyurethane matrix was 
according to fickian diffusion model. The release of theophylline was faster with the increase 
of the hydrophilicity of the polyurethane (163).  
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In 2008 Andrea Hafeman et al, showed a polyurethane for release a growing factor (I-PDGF) 
for tissue repair and regeneration. The polyurethane was prepared by the one-shot foaming 
process. The controlled release system formulated, described a two-stage release profile, 
characterized by a 75% burst release within the first 24h and slower release thereafter. By 21 
days 89% of the (I-PPGF) has eluted from the matrix of polyurethane (159).  
Chlorhexidine diacetate polyurethane controlled delivery system with the employ of 
polyurethane. In this work, the drug loaded to the film of polyurethane was released for 11 
days. The kinetic of the system was the zero-order (164).  
The polyurethane was used in the blend of chitosan microspheres. The system obtained 
permitted to release two cardiovascular drugs: isoxuprine hydrochloride and calcium 
dobesilate. The microsphere with chitosan and polyurethane were prepared by emulsion 
cross-linking method. The drug release from the microsphere followed the fickian to non 
fickian diffusion mechanism (165).  
The matrix of poly (ester ether urethane)s with rifampicim were prepared to employ different 
concentration of urethane groups. The release of drugs was higher than the minimum 
inhibitory concentration of rifampicim for gram-positive bacteria (166).  
Another example of the release of drug from polyurethane was the heparin. In this work, the 
heparin was blended with the polymer. The quantitative of heparin released from the system 
was controlled by the thickness of polyurethane films (167). 
The polyurethane was synthesized with vancomycin. The medical device permits inhibition of 
infection of the bone wound in a rat femoral segmental defect model. The antibiotic 
quantitative released after 8 weeks exceeding the minimal concentration for bactericide 
action. The system was promisor for the treatment of osteomyelitis (168). 
In 2008, the 7-ter-butyldimethylsilyl-10-hydroxyl-camptothecin was employed in a 
formulation with polyurethane. This drug formulation was studied for the treatment of cancer. 
The drug was covalently incorporated into the delivery system and released 0,1% of the total 
drug load to the polymer in 65 days (169). 
 Polyurethanes have a great application for controlled release of the drug. The use of such 
compounds for the release of antifungal has not been explored so far. Thus, the use of 
polyurethane for the active principle release against onychomycosis is still a challenge. 
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Chapter 2: Synthesis and Characterization of Polyurethanes 
employing Carbohydrates 
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 1.Introduction 
The covering of drugs with biodegradable polymers is one of the processes for producing 
sustained and controllable drug release systems, also preventing the degradation of the drugs 
(1). Film coating has been successfully utilized to control the release of active ingredients, 
prevent interaction between ingredients and external medium and increase the strength of the 
dosage form by maintaining the product integrity during storage (2). 
Biomaterials in drug delivery systems have an enormous impact on human health care (3). 
During the last years, the synthesis of new polymers for this application has increased 
markedly (4). One of the polymers that have recognized application for coatings in the 
pharmaceutical industry is the polyurethane (1). Polyurethanes have generated large interest 
among the research community because they offer the greatest versatility in compositions and 
properties of any other family of polymers. The use of elastomeric polyurethanes as 
implantable medical devices have demonstrated a combination of toughness, durability, 
biocompatibility and biostability not achieved by any other available material (3). 
The PUs are composed of repeating units of monomers bonded by the urethane group (4,5). 
Their versatility arises from the possibility of producing tailored PU and PUU. These 
materials are obtained by the addition of different chain extenders or by varying the pre-
polymers’ composition using different polyol structure and functionality, and also changing 
the NCO content (6). The polyurethane has been applied in the medical and pharmaceutical 
industries since 1970 as a biomaterial in a variety of situations, e.g. prosthesis (7,8), 
microspheres (9), apposite (10,11), patches (12) and others (13–15). The PUs are 
conventionally prepared by a so-called one-shot process (16,17) or by a prepolymer mixing 
process (18–23). In these processes, the ionic centers are incorporated as chain extenders and 
located among the hard segments. Consequently, the mobility of the ionic segments is very 
much limited by the rigidity of the hard segments, and the ionic groups are not well exposed 
to the particle surfaces, requiring more ionic groups to produce a stable dispersion (15,24).  
The biocompatibility of the polyurethanes becomes an attractive alternative for application in 
the pharmaceutical industry in therapeutic nail lacquer formulation (25). 
In this study, we synthesized, five different quasi-prepolymer polyurethanes using PEG 
(Mw1500) and pMDI. The quasi prepolymers were characterized by viscosity test, the content 
of NCO and FTIR. Later was select one quasi pre-polymer to synthesize different 
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polyurethanes employing carbohydrates as extensor monomers. Finally, the polyurethanes 
were characterized by FTIR, (1H and 13C) NMR spectroscopy, DSC and cytotoxicity test. 
 
2. Materials and methods 
2.1 Materials 
Polyethylene glycol (PEG) 1500, were purchased from Basf (Germany), sucrose, glucose, 
fructose, isopropyl myristate, 2-methyl-2,4-pentanediol, triethanolamine were obtained from 
Merck (Germany), DMSO, THF, polyethylene glycol 300,  glycerin was obtained from 
Sigma-Aldrich (Germany), ethanol was purchased from Across (France), Transcutol®GC and 
Labrasol® were obtained from Gattefossé (France). The acetone was acquired from Panreac 
(Spain). Polymeric 4,4-methylene diphenyl diisocyanate (pMDI) (Desmodur® 44V20L) was 
supplied by Bayer  Material Science. The molecular sieves 4 Å was acquired from Merck 
(Germany). 
 
2.2 Methods 
2.2.1 Synthesis of the polyurethane quasi-prepolymers  
The synthesis of quasi-prepolymers was carried out using the quasi-prepolymer method. The 
quasi-prepolymers were prepared by reacting pMDI and PEG 1500 (purchased from Basf, 
Germany) in a 50% w/v solution with DMSO and dried over molecular sieves 4 Å) in a glass 
flask of 500 mL, under a dry nitrogen atmosphere. An inert atmosphere was used to avoid the 
ingress of moisture and the consequent formation of urea linkages during synthesis. The 
reaction was developed with mechanical stirring (400 rpm) at 40ºC and with drop-by-drop 
addition of polyol for 8h. The syntheses of polyurethane quasi-prepolymers were done in 
triplicate. Further syntheses were carried out under identical conditions in the presence of 0.5 
mL of the catalyst triethanolamine, which was added to each polyol solution that later reacted 
with the isocyanate (8,23). The ratios of monomers employing for obtained the quasi-
prepolymer polyurethanes were presented in Table 2.1. 
 
 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
2 
 
73 
 
Table 2. 1. Relation of monomers for synthesis of quasi-prepolymers. 
 Pre-6 Pre -8 Pre-10 Pre-12 Pre-14 
m (pMDI) (g) 100 100 100 100 100 
m(PEG 1500)(g) 96 69 55 46 39 
NCO/OH 1.1 1.4 1.8 2.2 2.6 
 
2.2.2 Synthesis of polyurethanes 
The synthesis of polyurethane was carried out in a reactor of 250 mL with a quasi- 
prepolymer polyurethane selected. Later amount of carbohydrate (glucose, fructose or 
sucrose) dissolved in 10 mL of DMSO was added by dropping according to the relation 
presented in Table 2.2. The mixture was maintained under 400 rpm agitation for 1 hour, with 
a nitrogen stream. PUS was the polyurethane obtained employing sucrose as extender, PUF  
was the polyurethane obtained employing fructose as extender and PUG  was the 
polyurethane obtained employing glucose as extender. 
 
Table 2. 2. Relation of monomers for synthesis of polyurethane. 
 
 
 
 
 
 
 
 
 
 
 
 
PU NCO/OH Carbohydrate 
PUS 14/4 1 Sucrose 
PUS 14/6 0.75 Sucrose 
PUS 14/8 0.5 Sucrose 
PUF 14/4 1 Fructose 
PUF 14/6 0.75 Fructose 
PUF 14/8 0.5 Fructose 
PUG 14/4 1 Glucose 
PUG 14/6 0.75 Glucose 
PUG 14/8 0.5 Glucose 
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2.3 Characterization of polyurethane quasi-prepolymers 
2.3.1 Determination of viscosity  
The viscosity of the quasi-prepolymer polyurethanes was determined by parallel plate 
rheometer in a shear stress-controlled ICI, London, LTD rheometer, using parallel plates 
(upper plate diameter ¼ 20 mm); the gap selected was 0.4 mm. The viscosity was measured at 
25 0C and a frequency of 20 Hz. 
 
2.3.2 Free isocyanate content 
The NCO content in the quasi-prepolymer polyurethanes was determined by back titration of 
excess N,N-dibutylamine with standard HCl, described in research of Daniela da Silva et al 
2008 (12). 
 
2.3.3 FTIR 
The FTIR spectra were obtained with a Nexus Thermo Nicolet spectrometer equipped with 
attenuated total reflectance (ATR) device. 128 scans with a spectral resolution of 4 cm-1 were 
averaged to give the specimen spectrum from 4000 cm-1 to 600 cm-1. All FTIR spectra were 
recorded at room temperature. 
2.4 Polyurethane characterization 
2.4.1  Solubility studies for polyurethanes 
Polyurethane was added to different vehicles such as water, water-ethanol (1:1), ethanol, 
Transcutol®GC, isopropyl myristate, 2-methyl-2,4-pentanediol, glycerin, PEG 300, acetone, 
Labrasol® and DMSO. 
 
2.4.2 FTIR 
The FTIR spectra were obtained according description in  section 2.3.3 in the present chapter.  
 
2.4.3  NMR 
1H NMR and 13C NMR spectra in the liquid state were obtained using a BRUKER 300 MHz 
spectrometer. Samples were dissolved in CDCl3, at room temperature (the spectra were 
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referred internally using HDMSO, H 0.058 and  C 1.9 relative to TMS. The measurement 
was done using 10 mg samples of samples.  
 
2.4.4 Thermoanalytical measurements 
Thermoanalytical measurements were performed with a Mettler DSC system (Mettler, 
Switzerland) with a sample robot TS0801RO (Mettler, Switzerland). The sample and the 
reference (air) were placed in hermetically sealed pans. A scan speed of 10 °C/ min was used, 
from -100oC to 250oC. The weight of each sample were 5-6 mg. These values gave the best 
compromise between resolution, temperature accuracy and attenuation. 
 
2.4.5 Cytotoxicity assay 
2.4.5.1 Preparation of sample 
For this study, 350 mg of polyurethane in solid stated with a dimension of 0.5x 0.5cm was 
tested. 
2.4.5.2 Direct contact assay 
The biocompatibility of the polymer was evaluated in vitro by direct contact with cells, 
following the ISO 10993-5:2009 recommendation guidelines(26). Each material was added to 
a 0.5 mL of HaCaT cell suspension [a spontaneously immortalized human keratinocyte cell 
line (CLS, Germany)], in fresh culture medium [RPMI-1640® (Gibco, UK) medium 
supplemented with 10% fetal bovine serum (FCS, Life Technologies, Inc., UK), penicillin 
(100 IU/mL), and streptomycin (100 μg/mL)] (2.5 x 104 cells/mL), in sterile 24-well plates. 
Glass slides without any formulation were used as control. The plates were incubated for 72 h 
in a humidified atmosphere of 5% CO2 at 37 °C, without refreshing the culture medium. For 
cell proliferation quantification, the general cell viability endpoint MTT reduction (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) was used (27,28). Accordingly, 
the previous culture medium was removed and replaced with a fresh medium containing 0.5 
mg/mL of MTT. The cells were further incubated for 3 h. In the plates containing the reduced 
MTT, the medium was removed and the intracellular formazan crystals were solubilized and 
extracted with dimethylsulfoxide. After 15 min, at room temperature, the absorbance was 
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measured at 570 nm in a Microplate Reader (FLUOstar Omega, BMGLabtech, Germany).  
The relative cell viability (%) compared to control cells was calculated using Equation 1: 
 
       (1) 
 
The OD, is the optical density measurement. The data are expressed as the mean and the 
respective standard deviation (mean ± SD) of 6 experiments. The statistical evaluation of data 
was performed using one-way analysis of variance (ANOVA). The Tukey–Kramer multiple 
comparison tests (GraphPad PRISM 5 software, USA), were used to compare the significance 
of the difference between the groups; a p < 0.05 was accepted as statistically significant. 
 
3. Results and discussion 
3.1 Syntheses of polyurethane quasi-prepolymers 
The chemical structures proposed for the polyurethane quasi-prepolymers are given in Figure 
2.1. All the quasi-prepolymers were obtained in the liquid phase and presented an amber 
color.  
32
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Figure 2. 1. Scheme of the quasi-prepolymer reaction. 
 
3.2 Viscosity and NCO content of polyurethane quasi-prepolymers 
The NCO content and viscosity of all polyurethane quasi-prepolymers synthesized are 
presented in Table 2.3. The viscosity values of the samples decreased when the NCO content 
increased. These results are in good agreement with the results of other authors. A.L. Daniel 
pMDI                             PEG  
Polyurethane quasi-prepolymer  
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et al. 2007 (10), who comment that the decreasing of the NCO/OH molar ratio produced an 
increase in the average molecular weight and viscosity of the quasi-prepolymers. Almost all 
the quasi-prepolymers remained liquids for five months after the synthesis, maintaining 
constant viscosity values. Hardening was only observed for the Pre-6 sample on the seventh 
day after the synthesis. Table 2.3 shows a viscosity of 24 Pa.s for this quasi pre-polymer, 
which might indicate that it possesses the highest molecular weight and the highest degree of 
crosslinking than the rest of the quasi-prepolymers. The quasi-prepolymer 14 was the 
polymers with the highest percent of isocyanate free.  
 
Table 2. 3. Formulation, isocyanate content and viscosity of the polyurethane quasi pre-
polymers. (mean±SD, n=3). 
 
Polyurethane 
quasi-
prepolymer 
m(pMDI) 
g 
m(PEG) 
g 
NCO/OH  
m/m 
% NCO 
free 
Viscosity  
(Pa.s)  
Pre – 6 100 92 1.1 9 ±0.3 24 ± 0.1 
Pre –  8 100 69 1.4 10 ±0.3 11 ± 0.1 
Pre – 10 100 55 1.8 13 ±0.6 10 ± 0.1 
Pre – 12 100 46 2.2 14±0.2 8 ± 0.2 
Pre – 14 100 39 2.6 15±0.4 5 ± 0.1 
 
3.3 FTIR analysis of polyurethane quasi pre-polymers 
All quasi polyurethane pre-polymers show a similar FTIR spectrum. In Figure 2.2 and Figure 
2.3 were presented the spectrum of quasi pre-polymers and the monomers employing in the 
syntheses. The weak band to NH around 3000 cm-1 was not observed. The bands between 
2980-2976 cm-1 corresponding to CH2 groups of PEG were observed. The strong band at 
2265–2260 cm-1 confirms the existence of free NCO groups in the quasi-prepolymer 
polyurethane (10,15). The band from 1716 to 1712 cm-1 was attributed to the stretching 
vibration of C=O bond (13,15) characteristic of urethane group, due to the deformation of the 
NH bond and C–N stretching vibration. The peak about 1600-1595 cm-1 corresponds to C=C 
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stretching in the aromatic ring (6,8). Two peaks at 1012 and 1510 cm-1 arise from symmetric 
and asymmetric stretching vibrations of N–C–N, respectively, corresponding to the reactions 
of the NCO groups with the OH groups (22). This behavior has been reported previously for 
polyurethane (10). The DMSO did not influence in the synthesis process of the quasi-
prepolymers. 
 
Figure 2. 2. FTIR in ATR mode spectra of the Pre-6, Pre-8, Pre10 and Pre-12. 
 
Figure 2. 3. FTIR in ATR mode spectra of the Pre-14, PEG 1500, DMSO and pMDI. 
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3.4 Synthesis and characterization of polyurethanes 
The polyurethane quasi-prepolymers hardening in contact with the chain extender in the few 
minutes of the beginning of the syntheses, except in the synthesis were Pre-14 was employed. 
These results were due to the high viscosity of the quasi-prepolymers and a low content of 
free NCO, which causes immediate crosslinking. 
The quasi-prepolymer 14 presents the highest content of isocyanate free (see Table 2.3), it 
was selected for the syntheses of polyurethanes. Different content of sucrose, fructose or 
glucose were incorporated, leading to ratios NCO/OH  1, 0.75 and 0.50. 
 
3.4.1 Solubility of PU 
The solubility of PUs was studied in different solvents. Only the PUS 14/4 present solubility 
in DMSO, in the rest of solvent, the polymers not present solubility. The polymers:  PUS 
14/6, PUS 14/8, PUG 14/4, PUG 14/6, PUG 14/8, PUF 14/4, PUF 14/6 and PUF 14/8, not 
present solubility in the solvent study. In the literature is mentioned that the amount of 
primary alcohol reacts first that the second alcohol in the same molecular (29). According 
this, one hypothetical and ideal structured for these polyurethanes are presented in Figure 2.4.  
 
 
 
 
Figure 2. 4. Ideal structure for polyurethanes: a) PUS, b) PUF, c) PUG. 
a) 
b) 
c) 
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However, the resulted obtained indicated that not only one hydroxyl group reacted with the 
quasi-prepolymer polyurethane. In the real structure of polyurethane, all the hydroxyl group 
from sucrose, fructose and glucose reacted with quasi-prepolymer and formed a hydrophobic, 
non- linear polyurethane, as presented in Figure 2.5. These type of polymers does not present 
solubility properties in the usually solvent employed in  pharmaceutical industry, such as 
ethanol (30). 
 
 
 
 
 
R: quasi- prepolymer polyurethane 
 
Figure 2. 5. Structure of polyurethanes obtained, a) PUS, b)PUF, c) PUG. 
 
3.4.2 FTIR analysis of polyurethanes 
The characterization by FTIR was performed only for the PU obtained from sucrose. 
Comparative analysis of the full spectra (Figure 2.6) shows a similarity between the 
polyurethanes obtained. This evidence indicates that it is possible to achieve the polyurethane 
in all cases.  
a) 
b) 
c) 
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Figure 2. 6. FTIR in ATR mode spectra of polyurethanes prepared with Pre-14. 
 
The presence of a weak band to 3326 cm-1, corresponding to the stretching vibrations of NH 
groups is observed in all the polyurethanes synthesized. The confirmation of the complete 
polymerization and formation of all urethane groups is obtained by the disappearance of the 
band to 2265 – 2260 cm-1 in the spectrum and the formation the band from 1716 to 1712 cm-1 
attributed to the stretching vibration of C=O bond (24,31,32) characteristic of urethane group. 
 
3.4.3 NMR analysis of polyurethane 
3.4.3.1 1HNMR of polyurethane 
The analysis by NMR only will be obtained for PU14/4 because the rest of polyurethanes 
don’t present solubility in the deuterated solvents used.  
For the interpretation of polyurethanes spectra, the signal corresponding to PEG 1500, pMDI  
and sucrose were studied 
The structure of PEG 1500 presented in Figure 2.7, shows four chemically different protons, 
its 1H-NMR spectrum is presented in Annex 1. In the Table 2.4 are observed the chemical 
shifts obtained for PEG 1500, as well as those found in the literature. However, in the 
presented spectra due to the chemical environmental those chemical shifts which should 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
2 
 
82 
 
present distinguished peaks appeared very closed to each other, this effect was corroborated 
by some studies found in literature. 
 
 
 
 
Figure 2. 7. Structure of PEG. 
Table 2. 4. Chemical shifts of PEG 1500. 
 
Type of H 
Experimental chemical 
shifts CDCl3 (ppm) 
Chemical shifts of 
reference* 
CDCl3 (ppm) 
1 3.38 3.4 
2 3.83 3.6 
3 3.62 3.6 
* (33) 
 
Furthermore, (see Annex 1) were observed the sign of hydrogen corresponding to hydrophilic 
group. These results are similar to report for PEG in the literature (34). 
Similarly, to previous compound, the structure of pMDI (see Figure 2.8) presented three types 
of chemically different protons, observed in Table 2.5. The 1H-NMR spectrum of pMDI was 
presented in Annex 2. 
 
 
 
 
 
 
Figure 2. 8. Structure of pMDI. 
HO
O
O
OH
1 2 3 12
3
32
CH2 NN CC OO
HH
H H H H
HH
1
2
2 2
2
3
3
3
3
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
2 
 
83 
 
The detected signals are summarized in Table 2.5. There is complete correspondence with 
shifts reported in the scientific literature consulted. 
 
Table 2. 5. Chemical shifts of pMDI. 
Type of H 
Chemical shifts  
CDCL3 (ppm) 
Chemical shifts 
reference* 
CDCL3 (ppm) 
1 3.87 3.9 
2 7.08 7.1 
3 6.87 7.0 
* (10) 
 
The sucrose was another monomer for analyses, the 1H NMR spectrum of sucrose was 
presented in Annex 2. The structure of disaccharide was presented in Figure 2.9 and in the 
Table 2.6 are  showed the chemical shifts. 
 
Figure 2. 9. Structure of Sucrose. 
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Table 2. 6. Chemical shifts of Sucrose. 
Type of H 
Chemical shifts  
CDCL3 (ppm) 
Chemical shifts 
reference* 
CDCL3 (ppm) 
1,7,8 3.94 3.8-3.9 
2,3,4,5,6 4.37-4.88 4.37-4.9 
9 5.40 5.3 
10,11,12,13 3.6-3.9 2.4-4 
14,15,16 4.05-4.51 4.1-4.5 
17,18,19 3.57-3.90 3.5-3-85 
*(32,35)  
 
All the spectroscopy information obtained from the monomers employ in the synthesis of 
polyurethane, permitted confirm the structure of the final polymer. The 1H-NMR spectrum of 
PUS 14/4 is presented in Figure 2.10. 
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Figure 2. 10. Spectrum 1H-NMR of PUS 14/4. 
The signals presented in the spectrum corroborated the structure of polyurethane. Considering 
the small amounts of sucrose employed for the synthesis of the macromolecule, most signals 
of sugar are lost in the spectrum. However, in the spectrum appear signs between 2-4 ppm 
that indicated the presence of sucrose in the polyurethane. 
In the aromatic polyurethane section (6.9-7.3 ppm) observed increased complexity due to the 
loss of symmetry of the aromatic protons compared with pMDI. In this case, it was not 
possible to assign the signals of each one of the hydrogens. The sign corresponded CH2 to 
aromatic isocyanate, was identified at 3.85 ppm, agree with the identified in other research 
(10). On the other hand, signals between 3.3 to 3.5 ppm helped to identify the presence of 
PEG 1500 in the structure of the polyurethane. 
The characteristic signals of the protons bonded to heteroatoms, between 7.9 – 8.0 ppm 
correspond to the amine groups present in the compound (10,32). These signals are 
imperative because it confirms the proposed reaction between hydroxyl groups (PEG 1500) 
and isocyanate groups (pMDI) (Figure 2.10). 
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3.4.3.2 13C NMR of polyurethanes 
 To support the above results, another experiment was done, 13C-NMR.  The 13C-NMR 
spectrum is presented in Figure 2.11, the signals which are in line with the proposed structure 
of the polyurethane. 
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Figure 2. 11. Spectrum 13C-NMR of PUS 14/4 
 
The signals corresponding to sucrose lost in the 13C-NMR spectrum of polyurethane situation 
previously detected in the assay of 1H-NMR. The sign of 40.6–41.6 ppm corresponded to CH2 
of  pMDI (32). The signs of carbons corresponding to PEG were found in 65 ppm. The 
aromatic area of pMDI  were observed at 70.4 ppm and 80 ppm. The signs detected between 
118-154 ppm corresponding to carbonyl  of polyurethane (36). 
 
3.5 DSC analysis of polyurethanes 
The study by DSC of polyurethanes synthesized employing sucrose showed different values 
of Tg. This behavior is entirely logical considering that small variations in the formulation of 
a polymer can lead to substantial changes in its structure(37). 
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As a result of the analysis of polyurethanes PUS 14/4, PUS14/6 and PUS14/8, the values of 
the respective Tg are shown in Figure 2.12. It was found temperatures in the range between 
24.00 to 34.49 oC for the three studied cases, that correspond with Tg. 
 
 
Figure 2. 12.  DSC thermograms of polyurethane PUS 14/4, PUS 14/6, PUS 14/8. 
 
Tg values in this study are less than those reported by Ganta (38), which means that the 
structure of the polyurethane contains predominant soft segments confering flexibility to the 
polymer, explaining thus why the developed materials have the characteristics of elastomers. 
 
3.6 Results of cytotoxicity assay  
This test was carried out for PUS14/4 and control slide glass (Figure. 2.13). Significant 
morphologic change was observed in the cells in contact with the polyurethane, in the studied 
time periods, the cells studied present different appearance compared with the structure of 
HaCaT.  
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Figure 2. 13. HaCaT cells after 72h of proliferation under contact with polyurethane. A glass 
slide (control), B PUS 14/4. 
 
The cell viability of PUS 14/4 was 21±2% (p<0.001) thus this polymer is not biocompatible 
and thus not allow cell growth. 
The incompatibility of the polyurethane probably present relation to the concentration of 
DMSO residual.(39) 
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4. Conclusions 
Five quasi-prepolymers with free isocyanate between 9-15% and viscosity between 24-5 Pa.s 
were synthesized. All the polyurethane quasi-prepolymers were characterized by FTIR. From 
the quasi-prepolymer 14, three polyurethanes with different content of sucrose were obtained 
with high cross-linking bonds density. The polyurethanes were characterized by 
Spectroscopic techniques (FTIR and NMR). The glass transition temperature of the 
polyurethanes obtained was between 24-34 °C, similar to elastomers. However the 
biocompatibility of the polyurethanes obtained was affected probably by the structure of 
pMDI and the DMSO residual. These preliminary results in the synthesis of polyurethane 
from carbohydrate led the study of another isocyanate that permit to obtain polyurethanes 
with better solubility and biocompatible with HaCaT cells. 
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Chapter 3: Synthesis of biocompatible polyurethanes. 
Characterization by Techniques Spectroscopy, GPC and MALDI-
TOF 
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1. Introduction 
The synthesis of polyurethanes has been extensively studied by several groups with the aim of 
investigating the novel combination of monomers that allow obtaining polyurethanes with 
greater versatility of properties (1–6).  
The choice of monomers used to synthesize PUs are dependent on the ﬁnal applications of the 
material (7). For example, monomers that offer good durability will be selected for polymers 
to be used  for prostheses (8), those  that increases the compatibility of PU with tissues will be 
applied for  pacemakers (9)  and  monomers that offer thermal stability will be carefully 
chosen for catheters that required sterilization process (7,10). The properties of PUs are 
remarkably affected by the content, type, and molecular weight of the soft segments (7). 
We are interested in the synthesis of linear polyurethanes from carbohydrates suitable 
functionalized for application in pharmaceutical industry. Recent work has shown that the use 
of disaccharides such as sucrose increase the crosslinked of the polymer. This result is a 
consequence of the number of OH in the structure of glycol. A monomer with 2 OH groups 
permits obtained linear polyurethane. 
Isosorbide is a monomer already used in the synthesis of biocompatible polymers(3,7,11,12). 
This glycol is a chiral and relatively thermostable diol. It is technically produced from 
glucose, as showed in Figure 3.1. 
 
 
Figure 3. 1. Two step procedure for the synthesis of isosorbide from D-glucose adapted from 
(13). 
On the other hand, the PPG is a biocompatible polyether which has been extensively 
investigated for application as a biomedical material that confers elastomeric properties to 
polyurethanes(14–16). This monomer was then chosen as a second glycol in outlined 
synthesis. 
      D-glucose                                              D-glucitol                                     D-isosorbide 
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To avoid the use of monomers that, probably yield toxic compounds, the IPDI and HMDI are 
envisaged as  option to access to non toxic formulation since those isocyanates have been 
already used in the synthesis of several biocompatible polyurethane (15,17,18). 
Our work aims is to synthesize new polyurethanes from D-isosorbide by polyaddition. The 
novelty of this work consists not only in the synthesis of this type of polymer but also in the 
production of innovative building block to synthesize a biocompatible polyurethane. 
Moreover, we established a methodology for the study of the chemical structure of this type 
of PUs by FTIR, 1H NMR, 13C NMR, their molecular weight being determined by GPC/SEC 
and MALDI-TOF. 
  
2.Material and Methods 
2.1 Materials 
The D-isosorbide was provided by Acrös (Belgium). The HMDI was acquired from Bayer 
Material Science (Germany). IPDI and DMDEE were supplied from Aldrich (Germany) and 
PPG (VORANOL 1010L) from Dow Chemical (Germany). Anhydrous ethanol was acquired 
by Carlo Erba (France). The DMSO-d6, CDCl3, TMS (99.9% purity), THF, Polystyrene 
standards (TSK Tosoh Co), NaBF4 and DHB for MALDI-MS were purchased from Sigma-
Aldrich (Germany). The methanol (HPLC) was provided by Panreac (Spain).  
 
2.2 Methods 
2.2.1 Synthesis of quasi-prepolymers 
The quasi-prepolymers were synthesized using the pre-polymerization method. As a first step, 
a quasi-prepolymer was prepared by reacting of IPDI or HMDI and PPG in a 250 mL glass 
flask, under a dry nitrogen atmosphere, to avoid the presence of moisture and subsequently 
the formation of urea bonds during the synthesis. The reaction took place with the dropwise 
addition of PPG under mechanical stirring (400 rpm), at 80 ºC and in the presence of 0.5 mL 
of the catalyst (DMDEE). This reaction practically completed in 3 h. The ratios for the 
syntheses are presented in Table 3.1. 
. 
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Table 3. 1. Molar ratios employed in the synthesis of the quasi-prepolymers. 
 Pre 1 Pre 2 Pre 3 
IPDI 6 6 - 
HMDI - - 6 
PPG 1 2 1 
 
2.2.2 Synthesis of polyurethanes 
The synthesis of polyurethanes was carried out in a 250 mL reactor starting from a selected 
quasi-prepolymer polyurethane. The D-isosorbide was then added to the quasi-prepolymer. 
The reaction took place in 1 h. The molar ratio of the monomer is presented in Table 3.2. 
 
Table 3. 2. Molar ratios employed in the synthesis of the PU. 
PU PU19 PU20 PU21 PU22 
IPDI 6 6 6 - 
HMDI - - - 6 
PPG 1 2 1 1 
D-isosorbide 5 5 6 5 
 
2.2.3 Determination of viscosity  
The viscosity of the quasi-prepolymer polyurethanes was determined according to section 
2.3.1, Chapter 2. 
 
2.2.4 Determination of free isocyanate 
The NCO content in the quasi-prepolymer polyurethanes was determined according to section 
2.3.2, Chapter 2. 
 
2.2.5 FTIR Characterization 
The FTIR spectra were obtained for the quasi-prepolymer, according to section 2.2.3, in 
Chapter 2.  The solid samples of polyurethane were finely divided, (approximately of 1 mg) 
and dispersed in a KBr matrix (200 mg). A pellet was then formed by compressing the sample 
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at 784 MPa. For the sample of the liquid monomers, attenuated total reflectance (ATR-FTIR) 
spectra were obtaining using the same spectrometer equipped with an ATR accessory. The 
FTIR spectra were obtained at room temperature, in the range of 4000 cm-1 to 600 cm-1, 
during 128 scans with 4cm-1 resolution. 
 
2.2.6 NMR Characterization 
1H-NMR and 13C-NMR spectra were obtained using a Bruker Avance III 500 MHz 
spectrometer. The monomers employ in the synthesis of polyurethanes were analyzed by 1H 
NMR, in chloroformed deuterated (CDCl3). However, the samples of polyurethane (PU19, 
PU20, PU21, and PU22) were dissolved in DMSO-d6. All the spectra were obtained at room 
temperature employing one referred internally TMS. The measurements were performed 
using between 20-53 mg of samples of polyurethane. The chemical shifts are given in ppm 
relative to TMS. 
 
2.2.7 DOSY 
The DOSY experiment, which is an non-invasive analytic technique, enables the 
determination of diffusion coefficients, being based on the method of spin echoes with 
pulsed-field gradients (PGSE) (19).  
The molecular diffusion is based on the random translational movements (Brownian) of 
molecules, due to their thermal energy (20). Experimentally, it appears that the probability 
P(x,t) of the mass center of a molecule which diffuses from a position x to a position x+δx, 
after a time t, is given by this Equation 1:  
          (1) 
where D is the diffusion coefficient of the analyzed molecule (m2s-1). Typical values of 
diffusion coefficients, at room temperature, are around 10-9-10-12 m2s-1 (respectively for little 
molecules in less viscous solutions or for molecules with high molecular weight). 
This technique permits to make a 2D spectrum, similar to spectrum represented in Figure 3.2, 
whose represented dimensions are the chemical shift (δ) and  D of the species of the sample. 
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Figure 3. 2. Typical spectrum DOSY (D (m2s-1 vs δ (ppm)). 
To determine the diffusion coefficients, several experiences are performed, usually varying 
the strength of the gradient(21,22). In our study, the diffusion coefficients (D) were 
determined at infinite dilution of the polymers. The value of D was obtained from plots of D 
versus concentration. For this purpose, a series of five solutions was prepared with 
concentrations 0.34×10-3 g.mL-1, 0.74×10-3 g.mL-1, 1.74×10-3 g.mL-1, 3.42×10-3 g.mL-1 and 
11.4×10-3 g.mL-1 in DMSO-d6 and the diffusion coefficients D were measured using the  
PGSE method in a NMR Bruker Avance III 500 MHz spectrometer with a 3 mm BBO probe 
with a z-gradient shielded coil. The solutions of the polymers were poured in 3mm NMR 
tubes to a total volume of  0.3mL. To guarantee reproducibility of the results this volume was 
kept in all the samples. The temperature was controlled at 30°C by a BCU05 Bruker unit with 
an air flow of 521 L.h-1. 
The use of the exponential regression of the data allowed the determination of the diffusion 
coefficient. 
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The final processing and visualization of spectra was performed employing the software 
Topspin, version 3.2, of the Bruker spectrometer.  
 
2.2.8 Hydrodynamic radii (rh) 
The rh for each polyurethane  were determined by the Stokes-Einstein equation (Equation 2) 
in which diffusion coefficient and radius are in inverse proportionality(22). 
 
   (2) 
 
In the  Equation 2, 
kB: Constant of Boltzmann (1.38066 x10
-23 kg.m2.k-1.s-2) 
T: Temperature 
: viscosity of the solution (N.s.m-2 = kg.s-1.m-1), 
 
The Stokes-Einstein equation was originally developed for spherical colloidal particles, which 
are well defined the Brownian motion. However, it is also an approach for small non-
spherical particles. The use of the equation to predict the diffusion can be improved by 
replacing the radius of the molecules (r), for their effective radius rf, also called hydrodynamic 
radius (rh). The value of rh can be used to compensate the factors like non-spherical molecules 
and spheres of solvation. 
The viscosity of DMSO-d6 at 30ºC, η = 1.951x10-3 Pa.s, was estimated from that of the non-
deuterated solvent taking into account the isotopic effects of the viscosity(23). 
 
2.2.9 Gel Permeation Chromatographic 
The analyses were made in an HPLC Waters chromatograph containing a Waters 515 
isocratic pump and a Waters 2414 refractive index detector. In this apparatus, the oven was 
stabilized at 35 ºC, and the elution of samples was carried out through two PolyPore columns, 
protected by a PolyPore Guard column (Polymer Labs). The software Empower® performed 
the acquisition and data processing. 
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THF was used as eluent, at a flow rate of 1.0 mL.min-1. Before use, the solvent was filtrated 
through 0.45 μm PTFE membranes Fluoropore (Millipore or Pall Corporation) and degassed 
in an ultrasound bath for 45 min. The oligomer/polymer samples were also filtered across 
0.20 μm PTFE filters Durapore (Millipore). Molecular weights were calibrated relative to 
polystyrene standards (TSK Tosoh Co.). As a result, it should be taken into account that small 
deviations could occur when the present polymer samples were analyzed. 
 
2.2.10 MALDI-TOF 
The polyurethane samples were analyzed in a MALDI-TOF mass spectrometry Voyager-
DETM PRO Workstation, equipped with a nitrogen laser operating at a wavelength of 337 
nm. 
 A solution of polyurethane 4×10-4 mg.mL-1 in methanol was prepared (Solution 1).A second 
solution  of NaBF4 10 mg.mL
-1 in miliQ water (Solution 2). Finally, DHB was dissolved in 
Solution 2 at a concentration of 10 mg.mL-1 (Solution 3). The Solution 1 was mixed with 
Solution 3 (matrix) in a ratio of 1:10 (sample:matrix), later 1 µL of the whole solution was 
applied in the sample holder and allowed to dry. The resulting homogeneous solid mixture, 
which ideally consists of a thin layer of microcrystals, was then introduced into the ion source 
of the mass spectrometer. The time of ﬂight mass spectrometer was in reﬂector and/or linear 
mode. All spectra were obtained in the positive ion mode. Ionization was performed with a 
337nm pulsed nitrogen UV laser. All data were processed using the Data Explorer software 
package (Applied Biosystems). The spectra were averaged over 500 laser shots over the 
complete sample area. 
The equation of step-growth polymerization, with the name: Carothers (Equation 3) gives the 
degree of polymerization. (24,25) : 
 
          (3) 
 
Where r is the stoichiometric ratio of monomers, the excess of monomers is conventionally 
the denominator so that r < 1 and, p is the extent of reaction (or conversion to polymer), 
defined by Equation 4: 
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              (4) 
Where No is the number of molecules present initially and N is the number of unreacted 
molecules at the time (t). If neither monomer is in excess, then r = 1 and the equation reduces 
to the equimolar. In the limit of complete conversion of the limiting reagent monomer, p → 1  
The Mw (weight average molecular weight) of the polyurethanes  were calculated according to 
the Equation 5, and the Mn (number average molecular weight ) were calculated according to 
the Equation 6, (26) 
 
    (5) 
 
                                                 (6)                                        
 
A convenient measure of the molecular weight distribution is the ratio Mw/Mn, called 
polydispersity index (26). 
 
2.2.11 In vitro cytotoxicity assay 
2.2.11.1 Preparation of samples 
The polyurethanes were solubilized completely in ethanol, under stirring (200 rpm), at 250 
mg/mL. Later one side of the 0.5 mm diameter glass sheet was expared with this solution and 
dried for 30 min. 
 
2.2.11.2 Direct contact assay 
The morphological characterization of the cell behavior in the presence of the tested materials 
was performed according section 2.4.5.2, chapter 2. 
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3. Results and discussion 
A family of aliphatic biocompatible PU based on D-isosorbide and PPG were synthesized in 
order to design several polymers to convey the active principle. The segmented PUs were 
composed of various ratios of soft segments and hard segments. Polymerization of IPDI with 
various ratios of D-isosorbide and PPG was carried out by poly-condensation at 80 ºC for 4h 
catalyzed by DMDEE, as shown in Figure 3.3. On the other hand, correspondingly, the PU 22 
was obtained from the reaction of HMDI, PPG and D-isosorbide, with the same catalyst 
(Figure 3.3). 
 
 
 
 
Figure 3. 3. Synthetic route of polyurethane PU19, PU20, PU21, and PU22. 
 
3.1 Viscosity and free isocyanate of quasi-prepolymers 
In the Table 3.3 the values of free isocyanate and the viscosity of the prepolymers are 
presented. 
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Table 3. 3. Values of viscosity and free isocyanate of quasi-prepolymers, (n=3). 
 
Quasi-prepolymer 
polyurethanes 
NCO/OH   % NCO-
free ± SD 
Viscosity  
(Pa.s) ± SD 
Pre – 1 6/1 12 ±0.3 10 ± 0.1 
Pre – 2 6/2 9 ±0.3 21 ± 0.1 
Pre – 3 6/1 11 ±0.6 10 ± 0.1 
 
 
3.2 FTIR Characterization 
3.2.1 Characterization of quasi-prepolymers polyurethanes 
In the Figure 3.4 the FTIR of the quasi-prepolymer synthesized are presented, which 
correspond to the molar ratio of Table 3.1. 
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Figure 3. 4. Spectra of quasi-prepolymer polyurethanes. 
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In all the quasi-prepolymers a band at 2252 cm-1 is observed, indicating the presence of  
isocyanate groups (-NCO-) corresponding to the monomers IPDI and HMDI, which is in 
agreement with the reports of the literature (2270 to 2250 cm-1 for the N=C=O stretching  
vibration)(30–32). The spectra of quasi-prepolymers also showed bands at 2927 cm-1, 
corresponding to -CH2- groups, and the peak of the ether group at 1527 cm
-1. These bands 
correspond to PPG segments, (pure PPG presents a -CH2- band between 2970-2850 cm
-1 and 
another one corresponding to the ether group at 1526 cm-1 (33). The band corresponding to 
the carbonyl groups  is observed between 1677-1708 cm-1, which is indicative of the 
condensation reaction between the -OH group of PPG and the -NCO- group of HMDI and 
IPDI (34–36). 
 
3.2.2 Characterization of Polyurethanes 
Polyurethanes from IDPI 
The FTIR spectra of the PUs and monomers are showed in Figure 3.5. 
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Figure 3. 5. FTIR spectra of Isosorbide, PPG, IPDI and PUs. 
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In Figure 3.5 is observed the characteristic band of -OH- at 3366, this band correspond to the 
presence of isosorbide (37). The -CH2- is observed at 2973 cm
-1 corresponding to the position 
mention for other authors then identified the band of methylene (37). The band OH disappears 
in the spectra of PUs. The -CH2- identified in isosorbide and PPG, are detected in the spectra 
of PUs between 2954-2870cm-1. The hard segment of polyurethanes present bands 
characteristics, the stretching vibrations of -NH- and C=O group. The  -NH- bands are 
detected around 3300-3000 cm-1 and the carbonyl bands can be observed between 1705-
1691cm-1(34,38). These structures can interact and form intermolecular hydrogen bonding.  
The disappearance of –N=C=O stretching vibration around 2250cm-1 in the spectra of 
polyurethanes synthesized (Figure 3.4) suggested that there was no unreacted isocyanate 
group (18) and  meaning that all the isocyanate groups had reacted with the OH group  (39). 
On the other hand, NH bending bands of the PUs synthesized in our work were identified at 
1542 cm-1(Figure 3.5) (31). The position of this bands was observed in  the reaction between 
polycaprolactone and 2-isocyanate ethyl methacrylate (40). The NH bending from urethane 
group was detected too  by Daniel da Silva, et al,  at the same position (41). Furthermore, the 
C-O-C stretching was observed at 1089 cm-1 (38). 
In Figure 3.6, the intensity of some peaks in the PUs synthesized is observed.  
 
 
Figure 3. 6. FTIR of PU, C=O, C–H and C–O– C stretching bands of PUs. 
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The FTIR spectra of PU19, PU20 and  PU21 showed diﬀerences between the intensity of 
group amine –NH-, ethylene C–H stretching and ether combination absorption, band around 
3344 cm-1, 2967cm-1, 2875cm-1, represented in Figure 3.5 and bands at  1718cm-1, 1542 cm-1 
and 1108cm-1 presented in Figure 3.6,  indicating that the molar ratio of isosorbide and PPG 
inﬂuenced the spectrum intensities, that corresponding with report in the literature(7). 
Polyurethanes from HMDI 
In Figure 3.7 presents the FTIR of the PU22. 
 
Figure 3. 7. FTIR spectrum of PU22. 
 
 
 
 
 
 
 
1704 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
110 
 
In Figure 3.7, the peaks of CH2 stretching (from PPG) are observed between 2927 and 2854 
cm-1, the band of carbonyl of urethane is detected at 1704 cm-1. The bands typically of C-N 
stretching, combined with N-H in plane bending are observed  at 1523 cm-1 and  1446 cm-1, 
these signs demonstrating the occurrence of the reaction between the hydroxyl and the 
isocyanate group (42). The C-O-C characteristic band was identified  at  1079 cm-1. 
 
 3.3 1H NMR Characterization  
3.3.1 Characterization of some monomer by 1H NMR spectroscopy 
3.3.1. 1 Characterization of IPDI  
The structure observed in Figure 3.8, show different chemical environment for all the protons 
of IPDI.  
 
Figure 3. 8. The structure of IPDI. 
 
The spectrum of this aliphatic diisocyanate (Figure 3.8), are observed in the Figure 3.9.  
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Figure 3. 9. 1H NMR spectrum of the IPDI (500 MHz, in CDCl3 at room temperature). 
In the Table 3.4 was represented, the chemical shifts obtained for the IPDI as well as those 
found in the literature. 
 
Table 3. 4. Assignments of 1H NMR and chemical shifts of IPDI 
Assignments 
Chemical shifts 
CDCL3 (ppm) 
Reference of chemical shifts* 
CDCL3 (ppm) 
1H 3.45-3.70 3.2-3.8 
2H  - 4H 1.45 1.4-1.9 
6H 1.65-1.95 1.24-1.82 
7H-8H-9H 0.85-1.25 0.9-1.3 
10H 3.02 3.1-3.4 
*(16,43,44)  
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Usually, the IPDI consists in a mixture of cis and trans isomer, Z to E isomers in a 3:1 ratio. 
The two isocyanate groups presented in the asymmetric molecule are chemically different; 
one is bonded directly to a primary carbon (NCO-C10) and the other is bonded to the cyclo-
aliphatic ring to a secondary carbon (NCO-C1) (16). According to the spectrum of this 
isocyanate, the assign a chemical shift of each proton is complicated.  
 
3.3.1. 2 Characterization of PPG by 1H NMR 
The structure developed for PPG (Figure 3.10) shows three chemically different protons.  
 
 
Figure 3. 10. The structure of PPG. 
 
However, when considering the chemical environment can be observed very close to each of 
these types of hydrogens chemical shifts (Figure 3.10).   
In Figure 3.11 is presented the 1H-NMR spectrum of PPG. 
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Figure 3. 11.1H NMR spectrum of the PPG (500 MHz, in CDCl3 at room temperature). 
The chemical shifts of the PPG observed are described in Table 3.5, as well as those found in 
the literature. 
 
Table 3. 5. Assignments of 1H-NMR and chemical shifts of PPG. 
Assignments 
Chemical shifts 
CDCl3 (ppm) 
Reference of chemical 
shifts* 
CDCl3 (ppm) 
Ha 1.2 1.12-1.37 
Hb  - H b´ 3.2-3.5 3.4-4.0 
OH 3.9 3.1-3.9 
* (16,45,46)  
 
 
3.3.1. 3 Characterization of Isosorbide by 1H-NMR 
In Figure 3.12 the structure of isosorbide and the identification of the different protons found 
in the molecule is presented. 
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Figure 3. 12. The structure of Isosorbide. 
 
In the Figure 3.13 was observed the 1H-NMR spectrum of the Isosorbide 
 
Figure 3. 13. 1H NMR spectrum of the Isosorbide (500 MHz, in CDCl3 at room temperature). 
 
The hydroxyl of isosorbide appears at 2.2 ppm (7). Table 3.6 are presents the chemical shifts 
corresponding to the structure of Figure 3.12. The peaks identified are in accordance with 
isosorbide signals observed in other works for  the characterization by 1H-NMR (37,47). 
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Table 3. 6. Assignments of 1H NMR and chemical shifts of Isosorbide. 
 
Assignments 
Chemical shifts 
CDCL3 (ppm) 
Reference of chemical 
shifts* 
CDCL3 (ppm) 
1H,6H 3.8-4 3.9-4  
3H,4H 3.5 3.7-4.4  
2H 4.25 4.7 
5H 4.6 5.0 
OH 2.1 2.2 
* (7,37,48,47)  
 
 
3.3.2 Analysis of PUs synthesized of by NMR spectroscopy 
The analysis by 1H-NMR and 13C-NMR of the PUs presented in this study disclosed four 
structures. 
The structure that represents the fraction of IPDI- PPG-IPDI is presented in Figure 3.14A and 
the fraction of the structure corresponding to IPDI-(D-isosorbide)-IPDI is represented in 
Figure 3.14B.  
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Figure 3. 14. Segment of polyurethane with monomers IPDI and PPG (A). Segment of a chain 
of polyurethane with monomers IPDI and D-isosorbide (B). 
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The structure resulting from HMDI-PPG-HMDI is showed in Figure 3.15A and the fraction 
HMDI-Isosorbide-HMDI in Figure 3.15B.  
The 1H-NMR were performed in DMSO-d6 since it presented a better resolution regarding the 
–NH- proton. The identification of NH indicated reaction between diols and the isocyanate 
group (16).  
 
 
 
 
 
Figure 3. 15. Segment of a chain of polyurethane with monomers HMDI and PPG (A). 
Segment of a chain of polyurethane with monomers HMDI and D-isosorbide (B). 
 
3.3.2.1 Analysis of polyurethanes by 1H-NMR spectroscopy 
The 1H NMR spectra of polyurethanes PU19, PU 20, PU21 are depicted in Figure 3.16. 
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Figure 3. 16. 1H NMR spectra of PUs (500 MHz, in DMSO-d6 at room temperature). 
 
The principal signals of polyurethanes identified by 1H-NMR are summarized in Table 3.7.  
The 1H-NMR spectra of the synthesized PUs synthesized are confirmed the presence of the 
urethane group by the identifications of resonances of -HN-, near to 7.0 ppm. These results 
are agreement with those reported by Bessel et al, where the characteristic NH- of  the 
urethane group,was identified at 7.1 ppm as a result of the synthesis of polyhydroxy-urethanes 
by an isosorbide dicyclocarbonates from isosorbide with four commercial diamines (3). Other 
authors mention that the proton from the group -NHCOO- , obtained for the reaction between 
IPDI and polyester can also be  observed at 6.8, 6.82 and 7.2 ppm(43). In the literature the 
resonance of -NH- is described at 8.07 ppm in polyurethanes synthesized from isosorbide, 
HDI, and PTMG (7). 
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Table 3. 7. Assignments of 1H-NMR and chemical shifts of PU 19, PU 20 and PU21. 
 
Assignment 
Chemical  
Shifts 
PU19 (ppm) 
Chemical 
Shifts 
PU20 (ppm) 
Chemical  
Shifts 
PU21 (ppm) 
Reference of 
Chemical 
shifts (ppm) * 
1 3.80 3.90 3.75 3.20-3.80 
2,4,6 1.40-1.60 1.25-1.75 1.30-1.60 1.24-1.9 
7,8,9 0.70-1.10 0.60-1.20 0.80-1.20 0.90-1.30 
10 2.60 2.60 2.70 3.10-3.40 
11,12 7.1 7.2 7.1 7.1-8.02 
13 7.30 7.00-7.25 7.00-7.50 7.00-8.07 
1i 3.50 3.50 3.50 3.90-4.00 
2i 4.75 4.50 4.00 4.00-4.70 
3i 4.30-4.40 4.25-4.30 4.50 3.70-4.40 
4i 4.40 4.60 5.00 3.70-4.40 
5i 4.75 4.90 5.00 5.00 
6i 4.00 3.80 4.10 3.90-4.00 
a 1.20 1.00 1.20 1.12-1.37 
b 3.00 3.20 3.50 3.40-4.00 
b´ 3.50 3.50 3.50 3.40-4.00 
c 4.90 4.80 5.00 4.70-5.00 
*(7,16,43)     
 
 
 
The spectrum of PU 22 is presented in Figure 3.17. 
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Figure 3. 17. 1H NMR spectrum of PU22 in DMSO-d6. Bruker 500 MHz spectrometer. 
 
NMR spectroscopy provided more conclusive evidence of the structure of PU 22. The 
corresponding chemical shifts for 1H NMR assignment are listed in Table 3.8. The peak at 6.9 
and 7.2 ppm corresponds to urethane group. The signs between 4.0-5.2 ppm are evidence of 
the presence of isosorbide,in the structure of the polyurethane. The intense resonance at 1.2 
ppm and 3.5 ppm shows to the presence of -CH2 from PPG, being the peaks of HMDI 
identified in the range 0.75-0.9 ppm. 
In the work of M Rahman et al, polyurethanes were prepared using siloxane polyol 
poly(dimethyl siloxane), poly(propylene oxide glycol), poly (tetramethylene adipate glycol) 
and HMDI. In the 1H-NMR spectra of these polyurethanes were identified the protons of the 
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cycle of HMDI  between 0.3-0.65ppm. On the other hand the -NH- of the urethane was 
identified at 7.18 ppm(35,49). 
In synthesis of polyether poly(urethane urea), composed of poly(ethylene glycol) as the soft 
segment and 4,4′-methylenebis(cyclohexyl isocyanate) extended with ethylenediamine as the 
hard segment, the urethane group was identified in 1H-NMR spectra at 7.09 and the proton 
corresponds to HMDI between 0.87-1.75 ppm(50). 
 
Table 3. 8. Assignments of 1H-NMR and chemical shifts of PU 22. 
 
Assignment 
Chemical Shifts 
PU22 (ppm) 
Reference of Chemical 
shifts (ppm) * 
1a, 2a,3a,4a,5a 0.75-0.80 0.3-0.65 
12a 6.90-7.20 7.1-7.2 
1i 4.10 3.90-4.00 
2i 4.40 4.00-4.70 
3i 3.60-3.90 3.70-4.40 
4i 4.75 3.70-4.40 
5i 5.00 5.00 
6i 3.90 3.90-4.00 
a 1.20 1.12-1.37 
b 3.50 3.40-4.00 
b´ 3.60 3.40-4.00 
c 4.80 4.70-5.00 
*(7,16,35,49,50)    
 
 
 3.3.2.2 Analysis of polyurethanes by 13C-NMR spectroscopy 
13C NMR is a powerful tool to identify monomer groups, photopolymers and copolymers 
molecules of a very well defined composition. 
The study of the 13C NMR spectra of the polyurethanes synthesized depicted in Figure 3.18 
were relatively complex because the IPDI and the isosorbide employed in this work were used 
as mixture of isomers (cis/trans). Nevertheless, the experimental chemical shifts assigned are 
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according to the reference in the literature. The same phenomenon occurs in the interpretation 
of PU22, synthesized from HMDI (mixture of cis–trans isomers), the spectrum of this 
polymer is showed in Figure 3.19. 
The structure presented in Figure 3.14 and Figure 3.15 were useful in the interpretation the 
13C NMR spectra. 
 
 
Figure 3. 18. 13C NMR spectra of the polyurethanes (500 MHz, in DMSO-d6 at room 
temperature). 
In Table 3.9 summarizes the principal chemical shifts determined for the polyurethanes (44).  
The PU19, PU20 , and PU21 displayed resonances of carbonyl group between 153-157ppm. 
(16). 
On the other hand, the peaks of a  primary isocyanate at 121.7 ppm and the secondary -NCO- 
at 122.6 ppm, disappear in the 13C NMR spectra (44). These results indicate that the PUs are 
free of residual IPDI. 
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Table 3. 9. Assignments of 13C NMR chemical shifts for PU19, PU20 and PU21. 
 
Assignment Chemical Shifts 
PU19 (ppm) 
Chemical Shifts 
PU20 (ppm) 
Chemical Shifts 
PU21 (ppm) 
Reference of 
Chemical shifts 
(ppm) * 
Ca 16.5 16.7 16.5 17.12-18.24 
C9 23.00 22.5 22.5 23.33-29.95 
C7 27.9 26.8 26.7 27.19-27.71 
C3 31.9 32.0 32.3 32.11-32.24 
C8 34.5 34.3 34 34.92-34.97 
C5 36.0 36 36 36.87-36.92 
C6 - 41.5 41.5 43.63-44.13 
C1 44 44 44 48.97-49.25 
C4 45 45 45 46.40-46.64 
C2 46 45.8 46 48.20-48.44 
C10 54 54 54 51.18-57.24 
Cb 68 68.7 68 72-78 
C6i 70 70 70.5 70-75 
C1i 71 71 71.5 70-71 
Cc 72.5 72 72.5 72-78 
C5i 73 73 75.5 70-80 
Cb 74 74 75 72-78 
C2i 75 75 75.5 70-75 
C4i 81 80.5 81 80-81 
C3i 85.5 85.5 86 79-81 
C=O 154.3-157.5 154.3-157.5 153.3-157.5 153-157 
*(16,43,44,51) 
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13C NMR PU22 
 
In Figure 3.19 is presented the 13C NMR spectrum of PU22. The urethane carbonyl resonance 
are identified between 154 ppm and 155.5 ppm.  This result is similar to the findings observed 
in the characterization of the polyether urethane urea, prepared by reaction between HMDI 
and polyethylene glycol and ethylenediamine, where the carbonyls were detected at 155 ppm 
and 157 ppm (50). 
 
 
Figure 3. 19. 13C NMR spectrum of the PU 22 (500 MHz, in DMSO-d6 at room temperature). 
 
In the spectrum displayed in Figure 3.19 the resonance at 124ppm, which is characteristic of 
isocyanate group, carbon atom is absent. These means that all the diisocyanate reacted (35) 
which was also conﬁrmed by the FTIR analysis (Figure 3.7).  
Two strong and sharp peaks centered at 27.2 and 71.1ppm were observed in the spectrum 
corresponding to the PPG structure. The signal at 51 ppm, confirmed the HMDI backbone 
(35). Table 3.10 summarizes all the chemical shift from 13C NMR spectrum of the PU 22. 
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Table 3. 10. Assignments of 13C NMR and chemical shifts for PU22. 
 
Assignment Chemical Shifts 
PU22 (ppm) 
Reference of Chemical 
shifts (ppm) * 
Ca 28.00 27.00 
C2a 33.00 33.00 
C3a 30.00 31.00 
C4a 38.00 36.0 
C1a 45.00 44.00 
C5a 36.0 54.00 
Cb 72 71.1-72 
C6i 70 70-75 
C1i 71 70-71 
Cc 72.5 72-78 
C5i 73 70-80 
Cb 74 72-78 
C2i 75 70-75 
C4i 81 80-81 
C3i 85.5 79-81 
C6a 154.0-155.5 155-157 
*(16,35,43,50) 
          
 
3.5 DOSY of Polyurethanes 
 
The diffusion coefficient (D) represents the movement of a solute in a solvent. The D 
basically dependent on four factors: the size and shape of the solute, the temperature, and 
viscosity of the solvent(52). In the Figure 3.20 are presented the D corresponding to PUs. 
The values of D measurement at different concentration are represented in Figure 3.21. 
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Figure 3. 20. DOSY spectra of polyurethanes (1H 500 MHz, in DMSO-d6 at room 
temperature,0.348 mg/mL). 
 
From different concentration of polyurethanes were determined the value of D for each 
polyurethane. The different measurement is observed in Figure 3.21. 
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Figure 3. 21. Diffusion coefficient vs concentration for PU19‒PU22 in DMSO-d6, measured 
at T = 30 oC. 
In the Table 3.11, the values obtainedfor the D of the corresponding PUs are presented. 
 
Table 3. 11. Values of D for PU19- PU22, measured at T=30oC, DMSO-d6. 
 
 
 
 
 
 
The values obtained for D indicate that PU19 and PU21 presented high mobility in DMSO at 
a temperature of the study. However according to expected the PU 20 showed slowly 
diffusion in the solvent at the condition of the test. PU 22 also presented slow mobility, 
according to the low diffusion coefficient. This result should be analyzed together with the 
results of the molecular weight measurement. However, because the temperature and 
viscosity of the solvent are the same in the measurements, D values depend only of: the size 
and shape of the polyuretane, probably the PU 20 and PU22, present higher size and shape 
that the other polyuretanes, in this condition of the study.  
Polyurethane D*10-11 (m2/s-1) 
PU19 7.04 
PU20 4.49 
PU21 6.74 
PU22 4.52 
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3.6 Hydrodynamic radii 
The values of rh for the polyurethanes are presented in Table 3.12. 
 
Table 3. 12. Values of rh for PU19-PU22, measured at T=30 
oC, DMSO-d6 
 
 
 
 
 
 
The rh according to Stokes-Einstein equation are inversely proportional to the value of D. The 
rh  of  PU20  and PU22 are higher than the PU19 and PU21, probably they present higher size 
and shape. 
 
3.7 Result of the analyzis of polyurethanes by GPC 
Table 3. 13. Average Molecular weight by GPC. 
 
 
 
 
 
 
The higher number average molecular weight was obtained for the PU22, because the 
polyurethane presented D = 4.52*10-11 m2/s-1. The lower number average molecular weight 
was to PU21 because present higher diffusion coefficient and lower rh.  
The polyurethane synthesized presented similar polydispersity index and the values are closed 
to 1. 
 
 
Polyurethane rh 10-9(m) Δrh 10-9(m) 
PU19 1.62 0.04 
PU20 2.65 0.15 
PU21 1.69 0.04 
PU22 2.52 0.19 
Polyurethane Mw 
(Dalton) 
Mn 
(Dalton) 
Dispersity 
(Ð=Mw/Mn) 
PU19 15600 10300 1.50 
PU20 19200 12800 1.48 
PU21 9200 7200 1.27 
PU22 23500 15140 1.55 
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3.8 MALDI-TOF 
The objectives of the use of the MALDI-TOF technique are related to the determination of the 
molecular weight of the polyurethane without fragmentation. 
The MALDI-TOF mass spectra of polyurethanes were obtained using DHB matrix and 
sodium iodide salt as the cationization reagent, showed in Figure 3.22, Annexes 4-7 and Table 
3.14. The MALDI-TOF spectra contains one mass distributions in the range 400-4200 Da 
with mass intervals corresponding to the molar mass of the repeating unit (368 Mw and 408 
Mw).  
The PU 19 present one distribution, at m/z = 368n + 22.99(Na+) that corresponds to the D-
isosorbide and IPDI groups. This distribution allows calculated a Mw of 948.57 Dalton. 
 The PU 20 presents one distribution at m/z = 58N corresponding to fragment of PPG and 
another at m/z = 368n + 22.99(Na+) corresponding to IPDI+ D-isosorbide. This last allows 
the calculation Mw of 756.6 Dalton. 
 PU 21 present one distribution of chain at m/z = 368n + 22.99(Na+), that allows calculation 
Mw of 975.94 Dalton. 
Finally, the PU 22 present one distribution at m/z =408n + 22.99(Na+) corresponding to 
fragment of PPG, HMDI + D-isosorbide, that allow calculated a Mw of 921.1 Dalton. 
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Figure 3. 22. MALDI-TOF mass spectra of polyurethane after deisotoping procedure. 
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Table 3. 14. Higher mass identified by MALDI -TOF and mass calculated according to molar 
ratios. 
 
Maldi-TOF 
MS 
Calculated 
Mass 
PU19 2379 3013.67 
PU20 3379 4036.80 
PU21 2378 3195.14 
PU22 3691 3280.30 
 
The values showed in Table 3.14 indicated that the polymer with higher molecular weight, 
correspond to PU22, this agrees with the molecular weight measurement by GPC. 
Nevertheless, the values of Mw for each polymer obtained by MALDI-TOF are different 
compared with the determination done by GPC. The difference is justified by the 
hydrodynamic volume of the polymers. The measurement of Mw obtained by GPC was 
performed using polystyrene as a standard reference. The hydrodynamic volume of 
polystyrene is different from the polyurethane; however, this polymer is the available 
reference in GPC for polyurethane analysis. 
The MALDI-TOF and GPC demonstrated, the relation between the molecular weight 
expected according to the molar ratios employed in the synthesis of the polymer. 
The GPC didn’t present any accuracy in the values of Mw when compared with molecular 
weight determined according to molar ratios of PU19, PU21, and PU22. However, the 
MALDI- TOF revealed some correspondence between the molecular weight determined and 
the molecular weight calculated according the molar ratios used in the synthesis. 
 
3.9 Cytotoxicity assay 
The direct contact tests were carried out for PU19, PU20, PU21, PU22 and control slide glass. 
As shown in Figure 3.23, the HaCaT shows proliferation in contact with PU19. 
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Figure 3. 23. HaCaT cells after 72h  of proliferation a) glass slide (control) , b) PU19. 
 
The image obtained in Figure 3.23  show a monolayer of HaCaT in contact with the PU19 
after 72h  and demonstrated the compatibility of the polymer with keratinocyte cells. 
 
From Figure 3.24 it can be observed that polymers PU19, PU20 and PU 21 presents a cell 
viability (measured by the MTT reduction) that did not differ significantly from the control 
(glass slide) whereas the PU22 polymer the cell viability is 80%±5% (significantly different 
from control for p<0.05) 
 
 
* Not significantly difference (p˂0.05), ** significantly different (p˂0,05). 
 
Figure 3. 24. HaCaT cell viability by MTT after proliferation under different polymers 
material. Control (glass slide), (mean ± SD, n = 6). 
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4. Conclusions 
The structure of polyurethanes was confirmed by FTIR, 1H and 13C NMR spectroscopy in all 
the samples. This observation conﬁrms the higher reactivity of the secondary NCO group of 
IPDI compared to the primary group. 
The NMR spectroscopy showed the properties of the polyurethane, behind the elucidation of 
D and the hydrodynamic radii from DOSY. The polyurethanes with highest D, present lowest 
hydrodynamic radius, in the conditions of the study. 
The GPC, allowed the determination of the distribution of molecular weight according to a 
standard reference. The MALDI-TOF confirms that the molecular weights determined is 
according to the molar ration employed in the polyurethanes synthesized. 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
134 
 
5. References 
1.  Sarkar D, Yang JC, Sen Gupta A, Lopina ST. Synthesis and characterization of L-
tyrosine based polyurethanes for biomaterial applications. J Biomed Mater Res - Part 
A. 2009;90(1):263–71.  
2.  Han J, Chen B, Ye L, Zhang AY, Zhang J, Feng ZG. Synthesis and characterization of 
biodegradable polyurethane based on poly(??-caprolactone) and L-lysine ethyl ester 
diisocyanate. Front Mater Sci China. 2009;3(1):25–32.  
3.  Besse V, Auvergne R, Carlotti S, Boutevin G, Otazaghine B, Caillol S, et al. Synthesis 
of isosorbide based polyurethanes: An isocyanate free method. React Funct Polym. 
2013;73(3):588–94.  
4.  Chen TK, Tien YI, Wei KH. Synthesis and characterization of novel segmented 
polyurethane clay nanocomposite via poly(epsilon-caprolactone)/clay. J Polym Sci Part 
a-Polymer Chem. 1999;37(13):2225–33.  
5.  Bachmann F, Reimer J, Ruppenstein M, Thiem J. Synthesis of novel polyurethanes and 
polyureas by polyaddition reactions of dianhydrohexitol configurated diisocyanates. 
Macromol Chem Phys. 2001;202(17):3410–9.  
6.  Guelcher SA, Gallagher KM, Didier JE, Klinedinst DB, Doctor JS, Goldstein AS, et al. 
Synthesis of biocompatible segmented polyurethanes from aliphatic diisocyanates and 
diurea diol chain extenders. Acta Biomater. 2005 Jul;1(4):471–84.  
7.  Kim H-J, Kang M-S, C; K s J, Myoung-Seon G. Synthesis of highly elastic 
biocompatible polyurethanes based on bio-based isosorbide and poly(tetramethylene 
glycol) and their properties. J Biomater Appl. 2014;29(3):454–64.  
8.  Abraham GA, Marcos-Fernández A, San Román J. Bioresorbable poly(ester-ether 
urethane)s from L-lysine diisocyanate and triblock copolymers with different 
hydrophilic character. J Biomed Mater Res - Part A. 2006;76(4):729–36.  
9.  Zhang C, Zhang N, Wen X. Synthesis and characterization of biocompatible, 
degradable, light-curable, polyurethane-based elastic hydrogels. J Biomed Mater Res 
Part A. 2007;Volume 82A(3):521–776.  
10.  Spiridon I, Popa VI. Monomers, Polymers and Composites from Renewable Resources. 
Monomers, Polymers and Composites from Renewable Resources. 2008. 289-304 p.  
11.  Gogolewski S, Gorna K, Zaczynska E, Czarny A. Structure-property relations and 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
135 
 
cytotoxicity of isosorbide-based biodegradable polyurethane scaffolds for tissue repair 
and regeneration. J Biomed Mater Res - Part A. 2008;85(2):456–65.  
12.  Fenouillot F, Rousseau A, Colomines G, Saint-Loup R, Pascault JP. Polymers from 
renewable 1,4:3,6-dianhydrohexitols (isosorbide, isomannide and isoidide): A review. 
Prog Polym Sci. Elsevier Ltd; 2010;35(5):578–622.  
13.  Stoss Peter; Hemmer Reinhard. 1,4:3,6-Dianhydrohexitols. Adv Carbohydr Chem 
Biochem. 1991;49:93–173.  
14.  Marques MFF, Gordo PM, De Lima AP, Queiroz DP, De Pinho MN, Major P, et al. 
Free-volume studies in polycaprolactone/poly(propylene oxide) urethane/urea 
membranes by positron lifetime spectroscopy. In: Acta Physica Polonica A. 2008. p. 
1359–64.  
15.  Chattopadhyay DK, Raju NP, Vairamani M, Raju KVSN. Structural investigations of 
polypropylene glycol (PPG) and isophorone diisocyanate (IPDI) based polyurethane 
prepolymer by matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF)-mass spectrometry. Prog Org Coatings. 2008;62(2):117–22.  
16.  Prabhakar A, Chattopadhyay DK, Jagadeesh B, Raju KVSN. Structural investigations 
of polypropylene glycol (PPG) and isophorone diisocyanate (IPDI)-based polyurethane 
prepolymer by 1D and 2D NMR spectroscopy. J Polym Sci Part A Polym Chem. 
2005;43(6):1196–209.  
17.  Wen TC, Wang YJ, Cheng TT, Yang CH. The effect of DMPA units on ionic 
conductivity of PEG-DMPA-IPDI waterborne polyurethane as single-ion electrolytes. 
Polymer (Guildf). 1999;40(14):3979–88.  
18.  Boyer A, Lingome CE, Condassamy O, Schappacher M, Moebs-Sanchez S, Queneau 
Y, et al. Glycolipids as a source of polyols for the design of original linear and cross-
linked polyurethanes. Polym Chem. 2013;4(2):296–306.  
19.  Price WS. Pulsed-Field Gradient Nuclear Magnetic Resonance as a Tool for Studying 
Translational Diffusion. Part 1. Basic Theory. Concepts Magn Reson. 1997;9(5):no-no.  
20.  Price WS. ChemInform Abstract: Pulsed-Field Gradient Nuclear Magnetic Resonance 
as a Tool for Studying Translational Diffusion. Part 1. Basic Theory. ChemInform. 
2010;28(50):no-no.  
21.  Geil B. Measurement of translational molecular diffusion using ultrahigh magnetic 
field gradient NMR. Concepts Magn Reson. 1998;10(5):299–321.  
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
136 
 
22.  Mondiot F, Loudet JC, Mondain-Monval O, Snabre P, Vilquin A, Würger A. Stokes-
Einstein diffusion of colloids in nematics. Phys Rev E - Stat Nonlinear, Soft Matter 
Phys. 2012;86(1).  
23.  Holz M, Mao XA, Seiferling D, Sacco A. Experimental study of dynamic isotope 
effects in molecular liquids: Detection of translation-rotation coupling. J Chem Phys. 
1996;104(2):669–79.  
24.  Allcock HR, Lampe FW. Contemporary Polymer Chemistry,. Prentice Hall: New 
Jersey, 3rd Ed.,. 2003.  
25.  Barmar M, Barikani M, Kaffashi B. Synthesis of Ethoxylated Urethane and 
Modification with Cetyl Alcohol as Thickener. Iran Polym J. 2001;10(5):331–5.  
26.  Sperling LH. Introduction to Physical Polymer Science. Polymer. 2005. 845 p.  
27.  International Organization for Standardization. Biological Evaluation of Medical 
Devices Part 5: Tests for In Vitro Cytotoxicity. Iso 10993–5. 2009;5:1–52.  
28.  Cadete A, Figueiredo L, Lopes R, Calado CCR, Almeida AJ, Gonçalves LMD. 
Development and characterization of a new plasmid delivery system based on chitosan-
sodium deoxycholate nanoparticles. In: European Journal of Pharmaceutical Sciences. 
2012. p. 451–8.  
29.  Lopes R, Eleutério C V., Gonçalves LMD, Cruz MEM, Almeida AJ. Lipid 
nanoparticles containing oryzalin for the treatment of leishmaniasis. In: European 
Journal of Pharmaceutical Sciences. 2012. p. 442–50.  
30.  MCHEN-CHI KH-CCW-P; M. Synthesis and characterization of a clay/waterborne 
polyurethane nanocomposite. J Mater Sci. 2005;40:179–185.  
31.  Ferreira P, Pereira R, Coelho JFJ, Silva AFM, Gil MH. Modification of the biopolymer 
castor oil with free isocyanate groups to be applied as bioadhesive. Int J Biol 
Macromol. 2007;40(2):144–52.  
32.  Ferreira P, Silva AFM, Pinto MI, Gil MH. Development of a biodegradable 
bioadhesive containing urethane groups. J Mater Sci Mater Med. 2008;19(1):111–20.  
33.  Li G, Li P, Qiu H, Li D, Su M, Xu K. Synthesis, characterizations and biocompatibility 
of alternating block polyurethanes based on P3/4HB and PPG-PEG-PPG. J Biomed 
Mater Res Part A. 2011 Jul;98A(1):88–99.  
34.  Alves P, Coelho JFJ, Haack J, Rota A, Bruinink A, Gil MH. Surface modification and 
characterization of thermoplastic polyurethane. Eur Polym J. 2009;45(5):1412–9.  
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
137 
 
35.  Rahman MM, Hasneen A, Chung I, Kim H, Lee W-K, Chun JH. Synthesis and 
properties of polyurethane coatings: the effect of different types of soft segments and 
their ratios. Compos Interfaces. 2013;20(1):15–26.  
36.  Caracciolo PC, Buffa F, Abraham GA. Effect of the hard segment chemistry and 
structure on the thermal and mechanical properties of novel biomedical segmented 
poly(esterurethanes). J Mater Sci Mater Med. 2009;20(1):145–55.  
37.  Kricheldorf HR, Chatti S, Schwarz G, Krüger RP. Macrocycles 27: Cyclic Aliphatic 
Polyesters of Isosorbide. J Polym Sci Part A Polym Chem. 2003;41(21):3414–24.  
 
38.  Ferreira P, Coelho JFJ, Pereira R, Silva AFM, Gil MH. Synthesis and characterization 
of a poly(ethylene glycol) prepolymer to be applied as a bioadhesive. J Appl Polym 
Sci. 2007 Jul 15;105(2):593–601.  
39.  Vieira A, Ferreira P, Coelho J GM. Photocrosslinkable Polymers for Biomedical 
Applications. Int J Biol Macromol. 2008;43:325–32.  
40.  Ferreira P, Coelho J GM. Developmet of a new photocrosslinkable biodegradable 
bioadhesive. Int J Pharm. 2008;352:172–81.  
41.  Daniela da Silva A, Martinez J BJ. Influence of the storage of reactive urethane quasi-
prepolymers in their compositions and adhesion properties. Int J Adhes Adhes. 
2007;28:29–37.  
42.  Zhu R, Wang Y, Zhang Z, Ma D, Wang X. Synthesis of polycarbonate urethane 
elastomers and effects of the chemical structures on their thermal, mechanical and 
biocompatibility properties. Heliyon. Elsevier Ltd; 2016;2(6).  
43.  Zhang S, Cheng L, Hu J. NMR studies of water-borne polyurethanes. J Appl Polym 
Sci. 2003;90(1):257–60.  
44.  Götz H, Beginn U, Bartelink CF, Grünbauer HJM, Möller M. Preparation of 
isophorone diisocyanate terminated star polyethers. Macromol Mater Eng. 
2002;287(4):223–30.  
45.  Asha SK, Thirumal M, Kavitha A, Pillai CKS. Synthesis and curing studies of PPG 
based telechelic urethane methacrylic macromonomers. Eur Polym J. 2005;41(1):23–
33.  
46.  Woo; CI, Mamoru;Nomura, Hyun; KJ. Synthesis and aqueous solution behavior of 
water-soluble polyurethane (IPDI-PPG-DMPA) resin. 2000;201(17 November):2221–
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
3 
 
138 
 
2227.  
47.  Gunther H. NMR spectroscopy. John wiley. 1980. 342-343 p.  
48.  He X, Zhai Z, Wang Y, Wu G, Zheng Z, Wang Q, et al. New method for coupling 
collagen on biodegradable polyurethane for biomedical application. J Appl Polym Sci. 
2012;126(SUPPL. 1).  
49.  Rahman MM, Hasneen A, Jo NJ, Kim HI, Lee WK. Properties of Waterborne 
Polyurethane Adhesives with Aliphatic and Aromatic Diisocyanates. J Adhes Sci 
Technol. 2011;25(16):2051–62.  
50.  Wang H, Kao H, Digar M, Wen T. FTIR and Solid State 13 C NMR Studies on the 
Interaction of Lithium Cations with Polyether Poly(urethane urea). Macromolecules. 
2001;34(3):529–37.  
51.  Corcuera MA, Rueda L, Fernandez D’Arlas B, Arbelaiz A, Marieta C, Mondragon I, et 
al. Microstructure and properties of polyurethanes derived from castor oil. In: Polymer 
Degradation and Stability. 2010. p. 2175–84.  
52.  Holz M, Heil SR, Sacco A. Temperature-dependent self-diffusion coefficients of water 
and six selected molecular liquids for calibration in accurate 1H NMR PFG 
measurements. Phys Chem Chem Phys. 2000;2(20):4740–2.  
  
 
 
 
 
 
 
 
 
 
 
 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
4 
 
139 
 
Chapter 4: New polyurethane nail lacquers for the delivery 
terbinafine – formulation and antifungal activity evaluation 
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1.Introduction 
Tinea unguium, a fungal nondermatophytic nail infection is commonly referred as 
onychomycosis. This disease is often underestimated, being considered as “only” a simple 
cosmetic problem. As such, the solutions for its treatment and the investment made in 
developing new ones are limited. However, this disease causes, in patients suffering from 
such infection, pernicious effects on its interaction with society as well as emotional and 
psychological damage (1).  
One of the solutions to treat such condition is the use of nail lacquer formulations, which 
emerged in the pharmaceutical market in the late 1990’s (2). Generally, they comprise the 
drug dispersed in a polymer solution, which, after solvent evaporation, leaves a film on the 
nail plate. Upon solvent evaporation, a polymeric water resistant film is formed that acts as a 
drug reservoir, allowing the drug to permeate through the nail plate continuously (3). There 
are many drugs active against Tricophyton rubrum, the dermatophytic fungus responsible for 
onychomycosis (4,5). One of those drugs is terbinafine, an active antifungal drug with a 
minimum inhibitory concentration (MIC) against Tricophyton rubrum of 0.004-0.06 µg/mL 
(6).  Nail lacquers are being considered as a solution to deliver relevant drugs to infected 
nails, although there is no formulation containing terbinafine yet. The cause of this oversight 
is related to difficulties in formulating vehicles using currently available polymer excipients. 
The polymeric formulation must be carefully chosen since it may influence the therapeutic 
nail lacquer efficacy. Chitosan-based water soluble polymers allow an excellent drug 
permeation and adhesion to the nail plate, having a soft, flexible and matte finish, which may 
improve patient compliance (7,8). However, this excipient leads to a faster drug release when 
in contact with water, which occurs during the patient daily hygiene routines. Hydrophobic 
polymers, possessing a poor solubility in water, produce more durable and harder films with a 
glossier finish (9). Therefore, the development of new polymeric materials that adhere to the 
nail plate and allow a continuous transungual drug delivery is still a challenge. Polyurethane 
(PU) has been applied in the medical and pharmaceutical industries since 1970 in prosthesis 
(3), microspheres for bone regeneration (11) and patches (12). However, the use of PU as a 
vehicle for transungual drug delivery has never been explored. Aliphatic PUs are 
biocompatible and present an excellent nail plate adhesion, depending on the monomers used 
for their synthesis. Bachmann et al. have proven that the presence of carbohydrate monomers 
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like fructose, glucose, and isosorbide as chain extenders of PUs, increases the 
biodegradability of their polymers (13). Furthermore, a PU based on PEG 400 has been 
synthesized by the reaction of PEG hydroxyl groups with isophorone diisocyanate, presenting 
good bioadhesive properties (14). Another study disclosed a biomedical PU obtained through 
the reaction of hexamethylene diisocyanate, poly(Ɛ-caprolactone) and isosorbide. Such 
synthesis leads to a biodegradable and biocompatible elastomeric PU with an enhanced 
affinity for cells and tissues (15). 
The manuscript presented herein describes a new nail lacquer employing novel PUs 
formulations. The biocompatibility, as well as the wettability and the free volume of the holes 
found in the film formulations, were evaluated. Additionally, the nail lacquers’ morphology, 
bioadhesion and viscosity were assessed and in vitro release tests were performed. Finally, the 
in vitro antifungal activity was screened for the formulation which presented the best 
properties. 
 
2.Materials and methods 
2.1 Materials 
D-isosorbide was provided by Acros (Portugal). IPDI, Desmodur® I, was purchased from 
Bayer Material Science (Germany) and PPG, VORANOL® 1010L, from Dow Chemical 
(Germany). The DMDEE was provided by Aldrich (Germany). Anhydrous ethanol, butyl 
acetate and ethyl acetate were acquired from Carlo Erba (France). Terbinafine hydrochloride 
(TH) manufactured by Uquifa México S.A. was kindly offered by Generis (Portugal). Tagat® 
CH 60 (PEG-60 Hydrogenated Castor Oil) was purchased from Evonik (Germany). Methanol 
HPLC grade was purchased from Panreac (Spain). Triethanolamine was provided by Merck 
(Germany). 
 
2.2 Methods 
2.2.1 Preparation of the PU based nail lacquers 
Three PU were synthesized using the quasi-pre-polymerization method. They were prepared 
by reacting IPDI and PPG in the presence of the catalyst DMDEE. D-isosorbide was added 
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afterwards. The mole ratios used for each synthesis were: PU 19 (6:1:5), PU 20 (6:2:5), PU 21 
(6:1:6), of IPDI, PPG and D-isosorbide, respectively as previously was described in chapter 3. 
Three PU-based nail lacquer formulations containing terbinafine were prepared according the 
formulas described in Table 4.1. Firstly, PUs were fully solubilized in ethanol under stirring 
(200 rpm). Butyl acetate, ethyl acetate and terbinafine were added afterwards, one by one, 
until their complete dissolution. 
 
Table 4. 1. PU, terbinafine based nail lacquers composition. 
 Formulation 
A PU19 -10% 
TH 
Formulation B 
PU 20-10% 
TH 
Formulation C 
PU 21-10% 
TH 
PU 19 10.0 -- -- 
PU 20 -- 10.0 -- 
PU 21 -- -- 10.0 
Terbinafine HCl  1.0 1.0 1.0 
Ethyl acetate 7.8 7.8 7.8 
Butyl acetate 10.0 10.0 10.0 
Ethanol 71.2 71.2 71.2 
 
2.2.2 In vitro cytotoxicity assay 
The biocompatibility of the PU based nail lacquers was evaluated in vitro by direct contact 
with cells, following the ISO 10993-5:2009 recommendation guidelines (16). Each nail 
lacquer formulation material was added to a 0.5 mL of HaCaT cell suspension [a 
spontaneously immortalized human keratinocyte cell line (CLS, Germany)], in fresh culture 
medium [RPMI-1640® (Gibco, UK) medium supplemented with 10% fetal bovine serum 
(FCS, Life Technologies, Inc., UK), penicillin (100 IU/mL), and streptomycin (100 μg/mL)] 
(2.5 x 104 cells/mL), in sterile 24-well plates. Glass slides without any formulation were used 
as control. The plates were incubated for 72 h in a humidified atmosphere of 5% CO2 at 37 
°C, without refreshing the culture medium. For cell proliferation quantification, the general 
cell viability endpoint MTT reduction (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) was used (17,18). Accordingly, the previous culture medium was 
removed and replaced with a fresh medium containing 0.5 mg/mL of MTT. The cells were 
further incubated for 3 h. In the plates containing the reduced MTT, the medium was removed 
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and the intracellular formazan crystals were solubilized and extracted with dimethylsulfoxide. 
After 15 min, at room temperature, the absorbance was measured at 570 nm in a Microplate 
Reader (FLUOstar Omega, BMGLabtech, Germany).   
 
The data are expressed as the mean and the respective standard deviation (mean ± SD) of 6 
experiments. The statistical evaluation of data was performed using one-way analysis of 
variance (ANOVA). The Tukey–Kramer multiple comparison tests (GraphPad PRISM 5 
software, USA), were used to compare the significance of the difference between the groups; 
a p < 0.05 was accepted as statistically significant. 
 
2.2.3 Determination of wettability by measurement of contact angle  
The measurement of the static contact angle of water with the therapeutic nail lacquer samples 
was carried out by the sessile drop method (19). 
Drops (2 – 4 L) were generated with a micrometric syringe and deposited on the substrate 
surface, inside a temperature-controlled chamber (25 °C), which had previously been 
saturated with water to avoid the drops’ evaporation. A sequence of images, obtained with a 
video camera (JVC Colour) mounted on a microscope (Wild M3Z) and connected to a frame 
grabber (Data Translation DT3155), was recorded during 60 s, starting from the moment of 
the drop deposition. Images were analyzed using the axisymmetric drop shape analysis-profile 
(ADSA-P) program. At least 6 drops were analyzed on the air-facing surfaces of each film. 
 
2.2.4 PALS  
The PALSs of the nail lacquer formulations films were determined by detecting the prompt -
ray (1.28 MeV) from the nuclear decay that accompanies the emission of a positron from the 
22Na radioisotope and the annihilation -ray (0.511 MeV). A fast-fast coincidence circuit of 
the PALS setup (featuring Pilot-U scintillators and XP2020 photomultipliers), with a time 
resolution of approximately 260 ps (FWHM), was used to record the positron lifetime spectra. 
The positron 22Na source (ca. ~10µCi, closed between Kapton  foils) was sandwiched by two 
identical samples. Several spectra were collected at room temperature. The lifetime spectra 
had a total number of ca. 4x106 integral counts and were evaluated using the LT (version 9) 
software (20,21). 
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2.2.5 SEM 
The SEM Field Emission Gun (FEG) SEM JEOL JSM-7001F was used to obtain images of 
the surface of each therapeutic nail lacquer formulation film. Human nails were obtained with 
nail clippers from the fingers of a healthy Caucasian female of 24 years of age, after ethical 
approval and informed consent. The nail plates were cut 24 h before each test. The nail plates 
were stored in a glass jar with paper moistened with distilled water to avoid dehydration. 
First, the formulations were applied on the nails, by using a thin rectangular plastic rod (3 x 
0,5 mm). The nails were dried at room temperature. The samples were gold sputter coated (10 
nm) in a chromium deposition equipment (Q150T ES, Quarum Technologies). 
 
2.2.6 Adhesion test 
The assessment of the adhesion of therapeutic nail lacquers was developed as an adaptation of 
ISO 2409:2013(22). This manual measurement of film adhesion is used to measure the 
resistance of paint coatings with a Kit Elcometer® 107. A quantity of 0.25 ± 0.02 g of the 
therapeutic nail lacquers were weighed and spread in cow horn samples, to create a 
homogeneous film. Cow horn samples were cut in cylinders 35 mm in diameter, 1.5 mm 
thick. The samples were polished with a 600 mesh SiC paper under flowing water for 
lubrication, and then rinsed with water. Afterwards, the samples were dried with absorbing 
paper and stored at room temperature. The nail lacquer formulations were applied on the cow 
horn samples and dried at room temperature for 15 min. Subsequently, the samples with nail 
lacquer films were cut in a lattice pattern with a cutting blade (Kit Elcometer® 107, France). 
The first cut was made at 45o angle to the direction of the grain and the second cut was 
repeated at 90o angle to the first. Afterwards, the sample was brushed (Kit Elcometer® 107, 
France). Then, an adhesive tape (ISO 2409 Elcometer® 107, France) with the size of the cow 
horn samples, was placed over the lattice pattern. The adhesive tape was removed at an angle 
of 60o with the surface, and the latter was examined and evaluated according to the 
classification of the ISO 2409:2013 guideline, where 5 refers to ‘very damaged’, meaning the 
lattice pattern and the sample have bad adhesion, and 1 refers to a value for good adhesion, 
corresponding to the integrity of the lattice pattern. The test was repeated 5 times for each 
therapeutic nail lacquer. 
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2.2.7 Viscosity measurement  
The determination of viscosity was performed in a cone-plate Brookfield® viscometer, model 
DV-II + Pro coupled with a constant temperature bath, previously gauged with a CPE-40 
spindle. The temperature of the measurement was 32 ± 0.2 oC, shear rate 375 s1 and shear 
stress 0.8-1 N/cm-2. A volume of 500 µL of therapeutic nail lacquer was used for this test. 
 
2.2.8 In vitro release of terbinafine hydrochloride from therapeutic nail lacquers 
For the in vitro release studies of terbinafine release from the therapeutic nail lacquers, 200-
300 mg of each formulation (equivalent to 2-3 mg of terbinafine hydrochloride) was weighed 
in glass slides, dried and suspended in 15 mL of a 0.5% Tagat® CH 60 aqueous solution. 
Containers were placed in an incubator-shaker at 32 ± 0.5 °C for 24 h. Samples of 1000 µL 
were collected at predefined times (1, 2, 3, 4, 8 and 24 h) and the same volume was replaced 
with fresh receptor solution maintained at the same temperature.  
The samples of terbinafine were analyzed by HPLC-UV in a Hitachi Elite Lachrom System 
(VWR, USA) equipped with four L-2130 pumps, an autosampler L-2200, a column 
Lichrospher 100 RP18 (150 mm x 4 mm, 5 µm, Merck), a UV Detector L-2400 and a signal 
processing software EZ Chrom Elite Version 3.2.1. The method used an isocratic gradient 
mobile phase containing 0.5% (v/v) triethanolamine, 84.5% (v/v) methanol and 15% (v/v) 
water. A ﬂow rate of 1.0 mL/min was used with a 10 µL injection volume. The auto sampler 
chamber was maintained at room temperature and the eluted peaks were monitored at a 
wavelength of 283 nm. The run time was 5 min. All chromatographic separations were carried 
out at 25 ºC. A calibration curve was performed using 19.8 µg/mL, 39.7 µg/mL, 79.4 µg/mL, 
99.2 µg/mL and 119 µg/mL of terbinafine hydrochloride in methanol. Three replicates per 
formulation were analyzed.  
The data obtained from the in vitro release studies was computed using a DDsolver (23), 
which is an Excel-plugin module, and the obtained data were fitted to four different kinetic 
models: zero order, first order, Higuchi and Korsmeyer-Peppas24. For all models, the adjusted 
coefficient of determination (R2 adjusted) was estimated, fitted and used as the model ability to 
describe a given dataset. 
Statistical analysis was performed on the release profiles obtained using an ANOVA two 
factor with replication, assuming p values ≤ 0.05 as statistically significant. 
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2.2.9 In vitro antifungal activity 
Candida albicans ATCC 10240, Aspergillus brasiliensis ATCC 16404 and Trichophyton 
rubrum ATCC 28188 were used for the determination of in vitro antifungal inhibitory activity 
of a terbinafine nail lacquer formulation. The test was performed according to the standard 
disc diffusion method (DDM) in accordance with the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (25). The Mueller-Hinton agar (BioKar, Spain) microbiologic 
medium was used. 
The test took place over 2 days for Candida albicans and 7 days for Aspergillus brasiliensis. 
For Trichophyton rubrum the study took place over 20 days under 22.5 ± 2.5 ºC and humidity 
≥ 85%. The positive or negative activity of the formulation was assessed according to the 
presence or absence of growth around the disks and is an indirect measure of the ability of the 
formulation to inhibit those microorganisms. Fungal inoculum: stock inoculum fungi 
suspensions were prepared from 5 –7 days old cultures grown on Mueller-Hinton agar. The 
suspensions obtained were diluted with distilled water to obtain a turbidity equivalent to a 
McFarlard 0.5 turbidity standard (25), containing 1.5 x 108 cfu/mL of microorganisms.  20 
mL of the Mueller-Hilton agar mediums were poured into petri dishes (90 mm diameter) and 
inoculated with 100 µL of the suspension containing 1.5 x 108 cfu/mL of each microorganism. 
Sterile paper discs (6 mm, Sigma-Aldrich, UK), were loaded with 15 µL of Formulation A PU 
19 with a concentration of 10 mg/mL.  Placebo formulations were used to compare the 
inhibition zones. The antifungal activity of the formulations was compared to the antifungal 
activity of a commercial terbinafine cream, Lamisil® 1%.  All the results were recorded by 
measuring the zone of growth inhibition surrounding the discs. All determinations were made 
in triplicate. 
 
3. Results and Discussion 
3.1 In vitro cytotoxicity  
The direct contact assay tests were carried out for the nail lacquer formulations and control 
glass slide. No significant morphologic changes were observed in the HaCaT cells in contact 
with any of the tested materials for all the studied time periods (results not shown). All nail 
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lacquer formulations presented values superior to 70% cell viability (Figure. 4.1), thus it can 
be concluded that these materials are biocompatible according to this viability assay. 
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Figure 4. 1. HaCaT cell viability by MTT after proliferation under different nail lacquer 
formulations. Control (glass slide) (mean±SD, n = 6). 
 
The evaluation of the formulations’ toxicity over cells surrounding the application site 
according to the ISO 10993-5:2009(16), is an essential test for the regulatory authorities of 
the pharmaceutical industry. Nail lacquer formulations are not in contact only with the keratin 
of the nail plate, but also come into contact with the skin. 
The keratinocyte cell line was selected to evaluate the cytotoxicity of the nail lacquer 
formulations containing terbinafine, since these cells are the predominant cell type in the 
epidermis, the outermost layer of the skin, comprising 90% of the epidermic cells, thus 
presenting an adequate in vitro cell model that better mimic in vivo conditions (9). After 
analyzing the nail lacquer formulations by direct contact, a monolayer of HaCaT cells was 
observed, hence the conclusion that the formulations are biocompatible. These results are in 
agreement with other applications of PU polymers that demonstrated their biocompatibility in 
HaCaT cell line for proteins delivery (34) and in L929 cell line for other applications (35). 
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3.2 Wettability 
The presence of water in the nail is related to the diffusion of drug through the nail (9) and for 
this reason it is important to measure the wettability of nail formulations. 
A water contact angle lower than 90° indicates that wetting of the surface is favorable and that 
the fluid will spread over a large area on the surface. On the other hand, contact angles greater 
than 90° mean that wetting of the surface is unfavorable; the fluid will minimize its contact 
with the surface and form a compact liquid droplet (26). 
The average values of the angles obtained were: Formulation A PU 19-10% TH, ɵ = 45 ± 6°, 
Formulation B PU 20-10% TH, ɵ = 77 ± 4° and Formulation C PU 21-10% TH, ɵ = 61 ± 4°. 
The nail presented a contact angle of ɵ = 94 ± 8°. The one-way ANOVA statistical test 
highlighted a significant difference between the mean values of the different PUs and the nail. 
 
The wettability test results showed water contact angles lower than those observed for the nail 
surface alone, which presented a reference value of 94º. In the work of Mândru et al., the 
polymers synthesized with poly (ethylene glycol), poly (butylene adipate), methylene 
diphenyl-diisocyanate and 1,4-butane-diol, presented contact angle values of 73º and 87º. This 
result explained the hydrophilic properties of the nail lacquer preparations, which contained 
PU with polyester and derivatives of carbohydrates in their chain structures (36). 
 
3.3 PALS determination of free volume in films 
This technique is the most efficient method for studying subnanometer size distributions and 
free volume fractions, which has been used to explain the free electron property, structural 
relaxation, mechanic deformation, permeability and physical aging of polymers (27,28,29,30). 
PALS was used to assess the free volume of the formulations. This non-destructive technique 
probes local free volumes between molecular chains in polymeric structures. In this 
technique, the anti-electron, i.e. the positron, is employed as a probe and monitors the lifetime 
of the positron and Positronium, Ps (a bound atom which consists of an electron and the 
positron), in the polymeric materials under study (31). Due to the positron’s positive charge, 
itself and the Ps are repelled by the polymers core electrons and trapped in open spaces, i.e. 
the free volume. The trapped Ps could appear either as a para-Positronium (p-Ps, spin singlet 
state) or as an ortho-Positronium (o-Ps, triplet spin state), with a relative abundance of 1:3, 
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respectively. The annihilation photons come from these open spaces mainly, and the results of 
the positron annihilation lifetime (PAL) measurements give evidence that the positron and the 
Ps are located in these preexisting free volumes in polymers. In PAL measurements, the 
observed lifetime () is the reciprocal of the integral of the positron and the electron densities 
at the site where the annihilation takes place (31). A larger hole, which has a lower average 
electron density, is expected to have a longer Ps lifetime. A correlation between the free 
volumes in molecular systems and the observed o-Ps has been postulated (32,33). This 
correlation is expressed in a semi-empirical equation (Equation 1) (33) between the o-Ps 
lifetime ( ) and the mean radius of holes (R): 
 
  (1) 
 
where  and R are in the units of nanosecond and angstroms, respectively, and ΔR (= 1,66 
Å) is the best fitting parameter between observed o-Ps lifetimes and known mean hole radii in 
porous materials. With equation 2, the mean free volume hole size in a polymeric material can 
be determined, by measuring the o-Ps lifetime. As the holes are assumed to have a spherical 
shape, this lifetime is related to a mean radius R. With this assumption, the correspondent 
free-volume cavity was calculated with the equation V = (4/3)R3. The intensity of the o-Ps 
lifetime component, , is often treated as a measure of the density of the holes31. The free 
volume fraction (Fv), Equation 3, is directly related to  and  through the following 
expression (31): 
 
 (3) 
 
Where C is an empirical scaling constant that reflects the probability of o-Ps formation. 
In the systematic PAL analysis it was observed that all spectra were well fitted with the 
components showed in Table 4.2; two short-lifetime components of around 200 ps and 420-
470 ps, which could be assigned to  the annihilation of free and trapped positrons, 
respectively, and the longest lifetime component (>2100 ps) was due, of course, to the pick-
off annihilation of o-Ps in the free volume holes. The values of the lifetime components and 
the intensities of the positron and o-Ps annihilation are presented in Table 4.2. 
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Table 4. 2. PALS parameters (lifetime and intensity components), hole radius (R) and free 
volume cavity associated with the o-Ps lifetime for PU, terbinafine based nail lacquers. 
Samples 1 
(ps) 
I1 
(%) 
2 
(ps) 
I2 
(%) 
o-Ps 
(ps) 
Io-Ps 
(%) 
Volume 
(Å3) 
Formulation A 
PU19-10% TH 
196.8±7.6 27.2±2.4 436.2±9.8 46.0 ±2.4 2190.0±1.0 26.8±0.1 114.2±1.1 
Formulation B 
PU20-10%TH 
212.8±6.6 32.2±1.8 470.5±9.4 39.5±1.9 2490.0±7.0 28.3±0.3 145.1±1.3 
Formulation C 
PU21-10%TH 
192.0±3.1 26.5±1.0 420.7±4.2 46.5±1.0 2153.0±5.0 26.9±0.2 110.8±1.1 
 
The free volume concept is extensively adopted in polymer science to explain the change of 
microscopic structure and to relate it to macroscopic properties. In the last decades, PALS 
measurements have revealed that a strong correlation exists between the free volume of 
polymers and the possibility of charging them for sustained release or for selection 
permeability (38).  
The free volume of the tested formulations was determined using PALS: the lifetime of o-Ps 
was used to define the size of free volume in the molecular system (holes) of the films and the 
intensity of the o-Ps lifetime  , to quantify the density of holes. The PALS results are 
summarized in Table 4.2.  The two short-lifetime components of around 200 ps and 420-470 
ps are assigned to the annihilation of free and trapped positrons, respectively. The longest 
lifetime component (>2100 ps) was due to the pick-off annihilation of o-Ps in the free volume 
holes. The o-Ps lifetime component and its intensity are the only parameters significantly 
sensitive to the change in the free volume and all attention must be given to the variation of 
these parameters. The values of the lifetime component and the intensity of the o-Ps for these 
formulations revealed that Formulation A PU19-10%TH and Formulation C PU21-10%TH 
had a similar free volume; indeed, both the radius of the holes (R) and the density of holes 
( ) were similar. On the other hand, Formulation B PU20-10%TH showed, 
simultaneously, higher values for  and , which were considered to be associated 
with an increase of the free volume fraction of this polymer, compared to Formulation A PU 
19-10% TH and Formulation C PU 21-10%TH. The PU19 and PU21 had identical molar 
ratios of PPG in the process of synthesis, while the PU20 had a higher molar ratio of PPG. 
The observed amorphous characteristic of PU20 was corroborated with the increase in the free 
volume fraction of Formulation B PU 20. The mean radius of the cavities of this formulation 
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was higher than Formulation A PU 19-10% TH and Formulation C PU 21-10%TH. 
Additionally, the value of  was also higher, revealing an increase of the number of 
cavities in these films. 
 
3.4 SEM 
Images of a nail without varnish (A) and three nails containing the three developed 
formulations were obtained by scanning electron microscopy (SEM) (Figure. 4.2). It was 
observed that the nail lacquers leave a homogenous film covering the entire nail, making the 
surface of the nails uniform. 
 
 
 
Figure 4. 2. Scan Electron Micrograph with 1000x magniﬁcation. A) dorsal surface of nail 
plate B) film of Formulation A PU 19-10%, C) film of Formulation B PU20-10%, D) film of 
Formulation C PU21-10%. 
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The nail lacquer films’ elucidated morphology, by SEM, revealed them to be homogeneous 
and smooth. The application of the nail lacquers improved the homogeneity of the nail 
surface, making it smooth and uniform. The nail lacquer film homogeneity, porosity and 
distribution were similar for the three nail lacquers.  Nevertheless, Formulation A PU 19-
10%TH and Formulation C PU 21-10%TH presented a thinner film with almost no pores, 
while Formulation B PU 20-10% TH showed visible pores and cracks, on the surface (Figure. 
4.2 C). This was related to the amorphous characteristics of PU20, presented in formulation 
B. The presence of terbinafine hydrochloride had no influence in the homogeneity of the films 
obtained after the formulation had been applied on the nails.  
 
3.5 In vitro adhesion test 
All the PU terbinafine nail lacquers adhered to the keratin of cow horn. The values of flaking 
in the lattice pattern for Formulation A PU 19-10% was 1.8 ± 0.5 and for Formulation C PU 
21-10% TH the value was 0.7 ± 0.5, which means that both formulations presented good 
adhesion to the keratin of cow horn. On the surface of the cross-cut area some detachment of 
small flakes of the coating could be observed where the cuts were intersected. In the case of 
Formulation B PU 20-10%TH, the value was greater than 5.0 ± 0.5, corresponding to a 
appearance of surface of cross-cut greater than 65 %. 
 
The nail lacquer film must adhere to the nail plate. The adhesion test procedure examines the 
cut area and the results obtained are compared to a six-step classification. The first three steps 
classification are satisfactory for general purposes and are used when a pass/fail assessment is 
required. 
Regarding Formulation A PU 19-10%TH and Formulation C PU 21-10%TH, the obtained 
adhesion values showed some detachment of small flakes of the coating at the intersections of 
the cuts, on the surface of the cross-cut area. These results are promising when compared to 
previous studies that assessed the adhesion of a UV-curable gel formulation with 
methacrylates; in this study, the coating flaked along the edges of the cuts partly in large 
ribbons and some squares detached partly or wholly, corresponding to higher mean cross-cut 
score values (3 and 4) (38).  
In the case of Formulation B PU 20-10%TH, the value corresponded to a classification of 5, 
which means the coating flaked along the edges and at the intersections of the cuts. The PU 
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terbinafine nail lacquer that presented the higher flaking in the lattice pattern was Formulation 
B PU 20-10%. This means it is not effective in adhering to the keratin of cow horn. On the 
other hand, the formulation with better adhesion to cow horn was the Formulation C PU 21-
10%TH, with a degree of flaking in the lattice pattern of 0.7. The increased values of 
adhesion are thought to be related to the proportional increase of isosorbide in the PU chain, 
due to the formation of hydrogen bonds between the NH groups of the cow horn’s keratin and 
the oxygen of the isosorbide sub-structure in the polymer. 
 
3.6 Viscosity values 
The viscosity values for the therapeutic PU terbinafine nail lacquers at 32 oC were: 2.62 ± 
0.04 mPa.s for Formulation A PU 19-10%; 2.67 ± 0.98 mPa.s for Formulation B PU 20-10%; 
and 3.42 ± 0.07 mPa.s for Formulation C PU 21-10%. There are no significant differences 
among the formulations, probably due to the fact that viscosity was determined at the same 
temperature used for the study of drug release (32 ± 0.5 °C); the aim was to mimic nail 
lacquer application. 
 
3.7 In vitro release of terbinafine from Formulations A PU 19-10%, B PU 20-10% and C 
PU 21-10% 
Figure 4.3 shows the release profiles of terbinafine hydrochloride from the PU based nail 
lacquers for 24 h. 
 
Figure 4. 3. Release profile of terbinafine from PU based nail lacquer for 24 h in aqueous 
solution of 0.5% Tagat® CH 60 at 32ºC (mean ±SD, n = 3). 
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All the formulations released the drug from the matrix. Additionally, the release data were 
fitted to different mathematical models to describe the release profile. The best-fit was 
obtained with the Korsmeyer-Peppas function for Formulation A PU 19-10%TH and 
Formulation C PU 21-10% TH and Higuchi function for Formulation B PU 20-10%TH; as 
confirmed by the highest values for R2adjusted and model selection criterion (MSC) and the 
lowest values for Akaike Information Criterion (AIC), they statistically described the best 
drug release mechanism (23,24). 
Concerning the release results, Formulation B PU 20-10%TH released the highest amount of 
drug (32.4%) in 24 h, followed by Formulation A PU 19-10%TH (17.3 %) and Formulation C 
PU 21-10%TH (2.6%). Once again, the polymer composition is an important factor, because 
it influences the diffusion of the drug from the nail lacquers. Formulation B PU 20-10% TH 
contained PU with a high PPG content, which permitted the incorporation of the drug in an 
amorphous state. The degree of solvent permeability of Formulation B PU 20-10%TH, 
determined by PALS, resulted an increase of released terbinafine due to a higher water 
permeability (39). Formulations A PU19-10% and C PU21-10%TH, showed a delayed release 
of terbinafine in the tested time range. Therefore, the contact with the receptor solution was 
lower and the holes’ radii in these formulations reduced the permeation of solvents, leading to 
a lower diffusion of the drug through the nail plate. All release profiles suggested a diffusion-
controlled release over the tested time period. According to the kinetic models, the diffusion-
controlled release behavior was due to the dispersion of terbinafine in a homogeneous and 
uniform matrix, which acted as the diffusional medium, indicating a uniform drug distribution 
over the PU matrix (40,41). 
However, as formulation C PU 21-10%TH has more hydrophilic groups, leading to a more 
reticulated network (a gel) which does not allow the drug to be released. 
 
3.8 Antifungal activity 
The antifungal activity of the drug against Trycophyton rubrum, Candida albicans and 
Aspergillus brasiliensis was determined in terms of the mean diameter of zone inhibition. The 
results obtained are shown in Table 4.3. Formulation A PU 19-10% was proved to be more 
effective (higher inhibition halos) for the Trycophyton rubrum and Candida albicans when 
compared to the commercial cream. 
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Table 4. 3 Antifungal activity of different formulations with terbinafine against Trycophyton 
rubrum, Candida albicans and Aspergillus brasiliensis. 
  Inhibition zone (mm) 
 
Formulation A 
PU19-10%TH 
Formulation B 
PU20-10%TH 
Formulation C 
PU21-10%TH 
Solution of 
terbinafine 1% 
Commercial 
Cream 
Candida albicans 
ATCC 10240 
38.4±3.6 26.7±0.5 27.3±2.6 21.4±1.8 < 6 
Aspergillus 
brasiliensis 
ATCC 16404 
25.0±0.4 26.8±1.7 24.4±0.6 32.0±0.8 27.0±0.1 
Tricophyton 
rubrum 
ATCC 2818 
90.0±0.3 n.d. n.d. n.d. 26.6±0.1 
                n.d: not determined.  
 
The Minimum Inhibitory Concentration (MIC) is the lowest drug concentration that prevents 
microbial growth. A lower MIC value indicates that less drug is required for inhibiting the 
growth of a microorganism. Therefore, drugs with lower MIC scores are more effective. The 
reference terbinafine MIC values vary from 0.004 to 1 µg/mL against Tricophyton rubrum 
(6), Candida albicans and Aspergillus brasiliensis (42).  All formulations presented 
antifungal activity (Table 4.3). The controls presented inhibition zone ˂ 6 mm. 
The antifungal activity results demonstrated that Formulation A PU 19-10%TH showed 
activity against dermatophytes and non-dermatophytes. In addition, Formulation B PU20-
10%TH, Formulation C PU21-10%TH showed lower inhibitory effects against Candida 
albicans in compared to Formulation A PU 19-10%TH. 
Although the activity substance concentration is the same in all preparations, the commercial 
reference (Lamisil® 1% cream) is a formulation with higher viscosity values which may 
influence the release of terbinafine and consequently the microbiological efficacy. 
The Formulation B PU 20-10%TH showed the higher antifungal activity against Aspergillus 
brasiliensis. However, Formulation A PU 19-10%TH presented higher antifungal activity 
against Candida albicans, probably by the influence of -NH- of polyurethane in the pH of the 
medium that potential the antifungal activity of the drug. The in vitro activity of terbinafine is 
pH dependent and rises with increasing pH value (43). 
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4. Conclusions  
In the present work, three nail lacquer formulations employing polyurethanes for the release 
of terbinafine were characterized. Relevant properties for the intended application were 
studied, namely cell viability, wettability and free-volume. All the formulations were 
biocompatible with keratinocytes and presented hydrophilic properties. The PALS study 
indicated that the nail lacquer formulations have  an unusually high free-volume. The nail 
lacquers showed potential to adhere to the nail plate, and the formulation film (after 
application) formed a homogeneous layer of terbinafine hydrochloride, according to images 
obtained by SEM and the mechanical test. 
These studies contributed to the development of new nail lacquer formulations with adequate 
properties for controlled drug release, nail adhesion and biocompatibily for the treatment of 
onychomycosis. The antifungal activity of the nail lacquer formulations were demostrated. 
The Formulation A PU 19-10%TH allow more effective action against Trycophyton rubrum, 
Candida albicans and Aspergillus brasiliensis. 
Furthermore, it contributed to the fine-tuning of a novel controlled drug release system: PU 
based nail lacquers, containing terbinafine hydrochloride as a model drug.  
The novel system showed potential to be further developed as a topical polyurethane based 
nail lacquer for the treatment of onychomycosis. It is expected that this novel system may be 
used to release many other lower molecular weight, ionic drugs to keratinous surfaces. 
According the results obtained new formulations must be performed studing the content of 
PU19. 
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Chapter 5: Formulation optimization of PU based Nail Lacquers 
containing Terbinafine hydrochloride and Ciclopirox Olamine 
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1. Introduction 
Onychomycosis is a nail fungal infection caused by dermatophytes, non-dermatophytes and 
yeast species(1). 
Candida species have a high incidence in fingernail infection, present in as many incidence of 
as 75% of cases, and are more prevalent than dermatophytes(2). In contrast, the incidence of 
yeasts in toenail infections is much lower; approximately 2-10% cases. Infection attributed to 
non-dermatophytes are estimated to be 2-65% of cases although higher rates, 15% have been 
reported(3). 
The untreated onychomycosis may worsen, spread to other uninfected locations (other nails or 
to the surrounding skin) or infect other patient (4).  
Nail keratin is impermeable structure thus restricting drug access to the organisms causing 
onychomycosis(5). The development of therapeutic transungual drug delivery is an urgency 
for patients that are affected by such infection. 
Topical treatment would be of special interest for immunosuppressed, diabetic and elderly 
patients who suffers from chronic pathologies and follow long-term drug therapies and among 
whom the prevalence of onychomycosis is higher(5,6). Despite an active interest in method 
aimed at improving the efficacy of such formulations and the permeation study is testified by 
recent research report (7–10). 
Many antifungal formulations have been developed. Some of them are related with ciclopirox 
olamine and terbinafine hydrochloride. 
The ciclopirox olamine (CPX) is used in nail topical formulations have been marketed 
worldwide for about 25 years and it is available in different pharmaceutical preparations: 
creams (Selergo®, Mycoster®, 1%), lotion (Mycoster®, 10mg/L) (11), gel (Loprox®, 0.77%) 
(12) and solutions, such as  Penlac®, Batrafen®, Mycoster®, Ciclopoli®, Ony-Tec® and 
RejuveNail® containing 8% of active substance. They present butyl monoester of poly methyl 
vinyl ether/maleic acid (5) or hydroxy propyl chitosan as film formers (13). The CPX present 
a minimum inhibitory concentration value for Candida albicans and Aspergillus species 
between 0.13-4 µg/mL (14,15). 
On the other hand, terbinafine hydrochloride (TH) is used in systemic and topical 
formulations (Lamisil® cream, 1%, Mycova® nail coat, 10%, TDT 067 liquid spray, 15 
mg/mL and P-3058, hydroxypropyl chitosan based, 5%) (5,16).  These nail  formulations uses 
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dodecyl 2-(N,N dimethylamino)-propionate hydrochloride, soybean phosphatidylcholine and 
hydroxypropyl chitosan, respectively (5). TH, an allylamine derivative, represents the most 
effective antimycotic drug, presenting a minimum inhibitory concentration against 
dermatophytes of 0.004-0.06 µg/mL(17), non-dermatophytes of 0.063-2.5 µg/mL(18) and 
yeast of 0.06-8 µg/mL(18) 
All of them have proved to be effective presenting transungual permeation. However, there is 
a need to improve the patient compliance with less repeat applications meaning that topical 
nail’ formulations needs to be improved.  Nail lacquers, formulated with polymers that act as 
film former agents, could be an alternative to be used as of new drug carriers(9). 
In this study, the influence of polyurethanes (polymer) concentration on the properties of nail 
lacquer formulations is assessed and compared with a commercial formulation. The 
incorporation of two drugs (TH and CPX) validated the use of PU as versatile polymers in 
nail lacquer formulations. Direct contact cytotoxicity, wettability, SEM, adhesion, drying 
time, viscosity measurement, permeation studies and antifungal activity were performed in 
order to achieve these aims. 
 
2. Material and methods 
2.1 Materials 
Ethanol anhydrous, butyl acetate and ethyl acetate were acquired from Carlo Erba (France). 
The terbinafine hydrochloride manufactured by Uquifa México S.A. was kindly offered by 
Generis. Tagat® CH 60 (PEG-60 Hydrogenated Castor Oil) was a kind gift from Evonik 
(Germany). PU 19 was synthesized in laboratory of IST according to described in the chapter 
3. Ciclopirox was obtained from Fagron Iberica (Spain), Ony-Tec® was kindly offered by 
Laboratorio Medea, Reig Jofre (Spain).  
  
2.2 Methods 
2.2.1 Preparation of Nail lacquers 
The PU 19 was the polymer selected for preparing 5 different nail lacquers formulations 
containing 1% of drug (TH and CPX). Different polymer concentrations (10%, 15%, 20% and 
25%) were employed. The formulations were prepared according to component described in 
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Table 5.1. Firstly, polyurethanes have been fully solubilized in ethanol under stirring (200 
rpm). Afterward, the solvents and the drugs (TH and CPX) were added, separately, until its 
complete dissolution. Placebos, formulations with no drug, were also prepared. 
A commercial formulation containing 8% (w/v) of CPX was also used as a control: Ony-
Tec®. It´s qualitative composition is ethanol, water, ethyl acetate, hydroxipropyl chitosan and 
cetylstearyl alcohol.  
 
Table 5. 1. Nail lacquers composition. 
 Formulation A 
PU19-10%  
TH 
Formulation D 
PU 19-15%  
TH 
Formulation E 
PU 19-20% 
TH 
Formulation F 
PU 19-25%  
TH 
Formulation G 
PU19-10% 
CPX 
PU 19 10 15 20 25 10 
Terbinafine 
HCl (TH) 
1.0 1.0 1.0 1.0 - 
Ciclopirox 
(CPX) 
- - - - 1.0 
Ethyl 
acetate 
7.8 7.2 6.8 6.3 17.8 
Butyl 
acetate 
10 9.6 9.0 8.5 - 
Ethanol 71.2 67.2 63.2 59.2 71.2 
 
2.2.2 Direct contact cytotoxicity assay for Nail lacquer 
The cytotoxicity test are described in chapter 3, section 2.2.11. 
 
2.2.3 Determination of wettability by contact angle measurement  
The contact angle measurement is described in chapter 4, section 2.2.3 
 
2.2.4 SEM 
The nail morphology study before and after nail lacquer formulations were applied are 
described in chapter 4, section 2.2.6.  
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2.2.5 Adhesion test 
The adhesion of nail lacquers test is described in chapter 4, section 2.2.7 
 
2.2.6 Drying time for nail lacquer therapeutics 
The nail lacquer must dry. A quantity of 0.25±0.02g of the nail lacquers were weighed and 
spread into a glass, to create a homogeneous film. The drying time was measurement with a 
chronometer. This methodology was adapted from ISO 2409:2013(19). 
 
2.2.7 Viscosity determination  
The viscosity determination is described in chapter 4, section 2.2.7. 
 
2.2.8 In vitro release of terbinafine from nail lacquers containing different 
concentrations of PU  
In vitro release studies were performed using Franz diffusion cell apparatus through a 
hydrofilic membrane (Tuffryn® Membrane) (Pall corporation 79579I), with a diffusion area 
of 1cm2 for 6 hours (20). The receptor phase was solution Tagat® CH 60 in water 0.5% 
established based on a preliminary solubility study of terbinafine. The system was maintained 
at 37±0.5°C for approximately 30 minutes before starting the experiment and during the 
course of the same. The receptor medium was homogenized by small magnetic bar stirring. 
The amount applied was 200-300 mg for either formulation (equivalent to 2000-3000 µg of 
terbinafine). Samples of 200 µL were collected at predefined times (0, 1, 2, 3, 4, 5 and 6 
hours) and the same volume was replaced with fresh receptor solution maintained at the same 
temperature.   
The samples of terbinafine were analysed by HPLC-UV in a Hitachi Elite Lachrom System 
(VWR, USA) equipped with four Pumps L-2130, an autosampler L-2200, a column 
Lichrospher 100 RP18, (150mm x 4mm, 5µm, Merck), an UV Detector L-2400 and signal 
processing by software EZ Chrom Elite Version 3.2.1. The method used an isocratic gradient 
mobile phase containing, 85% (v/v) methanol and 15% (v/v) solution of water 0.5% 
triethanolamine. A ﬂow rate of 1.0 mL/min was used with a 10 µL injection volume. The auto 
sampler chamber was maintained at room temperature and the eluted peaks were monitored at 
wavelength of 283 nm. The run time was 5 min. All chromatographic separations were carried 
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out at 25ºC. A calibration curve was performed using 19.8 µg/mL; 39.7µg/mL; 79.4 µg/mL; 
99.2 µg/mL and 119 µg/mL of terbinafine hydrochloride in methanol. Six replicate containers 
for each formulation were analyzed. 
 
2.2.9. In vitro antifungal activity 
Candida albicans ATCC 10240 and Aspergillus brasiliensis ATCC 16404 were used for the 
determination of in vitro antifungal inhibitory activity of a terbinafine and ciclopirox nail 
lacquer formulations. The test was performed according to the standard disc diffusion method 
(DDM) in accordance with the Clinical and Laboratory Standards Institute (CLSI) 
guidelines25. The potato dextrose agar (PDA) (BioKar, Spain) and sabouraud dextrose agar 
(SDA) (BioKar, Spain) microbiologic media were used for A. brasiliensis and for C. albicans, 
respectively. 
The test took place over 2 days under 37 ± 2 ºC for C. albicans and 7 days under 22.5 ± 2.5 
ºC for A. brasiliensis. The positive or negative activity of the formulation was assessed 
according to the presence or absence of growth around the disks and is an indirect measure of 
the ability of the formulation to inhibit those microorganisms. A. brasiliensis inoculum was 
prepared from 5–7 days old cultures grown on Mueller-Hinton agar (BioKar, Spain). The 
suspensions obtained were diluted with distilled water to obtain a turbidity equivalent to a 
McFarlard 0.5 turbidity standard25, containing 3.4 x 108 cfu/mL of microorganisms.  C. 
albicans inoculum was prepared from 1 day cultures grown on Mueller-Hinton agar. The 
suspensions obtained were diluted with distilled water to obtain a turbidity equivalent to a 
McFarlard 0.5 turbidity standard25, containing 7.2 x 108 cfu/mL of microorganisms.  Sterile 
paper discs (6 mm, Sigma-Aldrich, UK), were loaded with 15 µL of each formulation.  
Placebo formulations were used to compare the inhibition zones. All the results were recorded 
by measuring the zone of growth inhibition surrounding the discs. All determinations were 
made in duplicate. 
 
2.2.10. Final formulations - Permeation studies 
The nail tips were obtained by cutting the free edge of the nail plate of healthy volunteer 
(female 25 years old) after ethical approval and informed consent. The samples had a 
minimum length of 5 mm. The nail tips were hydrated in 10 mL receptor solution (some in 
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aqueous solution of 0.5% Tagat® CH 60 and the other in phosphate buffer saline to which 
sodium azide) for 1 h. Ony-Tec® was used as control. The nail tip samples were sandwiched 
between two cylindrical adapters made of polytetrafluoroethylene (PTFE) (Mecanizados del 
noroeste, Santiago de compostela, Spain) with an o-shaped ring providing an effective 
diffusional area of 0.049 cm2. The set was placed between the donor and receptor chambers of 
vertical Franz-type diffusion cell (Vidrafoc, Barcelona, Spain) of the dorsal and ventral layers 
of the nails faced the donor and the receptor compartments, respectively. The donor chamber 
contained either 2 ml of one of the nail lacquer (Formulation A PU19-10% TH, Formulation 
G PU19 10% CPX) and was covered with parafilm®. The receptor medium, 5.5 mL receptor 
volume, was aqueous solution of 0.5% Tagat® CH 60 for Formulation A PU19-10% TH and 
phosphate buffer saline which sodium azide (30 mg/L) pH 7.4 (9) for Formulation G PU19-
10% CPX and Ony-Tec®. The receptor compartments were at constant temperature by use of 
thermostated (32± 0.5 oC) water. The sink conditions were assumed. Samples of 1000 µL 
were collected at predefined times (each day at same time) and the same volume was replaced 
with fresh receptor solution maintained at the same temperature. The experiments were 
performed for 11 days and three replicates were made for each condition (9). 
The amount of TH and CPX present in the nail plate at the end of penetration experiment was 
also determined by UV spectrophotometry (spectrophotometer diode array Hewlett Packard 
8452A). The wavenumber for terbinafine was 283 nm (21) and for ciclopirox 308 nm (9) after 
the drug extraction. The section of the nail exposed to the formulation was cut, weighed and 
cut in small fragments that were transferred into a vial containing either 5 ml of receptor 
solution at 5% in methanol. Later, the prepared solutions were incubated and shaken for 4 
days at room temperature to facilitate drug extraction. The CPX extraction method was 
adapted and validated from the literature (9,21) while the TH extraction method was validated 
for sensitivity, linearity and precision in the concentration range of 6.32 µg/mL-31.6 µg/mL 
(r2=0.9884, calibration curve standards were assayed together with every sample batch to 
account for inter day variability). 
Standard and blank solutions were made up using PBS buffer (pH 7.4) containing 30 mg/L of 
sodium azide and aqueous solution of 0.5% Tagat® CH 60. 
The data were normalized to account for thickness of the nails. 
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2.2.11 Porosity measurement 
Untreated and treated nail samples were analyzed using a Micromeritics 9305 pore sizer 
(Norcross GA, USA) fitted with a 3-mL powder penetrometer and working pressures in a 
0.004–172.4 MPa range. Nail tips were used as described in chapter 5, section 2.2.10. 
The nails were soaked in 10 mL of either water Ony-Tec and Formulation A PU19-10% TH. 
Later the samples were stored at room temperature for 24h. After the time, the nails were 
removed from the solution tested, dried and determined the porosity. The amount of nail tip 
for test was approximately 0.6 g. The pore size data were used for modeling the porous 
structure of the samples as simulated porous networks using poreXpert™ 1.3 software 
(Environmental and Fluid Modelling Group, University of Plymouth, UK)(22). 
 
3. Results and discussion 
3.1 Direct contact assay 
The cell viability test was carried out for nail lacquer containing different percentages of 
polymers and control slide glass. Phase contrast micrographs were taken at the interface of the 
cell layer with outer contact areas of the different matrices. 
In the Figure 5.1, were observed the color of HaCaT cells in contact with MTT. The purple 
color was detected in the almost every samples, confirming the viability of cell in contact with 
all the formulations. These results corresponding to the measurement of PU19 section 3.9, 
chapter 3. 
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Figure 5.1. Micrograph with 400x magniﬁcation of HaCaT cells after 72h of proliferation 
under contact with different therapeutic nail lacquer: A) glass slide, B) Formulation A PU19-
10% TH, C) Formulation D PU19-15% TH, D) Formulation E PU19-20% TH, E) 
Formulation F PU19-25% TH and F) PU19. 
Figure 5.2 represents the percent of  cell viability measured by the MTT reduction for  the nail 
lacquer formulations.  
 
Figure 5. 2.  HaCaT cell viability by MTT after proliferation under different nail lacquers. 
Control (glass slide), (mean ± SD, n = 6). 
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From Figure 5.2 it can be observed that PU 19, Formulation A PU19-10% TH, Formulation D 
PU19-15% TH, Formulation E PU19-20% TH and Formulation F PU19-25% TH presents a 
cell viability (measured by the MTT reduction) that did not differ significantly from the 
control (glass slide) and PU19 (section 3.9, chapter 3). The polymer concentration did not 
influence the cell viability. 
The Formulation G PU19-10% CPX cell viability is 12% (significantly different from control 
for p<0.05). This formulation is not biocompatible and not allow cell growth. 
The results of cell viability of PU19-10% CPX probably present relation to the proportion of 
ethyl acetate and the ciclopirox. Ethyl acetate is used as a solvent for chemical reactions and it 
is often used in cosmetics as nail polishes because is not toxic but in short-term exposure to 
high levels of ethyl acetate results in irritation of different tissues (23) 
All the samples tested with TH allow the cell proliferation under the surface covered by the 
polymers that was confirmed by the presence of a monolayer of viable cells.  
The Formulation G PU19-10% CPX, will be study in the rest of the chapter only with 
comparative objective. 
 
3.2 Wettability 
 As referred previously (section 3.2, chapter 4), the wettability tests show that the water 
contact angle of PU19 based nail lacquer is lower than the one observed for the nail surface 
alone, which presented an average value of 94º, indicating that the nail lacquer favors the 
wetting of the surface. However, different concentrations of the polymer in the solutions that 
were used to prepare the films led to variations in the water contact angle. An increase in the 
content of PU19 origins higher contact angles: while for 10% of PU19 a water contact angle 
of 45º4º is obtained, for 20% of PU19 it increased to 66º4º and for 25% to 68º11º (Figure 
5.3). This fact shall be related with the surface morphology of the films, since the chemical 
composition is the same after the evaporation of the solvent. As it can be observed in SEM 
images (see below, Figure 5.4), the surfaces of Formulation A PU19-10% TH are more 
irregular than those produced from solutions with higher contents of polymer. This behavior 
may be explained by the Wenzel theory(24). According to this author, the equilibrium contact 
angle in a rough surface (W, apparent Wenzel angle) is related with the real contact angle () 
trough Equation 1: 
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cos W = r cos        (1) 
 
where r is a roughness factor, defined as the reason between the real surface area and the 
corresponding projected area. This approach implies that an increase of roughness leads to a 
decrease of the observed contact angle when W is lower than 90º, as is the case. 
 
 
Figure 5.3.Water contact angle of PU terbinafine nail lacquers (mean ± SD, n= 3). 
Wettability measurements were also carried out with samples PU19-10% loaded with CPX, 
instead of TH. The water contact angle was similar in both cases (45º4º and 42º4º, 
respectively), being visible that the surface morphologies are similar (Figure 5.4 below). This 
means that the nature of the drug does not affect the wettability of the surfaces. 
Overall, these results allow to select Formulations A PU19-10% and G PU 19-10% CPX as 
those which present better wettability properties.   
 
3.3 SEM 
The images obtained by SEM of nail lacquers show homogeneous films, which cover the 
surface to the nail as observed in Figure 5.4. 
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Figure 5.4. Scan Electron Micrograph with 1000x magniﬁcation. A) dorsal surface of nail 
plate B) film of Formulation A PU 19-10% TH, C) film of Formulation D PU19-15% TH, D) 
film of Formulation E PU19-20% TH, E) film of Formulation F PU19-25% TH, F) film of 
Formulation G PU19-10% CPX and G) Ony-Tec®. 
 
The inclusion of the drug (TH or CPX) had no influence on film thickness and on the film 
thickness and on the microstructure of PU based nail lacquers. However, Ony-Tec® did not 
form a homogenous film in the surface of the nail. These measurements indicated that the 
application of the PU nail lacquers coated the roughness of the nail surface, making it smooth 
and uniform, while chitosan film from (9) was similar to the untreated nail with visible pores 
and cracks on the surface.  
 
3.4 Adhesion test results 
The nail lacquer must to adhere to nail. The duration of residence of the film on the nail plate 
is therefore critically important, because the film of nail lacquer acts as a drug depot, from 
which the drug can be continuously released and permeate into the nail. A film with a long 
residence time would need less frequent lacquer application, which could in turn lead to 
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increased patient compliance, improved treatment efficacy and reduced cost of treatment (25). 
In the Figure 5.5 are presented the evaluation of adhesion test. 
 
 
Figure 5.5. Nail lacquer adhesion test to keratin of cow horn. 
 
All the formulations presented adhesion to keratin of cow horn, as observed in Figure 5.5. The 
adhesion values in cow horn corresponding to better results in compared with the result of 
adhesion from nail lacquer formulated with methacrylates, where the cross cut mean score 
were between 4 and 5 (10). 
On the other hand, the nail lacquer that presents the higher flaking in the lattice pattern was 
formulation Ony-Tec®. The formulation Ony-Tec® is a chitosan derivative’ hydrogel.  
Previously study by SEM showed a film with pores and cracks on the surface of nail, 
furthermore hidroypropyl chitosan is a water soluble  film former with affinity to keratin(26). 
The results obtained permit to concluded that the polyurethanes films present more affinity to 
keratin that Ony-Tec®. 
The formulation with more adhesion to cow horn was the Formulation G PU 19-10% CPX, 
with a degree of flaking in the lattice pattern of 0.1, probably, because the  formulation G 
PU19-10% presented highest value ethyl acetate as solvent and permit more exposition of  the 
hydrophilic group of polyurethane to keratin of cow horn (27).  
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3.5 Nail lacquer’s drying time  
For complaint of patient the formulation must dry in the nail (29–32). In table 5.2 is observed 
the value of drying time of formulation. 
 
Table 5. 2. Nail lacquer’s drying time (mean±SD, n= 3). 
 
Formulation Time (min) 
Formulation A PU19-10% TH 9±0.1 
       Formulation D PU19-15% TH            10±0.3 
Formulation E PU 19-20% TH 15±0.1 
Formulation F PU19-25% TH 16±0.2 
          Formulation G PU19-10% CPX 7±0.1 
Ony-Tec® 13±0.1 
 
The PU formulations present drying times from 9 to 16 min. In fact, the higher the 
concentration of the polymer, the longer the drying time of the nail lacquer. These results are 
in agreement with the solvent contents because the higher the concentration of ethyl and butyl 
acetate the shorter the drying time. 
 
The Ony-Tec® presents a drying time of 13 minutes, which is related to its composition. 
Ethanol is main solvent of this formulation. According to these results, Formulation A PU19-
10% TH, Formulation D PU19-15% TH and the Formulation G PU19-10% CPX should be 
selected. 
 
3.6 Viscosity values 
The values of viscosity for the PU terbinafine nail lacquers at 32oC in order to mimic nail 
lacquer application are shown in Table 5.3. It observed that the higher the concentration of 
polymer increased the viscosity.    
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Table 5. 3. Viscosity values of therapeutic nail lacquers (mean±SD, n= 3). 
 
Formulation Viscosity (mPa.s) 
Formulation A PU19-10% TH 2.62±0.04 
Formulation D PU19-15% TH 4.70±0.06 
Formulation E PU19-20% TH 8.80±0.11 
Formulation F PU19-25% TH 17.03±0.07 
Formulation G PU19-10% CPX 2.24±0.04 
Ony-Tec® 5.47±0.06 
 
As already explained in chapter 4, formulations that presents more reticulated network (a gel) 
do not allow a high release of the drug. Thus, and using Ony-Tec® as a reference with regard 
to viscosity values, Formulation A PU19-10% TH, Formulation D PU19-15% TH and 
Formulation G PU19-10% CPX are the ones that, probably should release the amount of drug 
needed to be effective (35).  
 
3.7 Preliminary test for select formulation with better condition to release the 
terbinafine 
In order to confirm that the polymer concentration affect the drug release an in vitro 
preliminary test was assessed just using the TH formulations. The results confirm that the 
highest the polymer concentration the less amount of drug is released (Figure 5.6).  
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Figure 5.6. Release of TH from different formulations at 32 ºC (mean ± SD, n = 6). 
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The Formulation A PU19-10%TH release 66.96%, after 6h, while the rest of formulation 
retain the terbinafine in the matrix for the same time of study. The Formulation D PU19-
15%TH release 16%, the Formulation E PU19-20%TH release 10.6% and the Formulation F 
PU19-25%TH release 6%. These results indicated that the increase of amount of polymer, 
decreases the release of terbinafine from the formulations. 
In another study with the aim of investigate the role of hydrophilic polymers in sustaining the 
release of drugs in tablets dosages form, was find that the higher viscosity, have relation with 
resistance of matrix to dissolution and erosion. It was study that matrix prepared with hydroxy 
propyl methyl cellulose, present more viscosity of hydroxyethyl cellulose, this increase of 
viscosity could explain the release retardation property of the hydroxy ethyl cellulose (36). 
Furthermore, the movement of the drug solute through the matrix system is diffusion 
controlled, it may be expected that the dissolution process will be slower in the more viscous 
medium (35). 
 
3.8 Antifungal activity 
The antifungal activity of the drugs against Candida albicans ATCC 10240 and Aspergillus 
brasiliensis ATCC 16404 were performed. The results are shown on Table 5.4. 
The terbinafine present antifungal activity against Candida albicans(37) however the CPX is 
more effective against this yeast(18). 
On the other hand the CPX present lower activity against Aspergillus brasiliensis(18). 
 
Table 5. 4. Inhibition zone (mm) of all formulations in plate dish for Candida albicans, and 
Aspergillus brasiliensis (mean±SD, n=2). 
 
 Inhibition zone (mm) 
 
Formulation A 
PU19 10% TH 
Formulation D 
PU19 15% TH 
Formulation E 
PU19 20% TH 
Formulation F 
PU19 25% TH 
Formulation G 
PU19 10% CPX 
Solution 
TH(1%) 
Solution  
CPX(1%) 
Ony-Tec® 
Candida 
albicans 
ATCC 10240 
38.4±3.6 29.7±0.4 29.0±0.6 26.2±1.0 32.3±1.3 21.4±1.8 29.0±1.1 43.9±2.0 
Aspergillus 
brasiliensis 
ATCC 16404 
25.0±0.4 23.7±0.6 23.2±0.1 21.1±1.7 26.7±0.3 32.0±0.8 31.4±0.4 33.3±0.4 
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All the nail lacquer formulation presents antifungal activity against the fungi of the study. 
The results obtained demonstrated the nail lacquer formulations with higher antifungal 
activity, are the ones that have the lower polymer concentration probably, because they allow 
a higher release of the drug. All the control formulation presented inhibition zone < 6mm. 
The solution TH formulation presented higher inhibition zone against Candida albicans 
probably for the influence of -NH- of polyurethane in the pH of the medium that potential the 
antifungal activity of the drug. The in vitro activity of terbinafine is pH dependent and rises 
with increasing pH value (38). 
The Formulation G PU19-10% CPX present one interesting value of antifungal activity in 
comparison with Ony-Tec®.  
 
3.9 Permeation Test 
Know the amount of drug that permeates the nail in an animal model similar to that of man, 
for purposes of pre-clinical studies is still under study and to date has not been established. 
The optional solution to be able to study the passage of the drug is the use of healthy human 
nails (4,39,40). 
Permeation profiles of drugs into the nail are shown in Table 5.5. As it was observed, in 
release experiments (section 3.6), the presence of polyurethane allows the diffusion of 
terbinafine trough hydrophilic membrane and as expected the results of this study was similar. 
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Table 5. 5. Permeation profiles of formulations and Ony-Tec® trough the nail. (mean±SD, 
n=3). 
Time 
(h) 
Amount of Drug Diffusion (µg/cm3)  
Formulation A 
PU 19 10% TH 
Formulation G 
PU19 10% CPX 
Ony-Tec 
24 1542.24 ± 896.73 561.31 ±482.34 282.53 ±53.70 
48 4030.43 ± 3934.95 3502.19 ± 2639.37 290.53 ±43.50 
72 3809.94 ± 3435.92 3695.06 ± 2829.67 342.53 ±43.80 
96 3899.71 ± 3386.31 3850.59 ± 2938.92 582.53 ±43.70 
120 4273.13 ± 3659.95 3992.68 ± 2929.31 540.53 ±33.60 
168 4405.92 ± 3714.03 3691.65 ±2627.53 560.53 ±23.70 
192 4236.98 ± 3488.06 3723.40 ±2640.22 550.53 ±43.80 
216 4214.38 ± 3343.91 3810.57± 2671.87 586.53 ±53.20 
240 4389.38 ± 3454.15 3910.11±2785.01 593.53 ±67.20 
264 4435.47 ± 3391.68 3909.61 ± 2769.71 598.53 ±33.20 
 
The values of drugs permeated trought the nail from Formulation A PU19-10% TH after 11 
days was 4435.47 µg/cm3 and from Formulation G PU19-10% CPX was 2649 µg/cm3. The 
results showed that the total amount of TH permeated trought the nail was higher than the 
CPX and Ony-Tec®. 
The permeated profiles of both drugs indicate that the higher concentrations in receptor 
solution are obtained in the first 120 hours after application, probably attributed to the 
presence of ethanol in the tested formulation. The ethanol increased the drug solubility in the 
vehicle and has action as enhancer (41) . Furthermore, the small molecular size of both drugs 
allows the permeation through the nail (TH-291.43 g/mol and CPX-207.3g/mol)(5). 
Regarding to standard deviation find in all the formulation testing is possible to conclude that 
in the permeation process influence: the thickness of nail that if different from one individual 
to another and the composition of nail (percent of water, lipid, mineral)(42) and drug-keratin 
interactions(43). 
In another research where were testing the diffusion coefficient of amorolfine, terbinafine and 
caffeine, the standard deviation was significates. The author explains that the data which were 
not corrected in terms of nail thickness, however the number of replicated were n=5-7 for 
caffeine, n=11-13 for the amorolfine and n=13-15 for terbinafine did not prevent the finding 
of equal and superior deviations from the determination(4). 
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Then the quantities of each drug were determinate in the nail plate. Results are shown in 
Figure 5.7. 
 
Figure 5.7. Amount of drug determined in nail plate after 11 days of experiments. One-way 
ANOVA and Tukey’s multiple comparison tests indicates significant differences between 
Ony-Tec® and PU based nail lacquer formulations. 
 
The amount of CPX and TH determined in nail plate, showed similar values, furthermore the 
formulations based polyurethane retain more drug in keratin structure that Ony-Tec®, 
probably to the concentration of ethanol as vehicle in the formulation. 
The amount of TH determined in nail presented higher values (>0.004 -1 µg/mL), value of 
minimum inhibitory concentration of TH against Candida albicans  and Aspergillus 
species(18). 
On the other hand the values of CPX determined in nail are superior to the range 0.015- 4 
µg/mL corresponding to minimum inhibitory concentration of drug, against Candida albicans 
and Aspergillus species respectively (18). 
 
3.10 Porosity study 
The porosity of the nail is another parameter to take in count for explain changes in the 
diffusion of drug due to modification on hydration of nail plate. This hydration allows  drug 
flux from certain vehicles (22). Indeed, an increase in nail plate hydration was found to 
increase the permeation ketoconazole by three-fold and the diffusivity of water by more than 
400-fold, when relative humidity was increased from 15 to 100% (36). One method useful to 
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characterize the internal microstructure of the nail is mercury intrusion porosimetry (MIP) in 
combination with PoreXpert™ software. The combination of these techniques allow to obtain 
models useful to characterize the permeability properties of the nails (22). In the figure 5.8 are 
presented the values of porosity of nail obtained by MIP before and after different treatment. 
 
 
 
a) b) c) 
 
Figure 5.8. Cumulative curves of porosity obtained by MIP for treated and untreated nail and 
PoreXpert models of the microstructrure of a) untreated nail, b) Ony-Tec® treated nails and c) 
Formulation A PU19-10% TH treated nails. Cubes represent the pores and cilinders the 
conection between pores. 
No significant changes on the microstructure of the nail were observed after the application of 
nail lacquers. The cumulative pore distribution curve of Ony-Tec® seems to be relatively 
higher for lower pore diameter but the model and the parameters characteristic of the model 
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obtained by PoreXpertTM (table 5.6) indicates similar porosity and connectivity regardless the 
formulation. The values of correlation of the models, near the unity, obtained in treated and 
untreated nail indicates structures with high level order caused by the well delimited areas 
with high porosity at the top and bottom of the model and the low porosity structure in the 
middle of the model. Similar results were obtained by Nogueiras et al (9) for healthy 
untreated nail using MIP plus PoreCoreTM software.   
These results indicates that Formulation A PU19-10% TH and Ony-Tec® did not produce 
microstructural changes in the nail plate probably due to the presence of organic solvents and 
PU19-10% or the low proportion of water (Ony-Tec®) used in the elaboration of these nail 
lacquers.     
 
Table 5. 6. Main parameters of the models obtained from porosity data using PoreXpert. 
 
 
Porosity 
(%) 
Correlation Conectivity Water permeability 
(mD) 
Untreated nails 6.83 % 0.795 5.02 1.5775x10-6 
Ony-Tec® 6.75 % 0.796 5.02 1.5417x10-6 
Formulation A 
PU19-10%TH 
6.75 % 0.795 5.02 1.5775 x10-6 
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4. Conclusions  
This study reports the physic-chemical characterization of TH and CPX nail lacquer 
formulations based polyurethane. The TH nail lacquers obtained were compatible with 
keratinocytes cell and presented hydrophilic properties, however the CPX nail lacquer 
presented incompatible with skin cell.  
While the homogenous films obtained from the nail lacquer presented adhesion to nail. The 
viscosity studied demonstrated that the Formulation A PU19-10% TH and Formulation G 
PU19-10% CPX presented low viscosity compared to Ony-Tec®. 
In vitro release studies reveal that the amount of PU19 used had influence on the release 
profiles of drug, which was in agree with the antifungal activity of the formulations.  
All the nail lacquer formulations showed antifungal activity against Candida albicans and 
Aspergillus brasiliensis. The permeation profiled of antifungal formulation through the nail 
were higher that Ony-Tec®. 
The result obtained of permeation and determination of CPX in nail allow to prepare another 
formulation with used of PU19 with the aims to improve the compatibility with keratinocytes 
cells. 
The use of polyurethane in nail formulation can be a promising strategy for the release of 
lipophilic drug. 
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Chapter 6: Conclusions and Final Remarks 
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Conclusions and Near-Future Research 
 
Synthesis of polyurethanes employing isosorbide and aliphatic diisocyanate. Four 
polyurethanes (PU) obtained from isosorbide, PPG and aliphatic diisocyanate were 
synthesized and characterized. The soft segment segmentation (PPG) increased the molecular 
weight and the hydrodynamic radius of PU but decreased the diffusion coefficient of the 
macromolecules. On the other hand, increasing the extender of chain (isosorbide) the PU 
adhesion to keratin gave better results. The polyurethane presented adequate solubility 
properties.  
According to these properties and diffusion coefficient, determined by NMR, polyurethane 19 
(PU19), synthesized from 1 mol PPG, 6 mol IPDI and 5 mol of isosorbide, was selected for 
the final formulations. 
Further investigation may include:  
Experimental design using other molar relation and different temperatures should be assessed 
with this monomer.  
Determination of polymers’ molecular weight in different solvents according to 
hydrodynamic volume should also be performed.  
 
PU based nail lacquers: formulation and antifungal activity evaluation.  
PU-terbinafine based nail lacquers prepared with four PU selected showed keratinocyte 
compatibility, good wettability properties and adequate free volume. They formed a 
homogenous film after application, with suitable adhesion to the nail plate. Furthermore, the 
antifungal test results demonstrated that the terbinafine released from the nail lacquer 
Formulation A PU 19 showed activity against dermatophytes namely, Tricophyton rubrum. 
Further investigation may include:  
Structural studies using Wide- Angle X-ray Scattering (WAXS), Atomic Force Microscopy 
(AFM) and Differential Scanning Calorimetry (DSC) techniques would complement the 
physicochemical characterization of the PU based nail lacquers. 
Transungueal permeation studies 
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Preparation of 19 PU based nail lacquer.   
PU 19 was the polymer selected to prepared four nail lacquers with different amounts of 
polymer, 10%, 15%, 20% and 25%. The concentration of 10% permitted a nail lacquer with 
better adhesion properties, release and antifungal results.  
Further investigation may include:  
Study of the effect of lower quantities of polyurethane in order to determine the best nail 
lacquer formulation with drug effectiveness. 
 
Formulation optimization of PU based Nail Lacquers containing Terbinafine 
hydrochloride and Ciclopirox Olamine. 
The incorporation of two drugs (TH and CPX) validated the use of PU as versatile polymers 
in nail lacquer formulations. Direct contact cytotoxicity, wettability, SEM, adhesion, drying 
time, viscosity measurement, permeation studies and antifungal activity were performed. 
The results indicates that the total quantity of terbinafine hydrochloride permeated trought the 
nail was higher than the ciclopirox from the same matrix. The developed nail lacquers 
permitted better diffusion of antifungal drugs through the nail that reference one (Ony-Tec®). 
The amount of terbinafine hydrochloride and ciclopirox olamine determined in nail were 
higher than the minimum inhibitory concentration of these drugs against Candida Albicans 
and Aspergillus brasiliensis. However, CPX formulation was incompatible to keratinocytes 
cells. The antifungal activity of the terbinafine hydrochloride and ciclopirox olamine PU 
based nail lacquer against Candida albicans and Aspergillus brasiliensis was determined. The 
dresults obtained demonstrated that the amount of drug release from the nail lacquer 
formulations presented antifungal activity. The influence of -NH- of polyurethane in the pH 
of the medium, potential the antifungal activity of the terbinafine hydrochloride against 
Candida albicans 
Further investigation may include:  
Diffusion and permeation studies in keratin should be performed with TOWL determination 
in each nail. The development of new safe and biocompatible formulations with CPX 
effectiveness must be performed. 
Stability test should be done. 
Antifungal activity against dermatophytes and non dermatophytes. 
Clinic trials should be assessed. 
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The research work presented in this thesis, led to the development of a new nail lacquer with 
adhesive, biocompatible and improved the antifungal activity.  
Nevertheless, this new nail lacquers (polyurethane-antifungal drugs) and taking into account 
the challenge of treating nail infections, need further studies such as structural and clinical 
studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Chapter 
6 
 
198 
 
 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Annexes 
 
199 
 
Annexes 
New polyurethane nail lacquers for the delivery of antifungal drugs Annexes 
 
200 
 
New polyurethane nail lacquers for the delivery of antifungal drugs Annexes 
 
201 
 
Annex 1. Spectrum 1H NMR  PEG 1 500 
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Annex 2. Spectrum 1H NMR  pMDI 
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Annex 3. Spectrum 1H NMR Sucrose 
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Annex 4. MALDI-TOF mass spectra of PU19 
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Annex 5. MALDI-TOF mass spectra of PU20 
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Annex 6. MALDI-TOF mass spectra of PU21 
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Annex 7. MALDI-TOF mass spectra of PU22 
 
